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GEnERaL InTRODUCTIOn
Hemophilia
Hemophilia is a rare X-linked recessive bleeding disorder characterized by a lifelong 
bleeding tendency, specifically in muscles and joints. Hemophilia A and hemophilia 
B are caused by respectively a deficiency of coagulation factor VIII (FVIII) or factor IX 
(FIX) [1]. Hemophilia occurs in 1:5000 male individuals with a ratio of hemophilia A to 
hemophilia B of approximately 85:15 [2-4]. Severity is classified according to residual 
coagulation factor level in patient plasma. Severe hemophilia is defined as plasma levels 
< 0.01 IU ml-1; moderate severe disease as plasma levels between 0.01-0.05 IU ml-1; and 
mild disease as plasma levels > 0.05 to < 0.40 IU ml-1 [1]. Approximately 43% of patients 
are affected with severe disease, 26% with moderate severe, and 31% are mildly affected 
[5-7]. However, within each severity category of patients bleeding tendency is heteroge-
neous and not completely clarified [8-10].
In general, severely affected patients experience spontaneous bleeds from early infancy, 
moderately affected patients only sporadically experience spontaneous bleeds which 
usually develop after minor trauma or (dental) surgery, and patients with mild disease 
only experience bleeding after trauma or (dental) surgery. In the long run, when not 
treated adequately, muscle and joint bleeds lead to progressive joint destruction result-
ing in chronic pain and disability [2]. It has been reported that only a few hemarthroses 
may be sufficient to initiate progressive cartilage destruction and joint dysfunction 
[11, 12]. Other complications of hemophilia include life threatening intracranial or 
abdominal bleeds, and the development of alloantibodies (inhibitors) against FVIII or 
FIX concentrate. The latter greatly complicates treatment as these antibodies neutralize 
infused factor concentrate and necessitate treatment with bypassing products [13-15].
History of hemophilia treatment
Hemophilia treatment with factor concentrate is described as the intravenous replace-
ment of deficient coagulation factor to achieve specified levels which vary according to 
severity or risk of the bleed. Major progress has been made with regard to hemophilia 
treatment and subsequent clinical outcome in patients over the last decades. Since 
the introduction of first plasma derived factor concentrates in the 1960s, hemophilia 
has evolved from a crippling disease with a life expectancy of about 20 years into a 
disease with an almost normal quality of life and life expectancy [16, 17]. This decrease in 
morbidity is illustrated by a decrease in bleeding frequency and an improvement of the 
medical and social circumstances of hemophilia patients. This is clearly demonstrated 
in the observational Hemophilia in the Netherlands (HIN) follow up studies [18-20]. This 
progress is even more impressive when it is taken into account that pathophysiological 
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 1 mechanisms behind the disease were only recognised in the 1950’s. At that moment 
in time, Dr. Rosemary Biggs described seven patients with deficiency of the Christmas 
factor, later named FIX. It was reported that this factor seemed to structurally differ from 
antihemophilic globulin, the later FVIII, that had been discovered to be deficient in men 
with a bleeding disorder [21]. Subsequently, important steps with regard to treatment 
were only made in the 1960’s when cryoprecipitate became available for patients in 
cases of an acute bleed.
It was in the late 1960’s, that prophylactic replacement therapy (“prophylaxis”) was 
introduced by Ahlberg and implemented by von Creveld in the Netherlands [22, 23]. 
Prophylaxis with regular infusions of coagulation factor concentrate aims to convert 
the bleeding pattern of a severe patient into a moderate severely affected patient [24]. 
This not only prevents chronic arthropathy and long term disability but also reduces 
the risk of life threatening intracranial bleeding and directly increases quality of life 
[24-28]. Subsequently, prophylactic treatment in the home setting (“home treatment”) 
by patients and by parents became regular practice around 1974 in the Netherlands 
[29-33]. All developments were facilitated by the introduction of refined plasma-derived 
and later recombinant factor concentrate that enabled more optimal self-administration 
in the home setting.
Historically, dramatic setbacks during this period were the transmission of life threat-
ening viral diseases by plasma derived human blood products, including hepatitis B 
and C and HIV infections. This subsequently led to a temporary increase in morbidity 
and mortality of hemophilia patients in the 1980’s, although not due to the bleeding 
disorder itself [19, 34]. The last two decades, product development has evolved ever 
further. The hemophilia community now awaits wide spread application of extended 
half-life products and institutionalization of gene therapy and other cellular techniques 
[35]. However, it is important to realize in the light of the progress made in resource rich 
countries, that prophylaxis and home-based therapy with factor concentrates is still not 
uniformly available to all patients worldwide [36-38].
Current treatment guidelines
Currently, most prophylactic regimens in hemophilia A patients are based on dosages 
of 25-40 IU kg-1 two to three times a week [1]. In the Netherlands, prophylaxis is gener-
ally initiated at a young age after the first joint bleed [39, 40]. Current dosing of FVIII 
concentrates is still mainly based on an estimated in vivo recovery (IVR) of 2.0 IU dL-1 per 
IU kg-1 body weight. This means that one unit of infused FVIII concentrate per kilogram 
body weight will lead to a transient increase in plasma FVIII levels of 0.02 IU mL-1 [40-
42]. This however does not take clearance or volume of distribution, both important 
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 1pharmacokinetic parameters into account. Targeted plasma levels depend on indication 
for treatment and dosing on body weight. Although mainly based on body weight in 
kilograms, both prophylactic and on demand treatment in individual patients are also 
tailored according to bleeding tendency, the presence of target joints, daily activities 
and sports. Currently, only sporadically peak and trough coagulation factors levels are 
measured in plasma to monitor therapeutic interventions [43]. Overall according to 
guidelines in the Netherlands, perioperative treatment starts with a FVIII bolus infusion 
of 50 IU kg-1, followed by either continuous infusion or intermittent once or twice daily 
bolus infusions based on crude estimations of clearance rate [40]. To maintain periop-
erative hemostasis, FVIII plasma levels are targeted according to guidelines for up to 
two weeks after surgery. In the perioperative setting plasma coagulation factors are 
monitored frequently [40].
Comprehensive care
Hemophilia is a lifelong, life-threatening disease with significant impact on many 
aspects of life. Therefore, optimal management of hemophilia care requires a holistic 
approach. Besides long term medical management of complications, attention should 
be given to education, employment and other psychosocial needs. In this light, multi-
disciplinary comprehensive care teams were established quite early in various resource 
rich countries. These teams consist of a medical director often a hematologist, a nurse 
coordinator, a physiotherapist, a social worker, and sometimes a psychologist [30, 
44]. These world-wide established care programmes have led to an impressive overall 
improvement of care and are comparable to programmes installed for diabetes, cystic 
fibrosis and sickle cell disease [45-47]. Roles for nurses are important and diverse as they 
are often the first contact for patients with an acute problem or a symptom requiring 
follow-up. Furthermore, they provide educational services, and ensure a high quality of 
transitional care [48].
Patient outcome measures, adherence to treatment and personalized treatment
The World Health Organization has defined health as “a state of complete physical, 
mental and social well-being, and not merely as the absence of disease or infirmity”. 
Therefore, when evaluating patient outcome measures in chronic diseases such as he-
mophilia, it is essential to incorporate all these specific aspects in the analyses [49]. An 
important patient outcome parameter which encompasses most, is health-related qual-
ity of life (HRQoL). HRQoL is defined as a multidimensional construct which describes 
the patient’s (and his caregiver’s) experiences with respect to the domains of functional 
status, psychological aspects and social well-being, health perceptions, and disease - 
and treatment-related symptoms [50]. Generic quality of life measures aims to compare 
quality of life in patients with different (chronic) diseases. For children, commonly used 
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 1 instruments are the Child Health Questionnaire (CHQ), the Pediatric Quality of Life 
Inventory (PedsQoL), the TNO-AZL (Preschool) Children’s Quality of Life questionnaire 
(TAPQoL/TACQoL) and the KIDSCREEN/DISABKIDS [51-55]. Disease-specific quality of 
life measures give insight into the extent to which hemophilia specifically affects the 
quality of life of hemophilia patients. In pediatric patients, this most often measured by 
the Haemo-Qol and the CHO-KLAT as constructed by Von Mackensen et al. and Young 
et al., respectively [56-58]. Other measures which are becoming increasingly important 
with regard to well-being in chronic diseases are self-management and self-efficacy. 
Furthermore, measures with regard to behavior, both in the home setting as well as in 
school are of importance with this regard.
Another important condition to achieve optimization of care is adherence to prescribed 
treatment in a broad sense. In reviews on adherence a number of terms are frequently 
utilized and defined as follows. The term compliance suggests that patients passively 
follow doctor’s prescription and lifestyle advice. Therefore this term is not based on a 
therapeutic alliance between patient and doctor [59]. In contrast, the term adherence is 
now usually adopted. Adherence is defined by the WHO as “the extent to which a per-
son’s behavior – taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from the health care provider” [60]. Most 
recently, the alliance between physician and patient is underlined with shared decision 
making with regard to treatment options as an ultimate goal. This situation is named 
concordance, indicative of the mutual agreement between patient and doctor. It is 
believed that this may help to install a sense of control and self-efficacy in each patient. 
When regarded critically, concordance is an important aspect of individualization or 
personalization of treatment as this is defined as “care that is closely congruent with 
and in response to patients’ wants, needs, and preferences” [61-63]. More specifically, 
personalized treatment it is used to describe individualization of treatment by increased 
knowledge of disease, genetic disposition of the individual, as well as pharmacokinetics 
and pharmacodynamics of the medication involved.
areas of improvement
Although patient outcome has made great progress in last decades in the hemophilia 
population, there may still be room for improvement. Especially with regard to improve-
ment of adherence to treatment, aspects of quality of life, and more personalized dosing 
of factor concentrates.
In patients on prophylactic treatment, non-adherence rates have been reported up to 
50% in various studies [64-67]. Due to the lack of direct medical supervision, patients 
with home treatment report problems due to the increased responsibility associated 
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 1with home treatment [29, 32, 33]. During outpatient clinic visits there is often insufficient 
attention to therapeutic management, patient support and education. These aspects of 
care are essential to safeguard adherence, to increase self-efficacy and self-management 
abilities as is important in chronic diseases. Therefore, evaluation of mechanisms lead-
ing to non-adherence and development of related modalities such as self-efficacy are 
important in order to measure, monitor and improve adherence in hemophilia.
Currently, in resource rich countries, both prophylactic and perioperative hemophilia 
treatment are quite effective as morbidity due to joint and muscle bleeding and mortal-
ity are rare. However, with current dosing regimens, targeting of specific factor levels is 
challenging. This is due to significant inter-individual variation with regard to achieved 
factor levels due to inter-individual differences in various factors. One of these factors 
is pharmacokinetics (PK) of the specific factor concentrate in the individual [1, 42, 43, 
68-74]. Momentarily, the impact of PK-guided dosing has not yet been studied widely 
and consensus is still to be reached how to further develop and implement this innova-
tion. It is however most probably a more reliable dosing strategy as it takes important 
individual characteristics, such as clearance and volume of distribution into account. 
Furthermore, PK-guided dosing will make it possible to target specific factor concen-
trate plasma levels [26, 43, 72, 75-78] in the long run.
OPTIMIZaTIOn Of CaRE STRaTEGIES In HEMOPHILIa
aIMS Of THIS THESIS
The aims of this thesis are to study strategies that may further improve patient outcome 
in hemophilia, by optimization of both patient care by interventions in adherence as 
well as treatment innovations.
OUTLInE Of THE THESIS
This thesis consists of two parts. Part I will focus on strategies to further improve 
hemophilia patient care with regard to prophylactic home treatment and care in the 
outpatient clinic setting. In addition, two questionnaires to measure adherence and 
self-efficacy will be introduced that are of importance to quantify and monitor these 
aspects of treatment.
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 1 Firstly, we hypothesized that transmural support by a hemophilia nurse performing 
structured home visits may improve prophylactic treatment adherence, health-related 
quality of life, behavior, self-efficacy, and may lead to a reduced number of joint bleeds 
and less factor concentrate consumption in children with hemophilia on prophylactic 
home treatment. In chapter 2, a multicenter intervention study will be described that 
evaluates the effect of regular home visits by a hemophilia nurse. In order to be able 
to quantify and monitor treatment adherence, reliable and validated tools are neces-
sary. Therefore, we will describe in chapter 3, the value of the VERITAS-Pro adherence 
questionnaire by Duncan et al. This questionnaire was translated in Dutch and validated 
in a pediatric patient population within our studies. Self-efficacy is a very important 
measure in patients with chronic diseases, as it is associated with higher development 
of self-management skills and increased quality-of-life. In chapter 4, we will describe 
the development and validation of a novel Hemophilia-specific Self-Efficacy Scale. Dur-
ing regular outpatient clinic visits, time limitations may lead to insufficient attention to 
therapeutic management and patient education. In addition, patient support and edu-
cation by patients themselves may improve quality of care. The group medical appoint-
ment (GMA) therefore may be an effective and efficient option to improve the quality of 
the outpatient clinic visits. In chapter 5 an observational study will be presented that 
compares participant’s experiences with GMA to the usual standard of care.
Part II of this thesis will focus on strategies to improve current dosing of factor con-
centrates. To demonstrate the challenges involved with targeting of factor VIII values in 
the perioperative setting, we will present the results of the current dosing regimen in 
chapter 6. Subsequently, in chapter 7, a population PK model will be described that is 
applicable for various current FVIII concentrates in the perioperative setting. Although, 
the principle and benefits of PK-guided prophylactic dosing have been proven by oth-
ers, it has still not been implemented in routine hemophilia care. To facilitate imple-
mentation, in chapter 8 barriers and facilitators for PK-guided dosing of prophylaxis in 
will be reported as analyzed in patients, parents and professionals by Discrete Choice 
Experiment.
Finally, in chapter 9 and 10 a summary of the thesis will be provided as well as an 
overview of the most important conclusions of our studies and methodological con-
siderations. Moreover, we discuss the implications of our results with regard to current 
practice and future perspectives with regard to research.
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abSTRaCT
background Transmural support by a haemophilia nurse may improve treatment and 
may empower parents and patients.
aim To measure the effect of structured home visits by a haemophilia nurse in (parents 
of ) patient on aspects of prophylactic home treatment.
Methods A multicentre intervention study in two paediatric haemophilia treatment 
centres was performed. Primary outcome measures were: adherence to prescribed 
treatment, health-related quality of life, and behavioural scores. Secondary outcome 
measures were: total clotting factor consumption, self-efficacy, and number of joint 
bleeds.
Results Over a period of 22 months (median, IQR = 21-23) four to seven home visits in 46 
patients (mean age 9.4 ± 4.2 years) were made. No difference in adherence to prescribed 
treatment was seen after the home visits when compared to baseline measurements. 
Both the Child Health Questionnaire (CHQ) scales on ‘Role functioning - Emotional/
Behavioural’ (P = 0.02, d = 0.53) and ‘Parental Time Impact’ (P = 0.04, d = 0.33) were 
reduced after intervention. The disease-specific Haemo-QoL questionnaire showed 
improvement in domains: ‘Family’ (P = 0.04, d = -0.14), ‘Friends’ (P = 0.03, d = -0.29), and 
‘Perceived support’ (P = 0.03, d = -0.37). Significant improvement was observed with 
regard to domain ‘Communication’ of the VERITAS-Pro scale (P = 0.03, d = -0.28).
Conclusions After a period of transmural care by a haemophilia nurse, significant but 
small positive effects were demonstrated with regard to communication and increase 
of perceived support between parents and haemophilia treatment centre. No improve-
ment was observed in other outcome measures.
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InTRODUCTIOn
Haemophilia is an X-linked bleeding disorder which is characterized by a deficiency of 
coagulation factor VIII (FVIII; haemophilia A) or IX (FIX; haemophilia B) [1]. Depending 
on severity, haemophilia patients experience spontaneous and post-traumatic bleeding 
events, mainly in joints and muscles [2]. In the long run, these bleeds lead to progressive 
joint destruction with impairment of joint function and chronic pain, when not treated 
adequately. In most high resource countries, patients with severe and some with moder-
ate severe disease are treated by intravenous prophylactic replacement therapy with 
clotting factor concentrate. Prophylactic therapy is initiated at a young age after the first 
joint bleed, to prevent the development of arthropathy and subsequent disability [1, 3].
Almost all patients on prophylaxis are treated in the home setting, where parents and/
or the patient himself, regularly infuse clotting factor concentrate without direct medi-
cal supervision [4]. In the Netherlands, apart from an intensive training in the hospital 
and one home visit at the initiation of home treatment, no transmural care is offered. 
Home treatment has greatly improved quality of life and self-management abilities in 
haemophilia. Due to the fact that prophylactic treatment can be administered at home 
more rapid treatment of bleeding is possible, leading to less pain and disability, fewer 
hospitalizations, and less absence from school or employment [5-7]. However, home 
treatment also has disadvantages due to the lack of direct supervision, such as waning 
from prophylactic and on demand dosages and increased responsibility regarding self-
management of patient’s disease [5, 7, 8].
The full benefit of prophylactic treatment is only achieved by optimal adherence. 
Non-adherence to treatment in haemophilia has been reported to be associated with 
substantial increase in morbidity, mortality, and health care costs [9-11]. Besides social 
circumstances and developmental stages such as adolescence [12, 13], determinants 
of non-adherence include: lack of expertise or knowledge of disease, time investment 
involved to infuse prophylaxis, lack of balance between prophylactic treatment and 
social activities, anxiety towards needle insertion, lack of cooperation of the child, and a 
general feeling that treatment is not beneficial [5, 14]. Inversely, as described by Schrij-
vers et al. (2013) adherence and quality of life are positively influenced by adequate 
knowledge of the disease and belief in medical and psychological benefits of prophy-
laxis, mental health, disease symptoms, and an optimal relationship between patient 
and haemophilia team [12, 14-18].
We hypothesized that transmural support by a haemophilia nurse performing home 
visits may overcome the disadvantages mentioned above, attributed to home treatment 
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[19-23]. Therefore, we performed a multicentre intervention study with structured home 
visits by a haemophilia nurse in children on prophylactic home treatment. The aim of 
the study was to investigate the effect of home visits on adherence to treatment, health-
related quality of life, behavioural scores, self-efficacy, total clotting factor consumption, 
and number of joint bleeds.
PaTIEnTS anD METHODS
Design
The study is a multicentre pre- and post-intervention study in a cohort of paediatric 
haemophilia patients aged 1-18 years on prophylactic home treatment for at least one 
year (Dutch Trial Register: 2543) [24].
Patients
Patients were recruited from two paediatric academic haemophilia treatment centres 
in the Netherlands, i.e. Erasmus University Medical Centre-Sophia Children’s Hospital 
Rotterdam (Erasmus MC-Sophia, n = 22) and Academic Medical Centre-Emma Children’s 
Hospital Amsterdam (Emma Children’s Hospital AMC, n = 31). Exclusion criteria were in-
ability to understand the Dutch language or home treatment with bypassing agents due 
to the presence of inhibiting antibodies. The study protocol was approved by a Medical 
Ethics Committee (MEC-2010-097) with written informed consent from parents of all 
children and from patients aged 12-18 years. The study was not subject to the Medical 
Research Involving Human Subjects Act.
Intervention
The intervention was defined as five to seven home visits by two experienced haemo-
philia nurses over a total period of two years. During each home visit with a duration 
of one to two hours, the nurse was instructed to inform parents and patient(s) on all 
aspects of treatment according to a standardized checklist focusing on logistical, tech-
nical, therapeutic, safety, educational and psychological aspects of haemophilia (see 
Appendix 1).
Data collection
Before and after the intervention period, the caregiver primarily involved in daily hae-
mophilia treatment, as well as adolescents aged 10-18 years, were asked to complete a 
web-based questionnaire measuring health-related quality of life (HRQoL), behaviour, 
adherence, and self-efficacy (Figure 1). All endpoints were measured with validated 
questionnaires, which are described more explicitly in following sections. In the ques-
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tionnaire directly after the intervention, parents were also asked if they were satisfied 
with home visits and if these had improved home treatment in their opinion (visual 
analogue scale of 10 cm). Self-reported infusion log data were collected in patients from 
the Erasmus MC-Sophia Rotterdam treatment centre.
General patient characteristics were recorded: age, type and severity of haemophilia, 
body weight, prescribed treatment, number of bleedings, and pharmacy dispensations 
based on medical records. For level of education, the International Standard Classifica-
tion of Education (ISCED) division into low, medium, and high educational level was 
applied [25].
Primary outcome measures
Adherence to prescribed prophylactic treatment according to infusion logs
Self-reported infusion logs were available in the Erasmus MC-Sophia cohort (n = 22), 
and were used to assess adherence to prescribed haemophilia treatment. Adherence to 
prophylactic treatment was quantified as the percentage of weeks per year (ratio n/n = 
52) that the patient was adherent according to prescribed prophylactic regimen related 
to reported (i) frequency of infusions; (ii) interval between consecutive infusions; (iii) 
total consumption of clotting factor concentrate. Weeks with alterations in prophylactic 
treatment due to bleeding or dental care were excluded. Patients who underwent sur-
gery or were involved in intensive sport activities were excluded from these analyses, as 
these circumstances may lead to long-term alterations in frequency, dose and interval of 
the treatment regimen, masking real adherence rates.
Generic and disease specific health-related quality of life (HRQoL)
The Child Health Questionnaire (CHQ) was used to assess the generic quality-of-life in 
children aged 4-18 years. For the parental report the CHQ-PF50 was used (reliability: α 
= 0.59-0.94), which consists of 50 items covering 13 physical and psychosocial scales, 
including Physical summary scale and Psychosocial summary scale [26, 27]. For adoles-
01-01-2013
Questionnaire 2
Parental Report (n=46)
(After total study intervention) 
01-01-2010 - 27-12-2010
Measurement of infusion log data (Rotterdam subgroup, n=22)
and annualised bleeding rate (ABR) (Total cohort n=46)
31-12-2011 - 26-12-2012
Measurement of infusion log data (Rotterdam subgroup, n=22)
and annualised bleeding rate (ABR) (Total cohort, n=46)
27-12-2010
Questionnaire 1
Parental Report (n=46); 
(Baseline)
01-01-2010 - 27-12-2010
Baseline period
27-12-2010 - 1-1-2013
Intervention: 5-7 home visits by a trained haemophilia nurse in a period of two years
.
figure 1. Study design.
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cents aged 10-18 years, the self-reported 87-item CHQ-CF87 was used (reliability α = 
0.63-0.90), which encompasses 12 scales [27, 28]. In this questionnaire, higher scores 
indicate a higher generic quality of life (range = 0-100). The Haemo-QoL questionnaire 
was used to assess haemophilia-specific quality of life [29, 30]. This tool consists of 
21-77 items which encompass 9-11 domains depending on age group of the patient 
(4-7 years, 8-12 years, 13-16 years; α = 0.85-0.91). The age-specific versions contain an 
identical core item set. Because of small number of patients per age group, results were 
merged for total scores and domain scores (when available) for all age groups. Higher 
scores indicate a lower disease-specific quality of life (range = 0-100).
Behavioural scores
The Strengths and Difficulties Questionnaire (SDQ) was used to assess behavioral prob-
lems in children aged 4-17 years [31-33]. The SDQ consists of 25 items encompassing 5 
domains. Higher scores indicate increased severity of symptoms, and individual items 
are added to obtain a total scale score (range = 0-40).
Secondary outcome measures
Total clotting factor concentrate consumption and total number of joint bleeds
Total clotting factor consumption (kg-1 wk-1) and total number of joint bleeds were 
recorded in self-reported infusion logs and medical records. Weeks with alterations in 
prophylactic treatment due to bleeding, surgery or dental procedures were excluded 
for this analysis. For number of bleeds only joint bleeds in larger joints were recorded. 
A new bleed was defined as a bleed occurring more than 72 hours after completing 
treatment for the original bleed for which treatment was initiated [34].
Adherence to treatment according to the VERITAS-Pro adherence scale
To quantify adherence to treatment in children on prophylactic home treatment, the 
Validated Haemophilia Regimen Treatment Adherence Scale (VERITAS-Pro) was used 
[35]. This instrument was translated in Dutch according to international guidelines and 
validated within this study [36]. The VERITAS-Pro consists of six subscales with four items, 
concerning a specific domain of haemophilia patient care: ‘Time’, ‘Dose’, ‘Remember’, 
‘Skip’, ‘Plan’, ‘Communicate’. Higher scores indicate worse adherence (subscale range = 
4-20; total scale range = 24-120).
Self-efficacy
The Haemophilia-specific Self-Efficacy Scale (HSES) was used to quantify disease-specific 
capacities with regard to self-efficacy, and was validated within this study [37]. The HSES 
consists of 12 items focusing on an individual’s perceptions of haemophilia disease 
symptoms and the ability to cope with or reduce these symptoms. An unweighted sum 
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score was calculated by adding the 12 items scores, with higher scores indicating greater 
self-efficacy (range = 12-60).
Sample size calculation
Sample size calculation determined that minimally 40 patients were needed to measure 
a significant difference (Sd = 2δ/ Sd) in the primary endpoint HRQoL, with a measurable Z 
score difference of 0.55, given a power of 80% (1-β) and an α of 0.05 (Dutch Trial Register: 
2543). This number of patients also was sensitive enough to detect a minimal change of 
1.4 bleeding episodes, 2.6 treatment days, or 4785 IU kg-1 clotting factor use per patient 
(secondary outcome).
Statistical analysis
Descriptive study statistics are presented as mean and standard deviation (SD) for 
continuous variables which are normally distributed, and otherwise as median and 
interquartile range [IQR]. For comparison of parametric outcome parameters before 
and after the intervention, the Student’s t-test for paired data was used. Non-parametric 
data were compared using Wilcoxon signed rank test. Categorical data were compared 
using the Pearson Chi-Squared test. Effect size estimations (d) were calculated which 
relate the difference in mean scores to the dispersion of the scores. Given unequal score 
variance between groups, we used to following formula: d = [Mean(a)-Mean(b)]/√[((n(a)-
1)*SDd(a)2)+((n(b)-1)*SD(b)2)/n(a)+n(b)-2]; 0.20 ≤ d < 0.50 was taken to indicate a small 
effect size, 0.50 ≤ d < 0.80 a moderate effect size, and d ≥ 0.80 a large effect size [38]. To 
compare outcome measures of the infusion logs (i.e. total clotting factor use and an-
nualised bleeding rate) baseline data (median = 45 weeks, IQR = 43-51) were compared 
to data collected at the second half of the intervention period (median = 49 weeks, IQR 
= 43-55). Data were analysed separately for parental reported and adolescent reported 
data. Data management and statistical analysis were performed using IBM Statistical 
Package for Social Sciences (SPSS) program, version 21.0 for Windows (IBM Corp, Ar-
monk, NY, USA).
RESULTS
Patient characteristics
Between June 2010 and December 2011, 59 eligible haemophilia patients and their par-
ents were invited to participate in the study (Figure 2). Of these boys, 53 patients (90%) 
and their parents agreed to participate. Seven patients were lost to follow-up (13%). 
Data of the remaining 46 patients (87%) were included in our study, and provided writ-
ten informed consent (Table 1). Analysis of patient characteristics of the seven patients 
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not adherent with regard to the study protocol, showed that they were from one single 
centre (Emma Children’s Hospital AMC), they were significantly older in comparison to 
the study group (mean age = 13.4 years, SD = 3.2 versus 9.4 years, SD = 4.2; P = 0.02), 
had a medium or high maternal educational level (P = 0.02). Other patient characteristics 
were not significantly different.
There were no major differences between parental and adolescent reports. The Adoles-
cent reported data are depicted in Appendix 1.
Comparison of study groups from the Erasmus MC-Sophia and the Emma Children’s 
Hospital AMC, overall showed no significant differences with regard to age, type and se-
verity of haemophilia, duration of prophylaxis, parental age, marital status, or maternal 
Study population
Children aged 1-18 years with haemophilia A or B
on prophylactic home treatment for at least 1 year 
Eligible
n = 59
Total recruited
n = 53
Refused to participate, n = 6
Lost to follow up, n = 7
 No response questionnaire T2, n = 2  
 Withdrawal from the study, n = 5 
Data available for analysis
 Questionnaire T1 and T2 n = 46  
 Infusion logs (Rotterdam cohort) n = 22
Figure 2. Study flow diagram.
figure 2. Study flow diagram.
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paid employment. However, the maternal educational level was significantly higher in 
the study group from Emma Children’s Hospital AMC when compared to Erasmus MC-
Sophia (low = 24% vs 4%; medium = 67% vs 58%; high = 10% vs 38%; P = 0.03).
Intervention
During a median time period of 22 months (IQR = 21-23) two experienced haemophilia 
nurses performed four home visits in two patients (4%), five or more in 44 patients (96%). 
The median duration of the home visits was 71 minutes (IQR = 60-86).
Primary outcome measures
Log entries were available from all children in the Erasmus MC-Sophia (n = 22), of which 
six cases were excluded from analysis because of surgery and two cases were excluded 
because of intensive sport activities. Treatment adherence with regard to the frequency 
of infusions, interval between two consecutive infusions and dose did not change sig-
nificantly after the intervention, as described in table 3.
After the intervention two domains on the generic quality of life questionnaire CHQ 
scored lower: ‘Role functioning – Emotional/Behavioral’ (P = 0.02; d = 0.53) and ‘Parental 
Time Impact’ (P = 0.04; d = 0.33), as depicted in Table 2. No significant differences in 
other CHQ domains were observed. Disease-specific quality of life improved in the fol-
lowing three domains after the intervention: 1) ‘Family’ (P = 0.04; d = -0.14), indicating 
less limitations experienced by families due to the child’s general health and well-being; 
2) ‘Friends’ (P = 0.03; d = -0.29), indicating an improved relationships and higher activity 
levels with friends; and 3) ‘Perceived support’ (P = 0.03; d = -0.37), indicating an increased 
feeling e.g. recipient’s subjective judgment that providers will offer effective help when 
needed. No change was reported in other Haemo-QoL domains.
Behavioural scores on the SDQ questionnaire did not significantly change after the 
study intervention.
Secondary outcome measures
The total consumption of clotting factor did not change after study intervention in the 
Erasmus MC-Sophia population.
At baseline, median annualized bleeding rate was 1 (IQR = 0-3). The annualized bleeding 
rate did not change significantly after study intervention (Table 3).
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The domain ‘Communication’ of the VERITAS-Pro scale changed positively after the in-
tervention period, indicating communication between the patient and the Haemophilia 
Treatment Centre was reported to have improved significantly: P = 0.03; d = -0.3 (Table 2).
Table 1. Patient characteristics of total cohort (parental report) and subgroup (adolescent report) at study 
enrolment.
Characteristics
Total cohort (n = 46) Subgroup (n = 22)
Parental report adolescent report
N (%) N (%)
Patient characteristics
Age patients (years), mean (SD) 9.4 (4.2) 12.9 (2.4)
Sex patients, male 46 (100) 22 (100)
Diagnosis
  Haemophilia A 36 (78) 19 (86)
  Haemophilia B 10 (22) 3 (14)
Disease severity
  Severe (< 0.01 IU ml-1) 42 (91) 20 (90)
  Moderate severe (0.01-0.05 IU ml-1) 3 (7) 1 (5)
  Mild (0.06-0.40 IU ml-1)# 1 (2) 1 (5)
Duration of prophylactic treatment (years), mean (SD) 6.6 (3.7) 9.1 (2.5)
Parent characteristics
Age parents (years), mean (SD)$ 39.3 (6.3) .
Marital status$
  Married/living together 34 (76) .
  Single / Widow(er) / Divorced 11 (24) .
Highest level of education of mother$,&
  Low 6 (13) .
  Medium 28 (62) .
  High 11 (25) .
  Missing/ not specified
Paid employment mother$ 37 (82) .
Individual completing scale$
 Mother/female guardian 41 (91) .
 Father/male guardian 4 (9) .
 Adolescent . 22 (100)
N = number (percentages); Median [IQR = Inter quartile range 25-75%]; SD = Standard deviation; # On pro-
phylactic treatment due to bleeding tendency as a result of concomitant von Willebrand disease; $ Of one 
participant, no information is available on marital status, highest level of education of mother, paid employ-
ment of mother, and individual completing scale. Of three participants, no information is available on age 
of parents. & The usual ISCED division into Low, Medium and High is adopted here, as in the Eurostat Labour 
Force Survey. Low is equivalent to ISCED 0-2, i.e. less than upper secondary level of education. Medium is 
given by ISCED 3-4, i.e. upper secondary level. High is ISCED 5-6, meaning tertiary level, or two more years 
of education after upper secondary level [25].
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Self-efficacy measured at baseline was high in our population (median = 57, IQR = 53-59) 
and did not improve significantly after study intervention (P = 0.10; Table 2).
Other outcome measures
Parents of patients reported to be satisfied with home visits with a median of 8 (IQR = 
7-10), found the visits useful (median = 8; IQR = 6-10) and that they improved the quality 
of haemophilia treatment (median = 8; IQR = 7-8). Concomitantly, haemophilia nurses 
agreed with respect to usefulness of home visits (median = 8; IQR = 6-9). At baseline 
patients were absent form school due to haemophilia for a median of 5 days per year 
(IQR = 2-10). Non-attendance did not change significantly after the intervention.
DISCUSSIOn
This study shows that transmural care by a haemophilia nurse, does not improve 
adherence to prescribed treatment in a population that at baseline demonstrates 
high levels of treatment adherence as well high quality of life, high capacity of self-
Table 3. Infusion log variables in subgroup Erasmus MC-Sophia with detailed information (n = 22) and an-
nualised bleeding rate in total cohort (n = 46).
Òutcome measures
baseline# Intervention$ Effect
N Median [IQR] N Median [IQR]
Median 
difference
[IQR] P‡
Primary outcome
Compliance&
Frequencyi 14 86 [75-91] 14 87 [78-95] -3 [-5-11] 0.55
Intervalii 14 91 [85-96] 14 85 [78-93] -6 [-13- -0] 0.07
Doseiii 14 100 [100-100] 14 100 [91-100] 0 [-7-0] 0.24
Secondary outcome
Total clotting factor 
consumption
(IU kg-1wk-1)
22 27 [17-34] 22 26 [20-36] -0 [-5-5] 0.99
abR† 46 1 [0-3] 46 2 [0-6] 0 [-0-1] 0.87
N = number (percentages); Median [IQR = Inter quartile range 25-75%]; IU kg-1 wk-1 = International Units 
per kilogram per week; & Compliance to prescribed prophylactic treatment by comparison of prescribed 
prophylactic treatment dosages to actual infused units of clotting factor during prophylactic treatment as 
registered in infusion logs. Compliance is quantified as a percentage of weeks spent in compliance with 
prescribed therapy (%) to reported (i) frequency of infusions; (ii) interval between consecutive infusions; 
(iii) total consumption of clotting factor concentrate; † Annualised bleeding rate = number of bleedings/
number of weeks*52 weeks; # Baseline: Measurement before start of intervention (median 45 weeks, IQR 
= 43-51 weeks); $ Intervention: Second half of intervention period (median 49 weeks, IQR 43-55 weeks); 
‡  Wilcoxon signed rank test; *P < 0.05.
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efficacy, and a low number of joint bleeds. In addition, no improvement was observed 
in Physical and Psychosocial summary measures of the generic HRQoL as measured by 
CHQ. Contrastingly however, a small decrease over time was seen in CHQ scales ‘Role 
Functioning – Emotional/Behavioural’ and ‘Parental Time Impact’. Importantly, parents 
of patients did report a significant improvement of disease-specific HRQoL by means 
of the Haemo-QoL domains ‘Family’, ‘Friends’, and ‘Perceived support’ after home visits. 
Furthermore, communication between parents and the haemophilia treatment centre 
was reported to have improved significantly as reported by VERITAS-Pro adherence scale 
Although this effect was small, this is an important finding as communication with treat-
ing professionals is known to significantly influence adherence [14].Total clotting factor 
concentrate consumption, number of joint bleeds, and capacity to self-efficacy did not 
change significantly after study intervention. Overall, patients, parents and haemophilia 
nurses were satisfied with the concept of home visits as performed in the study.
These findings support a review of 182 randomized controlled trials (RCTs) on interven-
tions to improve treatment adherence by Nieuwlaat et al [22]. Analysis of data from 17 
RCTs (range n = 38-2097 patients, majority adults) of good quality studies, showed that 
interventions aiming to improve adherence have only modest overall effects. Further-
more, interventions varying from intense education to daily treatment support showed 
inconsistent effects on patient outcomes.
When interpreting effects of our intervention on HRQoL, a number of considerations are 
important. Firstly, the cohort reported a good HRQoL at baseline, which has been docu-
mented in several earlier studies [39-42]. This finding severely limits the ability of most 
instruments to detect improvement in endpoints after intervention [26, 29, 36, 37, 43]. 
In addition, such quality of life measurements are known to be influenced by age [44]. 
With regard to the generic HRQoL, no change was seen on the Physical and Psychosocial 
summary scales of the CHQ. However, two CHQ scales declined minimally after interven-
tion (‘Role Functioning – Emotional/Behavioural’, and ‘Parental Time Impact’), which is 
partially explainable. Smith et al. stated that adaptation to a chronic health condition 
requires a certain degree of disease acceptance and hope for improvement [45]. The 
home visits may have led to more intensive counseling of parents and patient, with more 
attention to actual problems and treatment of disease leading to an inverse effect on 
some quality of life scores [45-47]. The decrease reported in parental time, is most likely 
due to the time consuming nature of the intervention itself. However, it could be also a 
desired effect as parents are more aware of the importance of proper treatment for their 
child. With regard to the disease-specific HRQoL, Bullinger et al. reported satisfactory 
disease-specific HRQoL as measured by Haemo-QoL in a large cohort of 320 paediatric 
haemophilia patients from six European countries [48]. Although young children were 
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negatively affected in the areas ‘Family’ and ‘Treatment’, and older children showed 
impairments in social domains, such as ‘Perceived support’ and ‘Friends’ [48, 49]. In our 
study, except for the domain ‘Treatment’, an improvement was seen in these domains 
after intervention by haemophilia nurse.
Annualised bleeding rate in our population was low (median = 1.0, IQR = 0-3) when 
compared to earlier research by Fisher et al. in 1998, in a Dutch paediatric population 
that reported 3.7 joint bleeds per year (IQR 1.7-5.0; n = 86) [50, 51]. In part, the differ-
ence in joint bleeds could be explained by current more intensive treatment, an overall 
younger age of our study population and differences in activity level and behaviour 
associated with age (17.9 vs 9.4 years). Moreover, annualised bleeding rate will only 
crudely measure effectiveness of prophylaxis and is therefore less useful in patients with 
infrequent or minor bleeds [52]. In patients with few joint and muscle bleeds, improve-
ments in HRQoL and adherence can only be achieved by more optimal access to health 
care or improved factor concentrate administration. Inversely, aggravation of disease 
can only be measured by subtle soft tissue changes and assessment of participation in 
physical activities [52].
With regard to simple and effective measurement of adherence, patients’ self-reports 
are of importance as Osterberg et al. have recently stated [9]. The self-reported VERITAS-
Pro adherence scale as developed by Duncan et al., was translated and validated by 
Lock et al. in the Dutch population. Within this study, it was proven to be an easy to use 
instrument to measure adherence in the (moderate) severe haemophilia population on 
prophylactic treatment [35, 36] and showed slightly improved communication between 
(parents of ) patient, and the haemophilia treatment centre. It is well known that bond-
ing with treating professionals is important to optimize adherence to treatment [14]. 
In addition, long term investment in the relationship will uncover problems associated 
with non-adherence [53]. In literature, well-developed self-efficacy is related to better 
treatment adherence [54]. In our population, self-efficacy with regard to haemophilia 
treatment was high. This unfortunately also limited the possibility to detect an improve-
ment in self-efficacy capacities after study intervention.
To appreciate study results, some methodological aspects should be considered. Firstly, 
this paper describes a pre- and post-intervention study designed to evaluate the ef-
fect of standardised transmural haemophilia care. Although a randomised controlled 
trial (RCT) is the gold standard to evaluate an intervention, this was not feasible due to 
the very low incidence of haemophilia. A strength of our study design is that it is not 
restricted to a highly selected cohort, which often leads to a lower external validity in 
RCTs [55]. Secondly, a limitation of the design is that time-varying confounders of both 
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medical and social nature could not be eliminated and may have influenced outcome 
parameters [56]. Life events experienced by patients and parents such as divorce, moving 
of house, passing away of relatives and comorbidity, have both a psychological impact 
as well as an effect on daily routines and therefore certainly affect quality of life. Perhaps, 
more than our intervention could ever have. As data on life events were not collected 
from the year before start of the intervention, it was not possible to correct for these 
events [56]. Thirdly, although response rate was high, reducing possible selection bias, 
the (seven) patients lost to follow-up were a substantial part (15%) of the study popula-
tion. Analyses showed that these patients were significantly older than analysed study 
patients. Non-adherence to study participation may be suggestive of non-adherence 
to treatment in general. Therefore, the intervention may have had a larger effect in the 
lost to follow-up subgroup. Strikingly, mainly patients with a medium or high maternal 
educational level and maternal paid employment were lost to follow up. Although level 
of education is not consistently related with treatment adherence, selection bias cannot 
be ruled out completely with regard to the endpoints adherence to prescribed treat-
ment and total clotting factor concentrate consumption. Fourthly, good quality of life, 
high adherence and high self-efficacy scores at baseline limited measurement of effects 
of the intervention due to a ceiling effect of applied instruments. These high baseline 
values are most probably the result of the intensive training before initiation of home 
treatment and the existing intense relationship between (parents of ) patients and treat-
ing professionals as well as high accessibility of care in the Netherlands.
Importantly, a longitudinal study during a longer time span, in a high risk category for 
non-adherence (a.o. at initiation of home treatment, adolescence and older age, life 
events with a large social impact, socioeconomic level), may lead to more significant 
results. Lastly, only self-reported infusion logs from one single centre could be used for 
analyses.
Conclusions
Although effects are small, transmural care by a haemophilia nurse leads to improve-
ment of perceived support by parents and of communication between parents and the 
haemophilia treatment centre. Taking the lifelong relationship between patients with 
the haemophilia treatment centre this is an important finding to increase and maintain 
quality of care.
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adherence to treatment in a western 
European pediatric population with 
hemophilia: reliability and validity of 
the VERITaS-Pro scale
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abSTRaCT
background Treatment adherence in haemophilia is strongly associated with quality of 
life and the cost-benefit of treatment. Therefore, it is important to quantify and monitor it.
aim This study aimed to validate a translation of the VERITAS-Pro cross-culturally and 
analyse treatment adherence in a Dutch population of paediatric haemophilia patients.
Patients and Methods Children aged 1-18 years with haemophilia were included from 
three Haemophilia Treatment Centres, on prophylactic clotting factor replacement 
therapy for more than 1 year. Parents and adolescents were analysed separately. The 
adherence scale for prophylactic therapy (VERITAS-Pro) was translated according to 
international guidelines. This instrument contains a total of six subscales (‘Time’, ‘Dose’, 
‘Plan’, ‘Remember’, ‘Skip’, ‘Communicate’) each with four items. Lower scores reflect higher 
adherence.
Results Overall response rate was 85%, leading to a study population of 60 children. 
Mean age was 10 years (SD = 4.1). Internal consistency reliability: mean Cronbach’s alphas 
were adequate (> 0.70) for total score and the subscales ‘Skip’ and ‘Communicate’. Item-
own subscale correlations were stronger than most item-other subscale correlations. 
Convergent validity: Total scores were higher for non-adherent participants compared 
with adherent participants according to patient infusion logs (n = 48; P < 0.05). Test-
retest correlations: Significant for all scales except ‘Dose’ (n = 58; P < 0.01).
Conclusion This study demonstrates applicability of VERITAS-Pro outside the United 
States, as total score and most subscales effectively quantified treatment adherence in a 
Dutch paediatric population on prophylactic therapy. Non-adherent respondents’ total 
scores were significantly higher, demonstrating the ability of VERITAS-Pro to identify 
non-adherent individuals.
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InTRODUCTIOn
Patients’ adherence to therapy and recommended lifestyle measures are strongly cor-
related with clinical outcome, quality of life and cost-benefit of treatment in chronic 
diseases such as haemophilia [1-3]. In Europe, when indicated, haemophilia patients are 
treated prophylactically with clotting factor replacement therapy in the home setting 
(prophylaxis), which significantly decreases spontaneous bleeding and joint damage 
[4-7]. In case of acute bleeding, haemophilia patients are also treated on demand with 
clotting factor concentrate. Both strategies require patient adherence and responsibility 
with regard to treatment.
In a meta-analysis assessing general adherence and clinical outcomes of medical treat-
ment DiMatteo et al. found that 26% of patients experienced a better clinical outcome if 
adhering to treatment [2]. In haemophilia, non-adherence to prescribed clotting factor 
therapy is reported in up to 50% of patients on prophylaxis [8-11], clinically manifested 
by both under- and overtreatment. Expectedly, regular undertreatment leads to higher 
risk of repetitive joint bleeding, synovial hypertrophy, cartilage- and bone damage with 
arthropathy and disability as a result [1, 12]. On the other hand, overtreatment leads 
to unnecessary and avoidable costs, as well as a higher risk of complications such as 
development of inhibiting antibodies, adverse reactions, and infectious or thrombotic 
complications [13, 14].
The main reasons for non-adherence in haemophilia are the chronic and unpredictable 
course of disease, long-term dependency on treatment, obligatory lifestyle adjustments, 
and invasiveness of intravenous administration of clotting factor concentrate [15-19]. The 
importance of identifying treatment non-adherence was recently established in a review 
by Schrijvers et al. [11]. Primary determinants were infrequent or absence of symptoms 
and increasing age. Motivators of adherence were experience with the disease, posi-
tive ideas regarding necessity of treatment and an optimal relationship with the health 
care provider [9, 11, 20]. Recent developments with regard to pharmacokinetic-guided 
dosing of replacement therapy and the development of long-acting clotting factor 
products, underline the importance of adherence in the haemophilia population. This, 
as minimal and infrequent dosing schemes in combination with non-adherence, may 
lead to dangerously low clotting factor trough levels with increased risk of bleeding [21].
Although recognized as important, a recent study by Chan et al. indicated that up to 
18% of haemophilia professionals do not assess adherence in the clinical setting at all 
[22]. This is most likely due to the lack of accurate and inexpensive instruments to quan-
Adherence in hemophilia
50
  C
ha
pt
er
 3
tify adherence [23]. Healthcare professionals therefore rely on their personal judgment 
when evaluating treatment adherence; which has proven unreliable repetitively [24].
A valuable tool to quantify adherence in haemophilia is the Validated Haemophilia Regi-
men Treatment Adherence Scale - Prophylaxis (VERITAS-Pro), developed and validated 
by Duncan et al. (2010) in the United States [25]. This initiative combines qualitative 
research with quantitative survey techniques and has led to a time-efficient and feasible 
instrument to monitor adherence to prophylaxis, applicable in all age groups [26]. 
Until now, VERITAS-Pro has only been validated in the United States. However, to prove 
reproducibility and to promote broader application, it is necessary to validate it in other 
populations that differ with regard to language, culture and healthcare organization. 
In this study, we aimed to validate the Dutch-translated version of the VERITAS-Pro 
cross-culturally and analyse treatment adherence in a Dutch paediatric haemophilia 
population.
PaTIEnTS anD METHODS
Patients
In this cross-sectional, Dutch multicentre study data were collected as part of a larger pro-
spective study on the efficacy of home-treatment intervention by a trained haemophilia 
nurse (Dutch Trial Register: 2543). Between June 2010 and December 2011, we enrolled 
children aged 1 to 18 years with haemophilia A or haemophilia B on prophylactic home 
treatment for at least 1 year, and their parents from three Dutch Haemophilia Treatment 
Centres (HTC). Patients and parents with language difficulties and patients with inhibi-
tors were excluded. One caregiver, primarily involved in daily haemophilia treatment, 
and adolescents aged 10 to 18 years, were asked to complete the web-based question-
naire. To evaluate test-retest reliability of VERITAS-Pro, questionnaires were sent 2 weeks 
after the first administration to consenting participants. Participants not returning the 
questionnaire within 2 weeks received reminders and were considered lost to follow-up 
after two unreturned messages. The Medical Ethical Committee granted permission to 
perform the study and written informed consent was obtained [MEC-2010-097].
Data collection
Socio-demographic data were registered. For level of education the International Stan-
dard Classification of Education (ISCED) division into low (ISCED 0-2; less than upper 
secondary level), medium (ISCED 3-4; upper secondary level) and high educational level 
was applied (ISCED 5-6; tertiary level or the achievement of two more years after upper 
Adherence in hemophilia
51
  C
ha
pt
er
 3
secondary level) [27]. Haemophilia diagnosis, treatment and pharmacy dispensations 
were recorded. Infusion log data and bleedings were collected when available.
adherence
VERITAS-Pro
To quantify treatment adherence in children utilizing prophylaxis, we used the VERITAS-
Pro scale, which takes approximately 10 minutes to complete [25]. This instrument con-
sists of six subscales, concerning a specific domain of haemophilia care. Each subscale 
is represented by four questions, leading to a total of 24 items (Table 2). VERITAS-Pro 
evaluates the necessity and dosing of clotting factor concentrate (subscales: ‘Time’, 
‘Dose’) in relationship to prior prophylactic doses (subscales: ‘Remember’, ‘Skip’), and if 
the patient’s HTC was contacted (subscale: ‘Communicate’). Also, management of clot-
ting factor infusion and stock is monitored (subscale: ‘Plan’). Each item is quantified on a 
five-point Likert scale ranging from ‘Always’ to ‘Never’. Each rating on the five-point scale 
is given a numeric score, so that the response indicating the ‘best’ adherence scores 
one point and the response indicating the ‘worst’ adherence scores five points. Total 
cumulative score ranges from 24 to 120, with cumulative scores per subscale ranging 
from 4 to 20. Higher scores reflect lower adherence. We translated VERITAS-Pro into 
Dutch according to international guidelines with two forward (AdG and RvA) and two 
backward translations by native speakers (KS and MC) [28].
Self-reported infusion log
Adherence was also determined on the basis of prescribed prophylaxis and prophylactic 
infusions deduced from self-reported infusion logs, in relationship to recorded bleeds. 
Infusion log data were only included in statistical analyses if less than one-third of the 
data in the patient-reported infusion logs were missing [25]. We calculated the percent-
age of weeks per year that the patient was adherent according to prescribed therapeutic 
regimen related to reported (i) frequency of infusions; (ii) interval between two or three 
consecutive infusions; and (iii) total amount of clotting factor. Patients with an adher-
ence score ≤ 75% were considered to have low adherence, those with scores > 75% were 
considered to display high adherence, based on earlier studies [9, 10, 15, 25, 29]. Bleeds 
were recorded in infusion logs and medical records.
Data analysis
Psychometric properties of VERITAS-Pro
VERITAS-Pro scores were described by conventional descriptive statistics.
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Reliability
To evaluate consistency of results across items we determined internal consistency reli-
ability using Cronbach’s alpha. Assuming that test items measuring the same construct 
are correlated [30], we chose 0.70 to be an adequate alpha coefficient [31, 32]. Homoge-
neity of VERITAS-Pro was evaluated on the basis of inter-item correlations, which deter-
mines the correlation between each item and the subscale to which this item belongs. 
Inter-item correlations > 0.20 are generally acceptable [30, 33, 34]. Average inter-item, 
average item-own scale and average item-other scale correlations were assessed with 
standardized correlation coefficients.
To test reproducibility and consistency over time we determined test-retest reliabil-
ity with Spearman effect size correlation coefficients (r) for non-parametric data; it 
assumes there will be no change in the construct measured. The agreement between 
the perceived adherence of parents and adolescents was also assessed by Spearman 
correlation [35]. According to established guidelines, concordance was determined as 
poor (< 0.30), moderate (0.30-0.50), or good (> 0.50) [36]. To test stability of scores, we 
used the rank-sum test to evaluate whether scores of aggregate test-retest reliability 
and inter-rater agreement groups systematically changed over time or between parents 
and adolescents.
Validity
Validity is the extent to which a test measures what it intends to measure. To determine 
the degree to which two constructs that are theoretically related practically relate within 
the test, we assessed the convergent validity [37]. It was hypothesized that patients with 
a high adherence according to infusion log documentation would report better adher-
ence outcomes, thus lower VERITAS-Pro scores. In addition, that patients with the lowest 
quartile annual bleeding rate would report better adherence outcomes than patients 
with the highest quartile annual bleeding rate. Differences in median total scores were 
calculated and tested with Wilcoxon test, as a consequence of non-parametric data.
Data were analysed separately for parent-reported and adolescent-reported scales, 
except for the inter-rater agreement analysis which compared adolescent-reported with 
parent-reported scales. We considered P-values < 0.05 as statistically significant; all tests 
were two-sided. All analyses were performed using SPSS 20.0 for Windows (IBM Corp., 
Armonk, NY, USA).
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RESULTS
Parent-reported questionnaires
Participants
Seventy-one children and their parents were eligible for the study; eleven refused 
participation or did not complete the questionnaire. The remaining 60 parent-reported 
questionnaires were analysed (response 85%). All sixty children were male with mean 
age of 10 years (SD = 4.1). The majority had severe haemophilia A with a mean annual 
bleeding rate of 4.9 (SD = 7.3). Mean duration of prophylactic treatment was 7 years (SD 
= 3.6) (Table 1).
Psychometric properties
Median scores on the different scales for the parent-report questionnaire were relatively 
low (4-7). Scores were the highest for subscales ‘Plan’ and ‘Communicate’. Floor effects 
ranged from 20-57% and were observed most often in subscales ‘Dose’ and ‘Skip’. No 
ceiling effects were observed (Table 3A).
The Cronbach’s alpha mean over subscales was α = 0.71 (range = 0.01-0.79). The scales 
‘Time’ and ‘Dose’ showed the lowest Cronbach’s alpha scores (α = 0.38 and α = 0.01 
respectively). The homogeneity of the VERITAS-Pro determined by average inter-item 
correlations was adequate for total score and subscales ‘Plan’, ‘Remember’, ‘Skip’ and 
‘Communicate’ (range = 0.32-0.47, mean r = 0.30). Average inter-item correlation was 
lower for domains ‘Time’ (r = 0.18) and ‘Dose’ (r = 0.01). Scaling assumptions were met 
since all item-own scale correlations were considerably stronger than corresponding 
item-other scale correlations (Table 3A).
Test-retest Spearman’s rho ranged from 0.45 to 0.85 and were significant for all scales (P 
< 0.01), except for ‘Dose’. Scores did not significantly change over time (Table 4A).
In 32 patients, adequate infusion logs were available. Infusion log data in one HTC were 
not documented regularly and one participant was excluded due to underreporting of 
infusions. Median adherence with regard to reported (i) frequency of infusions per week 
was 90.7% [Interquartile range (IQR) = 73.3-94.1%]; (ii) interval between consecutive 
infusions was 91.1% (IQR = 79.7-95.9%); and (iii) total amount of clotting factor was 100% 
(IQR = 96.2-100%).
Patients with low adherence according to reported frequency of infusions showed signifi-
cantly higher VERITAS-Pro scores for total score and subscales ‘Time’, ‘Remember’, ‘Skip’, 
and ‘Communicate’, but not for subscales ‘Dose’ and ‘Plan’. Patients with low adherence 
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Table 1. Characteristics of the 60 participants at the time of study enrolment.
Characteristics N (%)
Patient characteristics
Age patients (years), mean (SD) 10.0 (4.1)
Sex patients, male 60 (100.0)
Diagnosis
Haemophilia A 49 (81.7)
Haemophilia B 11 (18.3)
Disease severity
Severe (<1%) 53 (88.3)
Moderate (1-5%) 6 (10.0)
Mild (6-40%)# 1 (1.7)
Duration of prophylactic treatment (years), mean (SD) 7.0 (3.6)
Annual bleeding rate, mean (SD) 4.9 (7.3)
Parent characteristics
Age parents (years), mean (SD) 39.3 (7.6)
Level of education$, &
Low 8 (14.0)
Medium 36 (63.2)
High 13 (22.8)
Marital status
Married/ registered partnership 33 (56.9)
Unmarried 12 (20.7)
Widow/ widower 2 (3.4)
Divorced 11 (19.0)
Family composition$
Living with partner and child(ren) 45 (77.6)
Single with child(ren) 12 (20.7)
Other 1 (1.7)
Individual completing scale$
Mother/ female guardian 52 (89.7)
Father/ male guardian 6 (10.3)
Adolescent 30 (50.0)
# On prophylactic treatment due to bleeding tendency due to concomitant von Willebrand disease; $ Of 
two participants no information is available on marital status, family composition and individual complet-
ing questionnaire. Of three participants no information is available on level of education; & The usual ISCED 
division into Low, Medium and High is adopted here, as in the Eurostat Labour Force Survey. Low is equiva-
lent to ISCED 0-2, i.e. less than upper secondary level of education. Medium is given by ISCED 3-4, i.e. up-
per secondary level. High is ISCED 5-6, meaning tertiary level, or two more years of education after upper 
secondary level [27].
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Table 2. Subscales and items evaluated by the VERITAS-Pro scale.#,$
‘Time’
1 I do prophylaxis infusions on the scheduled days.
2 I infuse the recommended number of times per week.
3 I do prophylaxis infusions in the morning as recommended.
4 I do infusions according to the schedule provided by the treatment center.
‘Dose’
5 I use the doctor-recommended dose for infusions.
6 I infuse at a lower dose than prescribed.
7 I increase or decrease the dose without calling the treatment center.
8 I use the correct number of factor boxes to total my recommended dose.
‘Plan’
9 I plan ahead so I have enough factor at home.
10 I keep close track of how much factor and how many supplies I have at home.
11 I run out of factor and supplies before I order more.
12 I have a system for keeping track of factor and supplies at home.
‘Remember’
13 I forget to do prophylaxis infusions.
14 Remembering to do prophylaxis is difficult.
15 I remember to infuse on the schedule prescribed by the treatment center.
16 I miss recommended infusions because I forget about them.
‘Skip’
17 I skip prophylaxis infusions.
18 I choose to infuse less often than prescribed.
19 If it is inconvenient to infuse, I skip the infusion that day.
20 I miss recommended infusions because I skip them.
‘Communicate’
21 I call the treatment center when I have questions about haemophilia or treatment.
22 I call the treatment center when I have haemophilia-related health concerns or when changes occur.
23 I make treatment decisions myself rather than calling the haemophilia center.
24 I call the treatment center before medical interventions, such as dental extractions, colonoscopies, visits 
to the emergency room, or hospital stays.
# Answer options (5): Always (all of the time, 100% of the time); Often (most of the time, at least 75% of the 
time); Sometimes (occasionally, at least 50% of the time); Rarely (not often, 25% of the time); Never (not at 
all, 0% of the time); $ Reproduced with permission from Ref 25.
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according to reported interval between consecutive infusions showed significantly 
higher VERITAS-Pro scores on subscale ‘Remember’, but not on other scales. Patients with 
low adherence according to reported total amount of clotting factor showed significantly 
higher VERITAS-Pro scores on subscales ‘Time’, but not on other scales (Table 3A).
No significant differences on VERITAS-Pro scores, both parent-reported and adolescent-
reported were seen between patients with lowest number of annual bleedings (lowest 
quartile) and patients with highest number of annual bleedings (highest quartile) (data 
not shown).
Adherence to prophylactic clotting factor replacement therapy according to VERITAS-
Pro total score and subscale ‘Time’ was significantly lower in patients with higher age 
(respectively r = 0.27, P = 0.04; r = 0.30, P = 0.02) and in patients with longer duration of 
prophylactic treatment (respectively r = 0.29, P = 0.03; r = 0.31, P = 0.02), and not associ-
ated with level of education. Single parents reported significantly lower adherence on 
subscale ‘Remember’ (median = 7.5, IQR = 4.5-8.0) than those who living with a partner 
Table 4. Test-retest reliability of the VERITAS-Pro scale.
(a) Parent report
(Sub)scales
Test (n = 41)
 Median [IQR]
Retest (n = 41) 
Median [IQR]
P-Value 
(wilcoxon)
Spearman’s 
Correlation
Total scale 38.0 [30.5-43.5] 38.0 [30.5-41.5] 0.28 0.69**
Time 6.0 [4.0-7.0] 5.0 [4.0-7.0] 0.44 0.75**
Dose 5.0 [4.0-6.0] 5.0 [4.0-5.0] 0.63 0.10
Plan 8.0 [4.0-10.0] 8.0 [4.0-9.5] 0.28 0.85**
Remember 5.0 [4.0-8.0] 4.0 [4.0-6.0] 0.06 0.45**
Skip 4.0 [4.0-6.0] 4.0 [4.0-6.0] 0.55 0.72**
Communicate 6.0 [5.0-11.5] 7.0 [5.0-11.0] 0.89 0.57**
** Correlation is significant at the 0.01 level (2-tailed).
(b) adolescent report
(Sub)scales
Test (n = 41),
Median [IQR]
Retest (n = 41),
Median [IQR]
P-Value 
(wilcoxon)
Spearman’s 
Correlation
Total scale 42.0 [39.5-50.5] 10.0 [35.0-47.0] 0.12 0.07
Time 6.0 [4.0-7.0] 5.0 [4.0-6.5] 0.84 0.62**
Dose 5.0 [4.0-7.0] 5.0 [4.0-6.0] 0.19 0.50*
Plan 10.0 [7.5-12.5] 10.0 [6.5-13.0] 0.51 0.54*
Remember 5.0 [4.0-6.5] 6.0 [4.0-7.0] 0.63 0.47
Skip 5.0 [4.0-5.5] 4.0 [4.0-6.0] 0.46 0.17
Communicate 5.0 [7.0-16.0] 8.0 [5.5-13.0] 0.13 0.26
* Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed).
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(median = 4.0, IQR = 4.0-7.0; P = 0.04); no significant differences were reported on the 
other scales.
adolescent-reported questionnaires
Participants
Forty adolescents, aged 10-18 years were eligible for the sub-study. Ten were unwill-
ing to participate or did not complete the web-based questionnaire. The remaining 30 
adolescent-reported questionnaires were analysed (response rate 75%).
The mean age of male adolescents was 13.5 years (SD = 2.5); the majority had severe 
haemophilia A; mean duration of prophylactic treatment was 9.8 years (SD = 3.0).
Psychometric properties
Median scores for the adolescent report were somewhat higher than the parent report 
(5-10). The highest scores were found for subscales ‘Plan’ and ‘Communicate’. Floor ef-
fects ranged from 13% to 50% and were observed most often in subscales ‘Dose’ and 
‘Skip’. A ceiling effect of 3% was observed in subscale ‘Plan’ (Table 3B).
Internal consistency was generally adequate with mean Cronbach’s alpha of 0.70 on 
the subscales (range = 0.39-0.73). Subscales ‘Time’ and ‘Dose’ had the lowest Cronbach’s 
alpha scores (α = 0.46 and α = 0.39 respectively). Average inter-item correlations were 
adequate for total score and subscales ‘Plan’, ‘Remember’, ‘Skip’ and ‘Communicate’ 
(range = 0.25-0.52, mean r = 0.27), but were lower for subscales ‘Time’ (r = 0.13) and ‘Dose’ 
(r = 0.14). All item-own scale correlations were considerably higher than corresponding 
item-other scale correlations (Table 3B).
Adolescents’ test-retest Spearman correlations were significant for subscales ‘Time’ 
(r = 0.62, P < 0.05), ‘Dose’ (r = 0.50, P < 0.01), and ‘Plan’ (r = 0.54, P < 0.01). No significant 
test-retest correlation was observed for the total scale and subscales ‘Remember’, ‘Skip’, 
and ‘Communicate’. Scores did not change significantly over time (Table 4B).
Sixteen of the 30 adolescent patients had infusion logs available. Median adherence 
with regard to reported frequency of infusions per week was 88.6% (IQR = 73.2-96.9%); 
interval between consecutive infusions was 93.0% (IQR = 81.5-96.0%); total amount 
of clotting factor was 100% (IQR = 95.6-100%). In this subgroup, the sum scores per 
subscale did not correlate significantly with adherence scores recorded by infusion logs 
(Table 3B).
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Adherence to prophylaxis according to the adolescent-report of VERITAS-Pro was not as-
sociated with age or education. Adherence on subscale ‘Time’ was significantly lower in 
adolescents on longer duration of prophylactic treatment (r = 0.43, P = 0.02). Adherence 
on subscale ‘Skip’ is significantly lower in adolescents with a single parent than in fami-
lies with non-single parents (respectively median 6.0 and 4.0; P < 0.01); no significant 
differences were reported on the other scales.
Inter-rater agreement
Inter-rater agreement between parents and adolescents showed a significant correla-
tion for subscales ‘Time’, ‘Remember’, ‘Skip’ and ‘Communicate’ (Spearman correlation 
range = 0.39-0.56, P < 0.05), but not for total scale (r = 0.19) and subscales ‘Dose’ (r = 
0.19) and ‘Plan’ (r = 0.26).
DISCUSSIOn
Adherence is of utmost importance in haemophilia treatment to ensure quality of life 
by decrease of morbidity due to joint arthropathy. Therefore, a reliable tool to routinely 
measure adherence is urgently required. The adequate psychometric properties shown 
by our data confirm that the VERITAS-Pro by Duncan et al. [25] is a reliable and feasible 
tool to quantify adherence from a Dutch paediatric perspective. The internal consistency 
of the total scale and almost all subscales is adequate. Moreover, test-retest reliability 
and the ability of the instrument to discriminate between high and less optimal treat-
ment adherence shows promising results.
Strengths and limitations
Feasibility is illustrated by the optimal acceptance of VERTIAS-Pro by the study popula-
tion as judged by the high response rate [11]. However, although the VERITAS-Pro was 
adapted by an interdisciplinary panel of experts, critical appraisal by respondents was 
omitted. Possibly, readability and perceived relevance could have been even greater if 
applied. Although the population tested by Duncan et al. was older and more hetero-
geneous in terms of age (mean 10 ± 4.1 compared to mean 15.2 ± 12.7 years), our data 
still shows that VERITAS-Pro is valid and reliable and applicable in varying populations. 
VERITAS-Pro was validated using patient infusion log data, in line with previous studies 
[10, 25]. Although the representativeness of a home infusion log has been questioned, 
we still regard it as essential, as there is no alternative and ethical method [38]. In one 
participant, infusion log data were excluded due to underreporting; therefore, selection 
bias could have occurred in favour of more adhering patients. Unfortunately, analyses of 
subgroups were limited by low number of participants.
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Psychometric properties and scores
VERITAS-Pro scores in the Dutch study population were somewhat higher than those 
from the United States, especially in subscales ‘Plan’ and ‘Communicate’, representative 
of less adherence. This may be explained by socio-demographic data and cultural dif-
ferences between populations, such as age, duration of prophylactic treatment, fam-
ily composition, and a tendency of Dutch haemophilia professionals to focus on self-
management [14, 23, 39]. Although the HTCs in the United States and the Netherlands 
provide high quality of care, transcontinental differences in care are most probably due 
to shorter distances to the HTCs in the Netherlands. Hypothetically, the more frequent 
regular HTC visits may paradoxically lead to greater patient- and parent autonomy with 
more emphasis on self-management as there may be more trust and the HTC is always 
nearby in case of problems.
Pronounced skewing towards greater adherence with a floor effect of more than 50% 
was seen in subscales ‘Dose’ and ‘Skip’. This phenomenon is unavoidable, but limits dis-
crimination among participants with a high perceived adherence and restricts detection 
of change in follow-up assessments in this subgroup [40].
VERITAS-Pro’s internal consistency was adequate and almost similar to the original 
survey, with exception of subscales ‘Time’ and ‘Dose’ [25]. Methodically, a lower Cron-
bach’s alpha in these subscales may be due to high floor effects and a small amount of 
random variance caused by the more homogeneous Dutch population [41]. In addition, 
the higher percentage of adolescents in our sample may have influenced reliability as 
adolescents often share responsibility for treatment with parents [17].
VERITAS-Pro test-retest reliability was adequate for all subscales, except for subscale 
‘Dose’. The most probable explanation is the high floor effect with small amounts of 
random variation and lower internal consistency of this subscale. As our study did not 
assess the VERITAS-Pro’s responsiveness to change, further studies with a repeated-
measures design in more varied samples are required [42].
Total score and most subscales were supported by the validity analysis. Particular atten-
tion should be paid to ‘Dose’ and ‘Plan’ subscales and items considering these subscales 
in future analysis. Overall, only five scale items (2, 5, 6, 9, and 21) failed to show any 
correlation at a P < 0.10 level with any of the validity indices (data not shown). In these 
items, there were indications of their potential value from either restricted range or 
internal consistency analyses. Retention of all items on the VERITAS-Pro at this time is 
therefore supported by either the validity or reliability data. No significant difference 
was found in median VERITAS-Pro scores between patients with lowest and highest 
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bleeding rates. However, this analysis is most likely affected by low bleeding incidence 
in our population.
The lower adherence score in adolescents is most likely explained by shared responsibil-
ity with regard to haemophilia treatment [25, 43]. This may also explain lower reliability 
and validity scores for the adolescent report and the lower agreement between per-
ceived adherence of parents and adolescents. The latter is not surprising, as quality of 
life studies with proxy observations regularly show divergent answers between parents 
and adolescents which is explained by a variety of different factors [44-46]. Therefore, 
both views are of importance for insights in actual adherence. Moreover, monitoring 
of adherence in adolescence may prove an important tool in the transitional process 
towards adult care, measuring the magnitude of adherent behaviour and pinpointing 
areas in need of improvement.
Conclusion
Our data support that the VERITAS-Pro is a valuable tool to quantify and specify adher-
ence to haemophilia treatment also in the Netherlands and therefore in other Western 
European countries in which prophylactic treatment is common.
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abSTRaCT
background Higher self-efficacy in chronic disease patients is associated with higher 
development of self-management skills and increased quality of life. Quantification 
and monitoring of self-efficacy is therefore of importance. Self-efficacy in haemophilia 
patients has received little attention due to lack of standardized scales.
aim To validate the novel Haemophilia-specific Self-Efficacy Scale (HSES) in haemophilia 
patients on prophylactic home treatment.
Patients and Methods Haemophilia patients aged 1-18 years on prophylactic treat-
ment ≥1 year were included from three Dutch Haemophilia Treatment Centres. The HSES 
consists of 12 items, relating to perceptions of the ability to function on a day-to-day 
basis with regard to patient’s disease. Retest was performed in a subsample. Validity 
was proven by the General Self-Efficacy Scale and by the health-related quality of life 
assessment tool Haemo-QoL.
Results Data were analysed from 53 children (response 75%), with a mean age of 9.8 
years (SD = 4.0). Mean total scale score of HSES was 55.5 (SD = 4.7; range = 38–60), with a 
ceiling effect of 17%. The HSES showed adequate internal consistency (Cronbach’s alpha 
0.72) and good test-retest reliability (Intra-Class-Correlation coefficient 0.75; P < 0.01; n = 
37). The convergent validity was adequate as haemophilia-specific self-efficacy correlated 
significantly with general self-efficacy (r = 0.38; P < 0.01). High HSES scores correlated 
significantly with quality of life as measured by the Haemo-QoL (r = -0.42; P = < 0.01).
Conclusion The novel HSES is a reliable and valid tool to assess self-efficacy in paediatric 
haemophilia patients on prophylactic home treatment. High self-efficacy correlated with 
higher quality of life, further underlining the importance to standardly assess, monitor 
and improve self-efficacy.
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InTRODUCTIOn
In haemophilia, as in other chronic diseases, self-management skills of patients and 
caretakers are of relevance for treatment adherence, prognosis of disease, and quality of 
life [1]. Prophylactic replacement therapy with clotting factor concentrate in the home 
setting requires a high ability of self-management as organization of care is complex 
[2, 3]. It includes insight on the necessity and dosing of clotting factor concentrate, 
taking prior prophylactic doses into account. Also practical and logistic capacities are 
of significance with regard to clotting factor concentrate infusion, stock and timely com-
munication with the Haemophilia Treatment Centre (HTC).
Bandura developed the concept of ‘self-efficacy’. This term describes the actual confi-
dence an individual possesses with regard to specific actions necessary to achieve cer-
tain results [4]. It summarizes the integration of a motivated attitude towards a disease 
and its treatment, a capacity towards adequate judgment with regard to therapeutic 
interventions and demonstration of adherence to prescribed therapy [5]. Patients with 
low self-efficacy are less likely to persevere in a specific task when impediments arise, 
obliterating usual proceedings. Those with high self-efficacy will deploy all abilities to 
master obstacles. In clinical practice, self-efficacy is considered an antecedent for modi-
fication of behavior [6, 7]. Furthermore, development of disease-specific self-efficacy 
questionnaires is required to take disease-specific aspects into account not dealt with 
by the current validated general questionnaire.
In various chronic diseases high levels of self-efficacy are associated with higher quality-
of- life and less clinical and psychological symptoms [6, 8-10]. In addition, Richardson et 
al. reported that patients with a wide range of chronic diseases value self-efficacy highly, 
and are willing to trade reductions in health-related quality of life for improvements 
in their self-efficacy [11]. In haemophilia, a number of studies have evaluated general 
self-efficacy and possible training modules, but few have looked at disease-specific self-
efficacy.
Kang et al. proved that a self-help program for mothers of children with haemophilia 
significantly improved knowledge, self-efficacy, and quality of life [12, 13]. Mulders et 
al. reported that an educational e-learning program in patients on prophylactic home 
treatment significantly improved general knowledge of treatment [14]. However, in 
this cohort, self-efficacy scores were relatively high at initiation and did not increase 
after intervention. Conflicting results were found by Barlow et al. and Buxbaum et al., 
as the first documented high levels of self-efficacy in haemophilia patients, indicating 
a well-developed confidence with regard to disease management, whereas the latter 
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found lower self-efficacy scores in haemophilia patients than in healthy controls [15, 
16]. All studies were performed using a general self-efficacy scale or a non-validated 
Haemophilia-specific Self-Efficacy Scale (HSES) as there is no validated HSES available. To 
adequately quantify and monitor self-efficacy and to identify subgroups at risk of higher 
morbidity and decreased quality of life, the HSES was recently developed and validated. 
This study aims to describe the psychometric properties of this novel instrument and 
the association between HSES and quality of life.
PaTIEnTS anD METHODS
Patients
Data for this cross-sectional, multicentre study were collected as part of a larger pro-
spective study on the efficacy of home-treatment intervention by a trained haemophilia 
nurse (Netherlands Trial Register: 2543). Between June 2010 and December 2011, we 
enrolled children aged 1-18 years with haemophilia A or haemophilia B on prophylaxis 
and home treatment for at least 1 year, from three HTC’s in the Netherlands (Erasmus 
Medical Centre - Sophia Children’s Hospital, Rotterdam; Academic Medical Centre - 
Emma Children’s Hospital, Amsterdam; University Medical Centre Groningen). Patients 
and parents were required to speak and understand Dutch sufficiently. Patients with 
inhibitors against FVIII or FIX were excluded. One caregiver, primarily involved in the 
child’s daily haemophilia treatment, and adolescents aged 10-18 years were asked to 
complete the questionnaire. To evaluate test-retest reliability of HSES, the questionnaire 
was sent two weeks after administration of the first questionnaire to consenting partici-
pants. Participants not returning the questionnaires within 2 weeks received reminders 
and were considered lost to follow-up after two unreturned messages. The Medical Ethi-
cal Committee granted permission to perform the study and written informed consent 
was obtained [MEC-2010-097].
Data collection
Socio-demographic data, including parental level of education, employment status, and 
family structure were provided. For level of education the International Standard Clas-
sification of Education (ISCED) division into low, medium and high educational levels 
was applied [17]. Low is equivalent to ISCED 0-2, i.e. ‘less than upper secondary level’; 
medium to ISCED 3-4, i.e. ‘upper secondary level’; and high to ISCED 5-6, meaning ter-
tiary level, or minimally two years of education after upper secondary level. Haemophilia 
diagnosis, treatment and clotting factor consumption were extracted from medical files.
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Self-Efficacy
Haemophilia-specific Self-Efficacy Scale 
To specify disease-specific self-efficacy qualities, a novel scale was developed and 
validated, specifically for haemophilia patients. The HSES was composed by a team of 
haemophilia professionals and psychologists with items from the validated Sickle Cell 
Self-Efficacy Scale [8, 18], from the Pain Self-Efficacy Questionnaire [19], and from the 
validated General Self-Efficacy Scale [20, 21]. The first two questionnaires were used 
as they specifically encompass disease aspects such as periodic immobilization and 
pain. The novel HSES consists of 12 items focusing on an individual’s perceptions of 
haemophilia disease symptoms and the patient’s abilities to cope with or reduce these 
symptoms (see Appendix S1). In our view, all aspects of treatment are incorporated: 
treatment efficacy, quality of life, infusion technique, state of mind in case of a bleed, 
pain modification, confidence, modification of prophylactic regimen, continuation of 
daily activities, other therapeutic interventions besides clotting factor treatment, belief 
in leading of a normal life, communication, and attainment of personal goals. Items are 
scored ranging from ‘I totally disagree’ to ‘I totally agree’ (see figure). On a five-point 
Likert-scale, the lowest score was given one point and the highest score five points. An 
unweighted sum score was calculated by adding the 12 item scores, with higher scores 
indicating greater self-efficacy (range: 12-60).
General Self-Efficacy Scale 
To assess the convergent validity of the HSES, we used the validated General Self-Efficacy 
Scale (GSES) [20, 21]. The GSES consists of 10 items on a four-point Likert-scale, ranging 
from ‘I totally disagree’ to ‘I totally agree’, with sum scores ranging from 10 to 40. Higher 
scores also indicate greater general self-efficacy. Although self-efficacy is considered 
to be task-specific, we assumed the concepts of general self-efficacy and haemophilia-
specific self-efficacy to be related, which is supported by literature in other diseases, 
when assessing self-efficacy [22].
Haemo-QoL
The disease-specific quality of life instrument Haemo-QoL was used to assess the diver-
gent construct validity. This is a self-report measure for children with haemophilia and 
their parents, consisting of 21-77 items which cover 9 to 11 domains depending on the 
age group of the patient. Higher scores indicate lower disease-specific quality of life [23].
VERITAS-Pro
To quantify treatment adherence in children on prophylaxis, we used the Validated 
Haemophilia Regimen Treatment Adherence Scale - Prophylaxis (VERITAS-Pro) [2, 3]. 
This instrument contains six subscales (‘Time’, ‘Dose’, ‘Plan’, ‘Remember’, ‘Skip’, ‘Communi-
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cate’), each represented by four questions concerning a specific domain of haemophilia 
patient care. Cumulative score of all subscales ranges from 24 to 120 and cumulative 
scores per subscale range from 4 to 20. Lower scores reflect higher adherence.
Data analysis
Psychometric properties of HSES
The following psychometric properties of the HSES were evaluated: feasibility, reliability 
and validity (convergent and divergent validity). Feasibility was expressed as response 
rate. Scale scores were described in terms of scale mean, SD, range, floor and ceiling 
effects, and percentiles.
The total scale internal consistency reliability was assessed using Cronbach’s alpha. 
Amidst varying standards in the literature, we considered 0.70 to be an acceptable alpha 
coefficient [24].
The test-retest reliability was assessed by the Intra-Class-Correlation Coefficients (ICC). 
The agreement between the perceived haemophilia-specific self-efficacy of parents and 
adolescents was also assessed by the ICC.
Validity was assessed by comparing HSES outcomes with the validated GSES and the 
Haemo-QoL. It was hypothesized that a low HSES outcome should correlate with low 
self-efficacy outcomes on the GSES and a low quality of life (i.e. higher score) by Haemo-
QoL. As data were not normally distributed correlations in overall median sum scores 
were calculated and tested with Spearman’s correlation coefficient. Low haemophilia-
specific self-efficacy was defined as the lowest quartile of HSES scores, while high 
haemophilia-specific self-efficacy was defined as the highest quartile of HSES scores as 
data were not distributed normally.
Subgroup analyses were assessed by comparing HSES outcomes with age, duration of 
prophylactic home treatment, number of siblings, level of education, marital status, and 
family composition. We compared the patient group with the lowest quartile of HSES 
scores with the patient group with the highest quartile of HSES scores. Due to non-
parametrical data, the continuous outcomes were assessed using the Mann-Whitney 
U-test and categorical data were analysed by Chi-square test or the Fisher’s exact test in 
case of low patient counts per subgroup.
Data were analysed separately for parent-reported and adolescent-reported scales, 
except for the inter-rater agreement analysis which compared adolescent-reported with 
parent-reported scales.
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We considered P-values < 0.05 as statistically significant; all tests were two-sided. All 
analyses were performed using SPSS 20.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
Participants
A total of 71 patients of which 40 adolescents (10-18 years) were invited for study partici-
pation. Eighteen parents of children, including parents of 12 adolescents declined or did 
not fill out the questionnaire. Reasons for non-participation included time burden, and 
logistical reasons. Fifty-three parents of both young children and adolescents (parent-
reported questionnaires; response 75%) and 28 adolescents (adolescent-reported ques-
tionnaires; response 70%) participated. Table 1 describes the baseline characteristics of 
all participants.
All 53 children were male with a mean age of 9.8 years (SD = 4.0), 81% were diagnosed 
with haemophilia A, 89% had severe haemophilia. Of the 53 children, 28 were adoles-
cents. The mean age of this subgroup was 13.6 (SD = 2.5). Mean duration of prophylactic 
treatment was 7.1 years (SD = 3.6), with a median time span between prophylaxis initia-
tion and start of the home treatment of 0.5 years. Of the 53 parents, the majority was 
female (88%), 8% were educated at a low level, 20% were single parents, and 30% had 
two children or more.
Psychometric properties of the HSES
Table 2 displays the total scale scores. Mean total scale scores were relatively high (55.5 
for the parent report and 55.7 for the adolescent report) as were the median scores (57.0 
for both the parent report and the adolescent report). Floor effects were absent. Ceiling 
effects were observed in 17% of the parents and in 29% of the adolescents.
The Cronbach’s alpha of the total scale was α = 0.72 for the parent report and α = 0.86 for 
the adolescent report, indicating an adequate internal consistency (Table 2).
The test-retest reliability showed promising results, with a ICC of 0.75 (95%CI = 0.56:0.86; 
P < 0.01; n = 37) for the parent report and 0.67 (95%CI = 0.29:0.87; P < 0.01; n = 17) for the 
adolescent report. For the parent report there was no significant difference between the 
test (mean = 55.70; SD = 4.16) and the retest (mean = 55.88; SD = 4.87; P = 0.34); also the 
adolescent report showed identical results (test mean = 55.88; SD = 4.87; retest mean = 
55.18; SD =  3.89; P = 0.37). The agreement between the perceived haemophilia-specific 
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self-efficacy of parents and adolescents was however not significant (ICC = -0.05; 95%CI 
= -0.43:-0.35; P = 0.59).
Table 1. Characteristics of the 53 participants at the time of study enrolment.
Characteristics N (%)
Patient characteristics
Age patients (years), mean (SD) 9.8 (4.0)
Sex patients, male 53 (100)
Diagnosis
  Haemophilia A 43 (81)
  Haemophilia B 10 (19)
Severity of haemophilia
  Severe (<1%) 47 (89)
  Moderate (1-5%) 5 (9)
  Mild (6-40%)# 1 (2)
Duration of prophylactic treatment (years), mean (SD) 7.1 (3.6)
Parent characteristics
Age parents (years), mean (SD) 39.8 (7.0)
Level of education$,&
Low level of education 4 (8)
  Medium level of education 33 (66)
  High level of education 13 (26)
Marital status$
  Married/ registered partnership 11 (22)
  Unmarried 30 (59)
  Widow/ widower 2 (4)
  Divorced 8 (16)
Family composition$
  Living with partner and child(ren) 40 (78)
  Single with child(ren) 10 (20)
  Other 1 (2)
Individual completing scale$
Mother/female guardian 45 (88)
Father/male guardian 6 (12)
Adolescent 28 (53)
# On prophylactic treatment due to bleeding tendency due to concomitant von Willebrand disease; $ Of 
two participants no information is available on marital status, family composition and whom filled out the 
questionnaire. Of three participants no information is available on level of education; & The usual ISCED divi-
sion into Low, Medium and High is adopted here, as in the Eurostat Labour Force Survey. Low is equivalent 
to ISCED 0-2, i.e. ‘less than upper secondary level of education’. Medium is given by ISCED 3-4, i.e. ‘upper 
secondary level’. High is ISCED 5-6, meaning tertiary level, or two more years of education after upper sec-
ondary level [17].
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Significant Spearman’s correlations were observed with the General Self-Efficacy Scale 
(parent report: r = 0.43; P < 0.05; adolescent report: r = 0.81; P < 0.01). For the quality 
of life determined by the Haemo-QoL, the correlation of the total score was only sig-
nificant for the parent-report of the HSES (r = -0.45; P < 0.01) and not significant for the 
adolescent-report HSES (r = 0.02; P = 0.92). Parents with a higher perceived self-efficacy 
(HSES) reported significantly less adherence with regard to subscales ‘Plan’, ‘Remember’ 
and ‘Communication’ on the VERITAS-Pro scale when compared with parents with a 
lower perceived self-efficacy (respectively r = -0.28; r = -0.29; r = 0.37; P < 0.05). No other 
correlations were seen between the HSES (parent report), the HSES (adolescent report) 
and other VERITAS-Pro (sub)scales (Table 3).
Parents with HSES scores in the lowest quartile reported significantly lower median 
scores on the: GSES (P < 0.01); the Haemo-QoL (sub)scales ‘Total score’ (P < 0.01), ‘Feeling’ 
(P = 0.02), ‘View’ (P = 0.01), ‘Others’ (P = 0.03), and ‘Sport’ (P < 0.01); and on the VERITAS-Pro 
subscales ‘Remember’ (P = 0.05), ‘Skip’ (P < 0.01), and ‘Communicate’ (P = 0.01), compared 
to parents with HSES scores in the highest quartile (Table 4). Adolescents with HSES 
scores in the lowest quartile reported significantly lower median scores on the: GSES (P < 
0.01); the Haemo-QoL subscales ‘Others’ (P = 0.04), and ‘Treatment’ (P = 0.02), compared 
to adolescents with HSES scores in the highest quartile (Table 4).
Perceived disease-specific self-efficacy was not associated with age, duration of prophy-
lactic treatment, level of education, number of siblings, marital status, or with family 
composition. Neither in parents, nor in adolescents (data not shown).
DISCUSSIOn
The novel Haemophilia-specific Self-Efficacy Scale (HSES) is a feasible and reliable 
instrument to evaluate self-efficacy in Dutch paediatric patients with haemophilia on 
Table 2. Score-distribution and internal consistency reliability of the Haemophilia-specific Self-Efficacy 
Scale (HSES).
 
Scale scores Internal consistency 
reliability
Cronbach’s alpha
Mean (SD) Range Median [IQR]
Ceiling 
effect (%)#
floor 
effect (%)$
Parent-report 
(n = 53)
55.45 (4.27) 45-60 57 [54-59] 17 0 0.72
Adolescent-report 
(n = 28)
55.68 (5.41) 38-60 57 [54-59] 29 0 0.86
# Ceiling effect; percentage of respondents with best possible score; $ Floor effect; percentage of respon-
dents with worst possible score.
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prophylactic home treatment. As timely communication and intervention is obligatory 
to modify prognosis in a disease with periodic episodes of pain and immobilization, 
we believe regular evaluation of self-efficacy is essential. In our study, HSES showed 
satisfactory psychometric properties and was able to discriminate between high and 
low self-efficacy. High HSES scores correlated significantly with quality of life measured 
by the Haemo-QoL. Further evaluation in other populations with regard to age and cul-
tural background is necessary to broaden application possibilities of this valuable tool. 
Differentiation of subgroups within the haemophilia patient population with regard to 
self-efficacy is of paramount importance in order to identify potential high risk patients 
with an increased risk of morbidity and decreased quality of life [25, 26]. Subsequently, 
Table 3. Convergent and divergent validity of the Haemophilia-specific Self-efficacy Scale (HSES) with vali-
dation measures.
 
HSES total scale
Parent report adolescent report
GSES# 0.43 * 0.81 **
Haemo-Qol$  
  Total score -0.45 ** 0.02
  Physical -0.11 -0.06
  Feeling -0.32 * -0.36
  View -0.38 ** -0.13
  Family -0.27 -0.25
  Friends -0.09 0.34
  Support -0.04 0.14
  Others -0.30 * -0.55 **
  Sport -0.30 * 0.02
  Dealing 0.05 0.31
  Treatment -0.13 -0.48 **
  Future -0.36 -0.23
  Relation -0.11 -0.14
VERITAS-Pro&
  Total score -0.12 0.08
  Time -0.10 -0.13
  Dose -0.11 0.16
  Plan -0.28 * -0.03
  Remember -0.29 * 0.22
  Skip -0.26 -0.12
  Communicate 0.37 ** 0.14
# General self-efficacy scale; $ Haemophilia-specific health-related quality-of-life questionnaire; & Validat-
ed haemophilia regimen treatment adherence scale – prophylaxis; * Spearman’s correlation coefficient is 
significant at the 0.05 level (2-tailed); ** Spearman’s correlation coefficient is significant at the 0.01 level 
(2-tailed).
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patients may undergo interventions aiming to increase self-efficacy, ultimately leading 
to cost-reduction of treatment in this era of rising health care costs.
Strengths of the HSES are diverse. Firstly, the 12 items chosen cover all aspects of hae-
mophilia care in which self-efficacy plays a role and follow the definition of self-efficacy 
as described by Bandura in 1977 [4]. Secondly, general self-efficacy and disease-specific 
self-efficacy correlated significantly as did a higher self-efficacy with a higher quality of 
life as evaluated by HaemoQoL, a validated and widely used tool to analyse quality of 
life in children and adolescents with haemophilia. Furthermore, a high response rate 
was reached among the study population, leading to reliability of conclusions. Fourthly, 
as the HSES is an easily applied tool, it will allow monitoring of interventions aimed to 
improve haemophilia-specific self-efficacy. Finally, HSES is another example of a combi-
nation of qualitative research and quantitative survey techniques, such as seen in the 
development of the VERITAS-Pro by Duncan et al. [3]. In our opinion, this approach leads 
to richer, more valid and more reliable findings, with clear clinical implications, than 
when adopting qualitative or quantitative methods alone [27].
The limitations of our study are discussed. Firstly, some may deliberate the capturing of 
self-efficacy by a limited number of questions with fixed answering categories. However, 
we have chosen to make HSES a feasible tool in daily clinical practice: quick, reliable 
and valid. Secondly, the lack of patient report in constructing of the questionnaire is an 
omission as solely expert opinion of haematologists, haemophilia nurses and clinical 
psychologists was employed. Therefore, patient interpretation of questions may differ. 
Thirdly, due to practical reasons we were forced to exclude patients with language dif-
ficulties due to the questionnaire-based nature of the study. We are thoroughly aware, 
that specifically this group is characterized by low self-efficacy and decreased adher-
ence to medical treatment [28]. Just as patients with inhibiting antibodies against FVIII/
FIX, may also be characterized by low self-efficacy. We excluded this group, due to the 
fact that their intensive treatment has such a severe impact on daily life that it is not 
comparable to standard prophylactic treatment. Exclusion of these groups may have 
biased results towards underreporting of low self-efficacy. However, despite exclusion 
of these groups, HSES still differentiates between high and low self-efficacy [29], prov-
ing the sensitivity of the tool and its applicability in daily clinical practice. Fourthly, we 
administered a parent report asking how parents perceive their own self-efficacy, but 
unfortunately omitted how they perceive the self-efficacy of their children, which would 
have been a valuable addition. Furthermore, statistical analysis of subgroups was of 
course limited by small sample size. We therefore recommend future studies to assess 
reliability and validity in other subgroups of patients, and in other settings and to utilize 
other qualitative research methods such as cognitive debriefing.
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HSES scale properties were satisfactory. A floor effect was absent as is frequently the 
case in positively-skewed assessments of reported self-efficacy [22, 30, 31]. Skewing was 
observed towards the most positive category (‘ceiling effect’) as often reported in other 
surveys on self-efficacy in chronic diseases [22, 30, 31]. This limitation effects the dis-
crimination between participants with a high self-efficacy and restricts participants with 
a high self-efficacy to acquire better scores in follow-up assessments. The ceiling effect 
can be explained by several factors such as the extensive education of patients with re-
gard to disease. In addition, current treatment focuses intensively on self-management 
skills, patients and parents have been dealing with the disease for a longer period of 
time, and multiple family members may be affected, leading to more disease experience.
The HSES scale questionnaire’s internal consistency was good. Cronbach’s alpha coef-
ficients in similar questionnaires were comparable [8, 18, 32]. The test-retest reliability 
was adequate both in parents and adolescents. The agreement between the perceived 
haemophilia-specific self-efficacy of parents and adolescents showed no correlation, 
as is often seen when comparing parent-reported and adolescent-reported outcomes 
on self-efficacy and quality of life questionnaires [33, 34]. This is most likely explained 
by the differences in treatment experience between parents and adolescents as well as 
diverging management responsibilities between parents and adolescents.
The convergent and divergent validity analyses of HSES showed promising test results, 
which is of paramount importance to discriminate between optimal and less optimal self-
efficacy and to promote its future use. Both parents and adolescents clearly expressed 
similar opinions on their HSES report and their general self-efficacy report. In addition, 
parents also showed similar opinions on their disease-specific self-efficacy as expressed 
by the HSES and quality of life measurements by Haemo-QoL. However, the latter was 
only observed in some subscales of the Haemo-QoL in adolescents. Most probably, out-
come is influenced by growing and not yet complete responsibility of adolescents for 
their disease, which directly correlates with self-efficacy outcome and not with quality 
of life outcome. Adequate transition towards disease responsibility is of course expected 
of the adult haemophilia patient. This development could be measured and monitored 
by HSES, making it an important tool in the challenging transitional period [8, 35, 36].
In line with our hypothesis, we found that adherence to administered clotting factor 
concentrate doses in relationship to prior prophylactic doses (subscales “Remember” 
and “Skip”) was higher in parents with a higher perceived haemophilia-specific self-
efficacy. In contrast, we found evidence that adherence to communication with the 
HTC determined by the VERITAS-Pro was significantly lower in parents with a high per-
ceived disease-specific self-efficacy than in parents with a low perceived self-efficacy. 
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Our hypothesis is that the latter may be the consequence of the well-developed self-
management strategies of these parents, decreasing communication moments. Further 
research is necessary to objectify patient outcome in these patients.
Conclusion
The HSES shows satisfactory psychometric properties to describe the self-efficacy in 
paediatric haemophilia patients on prophylactic home treatment. HSES parent report 
correlated with quality of life measures, further underlining the importance to standard-
ly assess, monitor and improve self-efficacy. Validation in other cohorts is impending to 
augment the value of HSES.
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appendix S1. Hemophilia-specific Self-Efficacy Scale.
Haemophilia Self-Efficacy Scale (HSES-parent) 
- Parent Form - 
English version  
 
Options (5): Not at all - Hardly true - No opinion - Moderately true - Exactly true 
 
1. In case my child has a bleed, I am confident I can treat him/her adequately with 
clotting factor concentrate. 
 
2. I am confident I can manage my child’s haemophilia in such a way that I can 
participate in activities I like to do. 
 
3. I am confident I administer prophylaxis correctly. 
 
4. I remain calm when my child has a bleed because I am confident about what to 
do. 
 
5. I am confident I can adequately treat pain caused by a bleed. 
 
6. I am confident I will manage, no matter what happens. 
 
7. I know exactly how to adjust my prophylaxis in certain circumstances. 
 
8. I am confident I can continue my daily routine in case my child has a bleed. 
 
9. In case my child has a bleed, I know what to do besides infusion of clotting factor 
concentrate. 
 
10. I am certain I can lead a normal life, despite my child’s haemophilia. 
 
11. I know exactly who to contact/warn in case I do not know how to handle a bleed. 
 
12. I am certain I can achieve most of my goals in life, despite my child’s 
haemophilia. 
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Haemophilia Self-Efficacy Scale (HSES-patient) 
- Patient Form - 
English version 
 
Options (5): Not at all - Hardly true - No opinion - Moderately true - Exactly true 
 
1. In case I have a bleed, I am confident I can treat myself adequately with 
clotting factor concentrate. 
 
2. I am confident I can manage my haemophilia in such a way that I can 
participate in activities I like to do. 
 
3. I am confident I administer prophylaxis correctly. 
 
4. I remain calm when I have a bleed because I am confident about what to do. 
 
5. I am confident I can adequately treat the pain caused by a bleed. 
 
6. I am confident I will manage, no matter what happens. 
 
7. I know exactly how to adjust my prophylaxis in certain circumstances. 
 
8. I am confident I can continue my daily routine when I have a bleed. 
 
9. In I have a bleed, I know what to do besides infusion of clotting factor 
concentrate. 
 
10. I am certain I can lead a normal life, despite my haemophilia. 
 
11. I know exactly who to contact/warn in case I do not know how to handle a 
bleed. 
 
12. I am certain I can achieve most of my goals in life, despite my haemophilia. 
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The group medical appointment (GMa) 
in hemophilia and von willebrand’s 
disease: a new development in 
outpatient pediatric care
J Lock, A de Bruin, M Scholten, M Joosten, FM Seesing, A Beishuizen,
 A de Goede-Bolder, MH Cnossen
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abSTRaCT
background The Group Medical Appointment (GMA) is a novel consultation form in 
which patients undergo individual consultations in each other’s presence.
aim To compare participants’ experiences with GMA and Individual Medical Appoint-
ments (IMA), the usual standard of care.
Methods Our team recently implemented the GMA for children aged 0-18 years with 
haemophilia or von Willebrand’s disease. Participants’ experiences with GMA were 
measured using a standardized QUOTE-questionnaire. Of 100 addressed families, 53 
participated in GMA. Of these 53 families, 38 parents (72%) and 14 adolescents (82%) 
filled in the questionnaire about the GMA. Patients not on prophylaxis were defined as 
less experienced and patients on prophylaxis, as experienced.
Results Although parents were satisfied with both GMA and IMA (median score 8.0 ver-
sus 9.0 out of 10), a significant difference was demonstrated between less experienced 
and experienced parents. After GMA, less experienced parents were significantly more 
satisfied (median score 8.0 vs 5.0; P = 0.006), felt more social support (82% vs 30%; P = 
0.005) and reported additional learning effects with regard to disease and treatment 
(64% vs 0%; P < 0.001) than experienced parents. None of the less experienced parents 
reported privacy problems during GMA compared with 40% of experienced parents. In 
adolescents an identical trend was reported. Sixty-six percent of parents would join a 
GMA in the future and 87% would recommend a GMA to others.
Conclusion GMA is a valuable addition in haemophilia and von Willebrand care, espe-
cially for less experienced patients. It leads to improved satisfaction, social support and 
improved information.
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InTRODUCTIOn
Patients with chronic haematological diseases, such as haemophilia or von Willebrand’s 
disease, require intensive therapeutic management and patient education to acquire 
adequate self-management abilities [1-4], apply lifestyle modifications and to under-
stand the inheritance of the disease. During an individual appointment, time limitations 
often lead to insufficient attention to these important, but time consuming aspects of 
disease care. A novel outpatient consultation form, leading to improvement of patient 
self-management may lead to benefits for patients and the health-care system as a 
whole [5, 6].
The Group Medical Appointment (GMA), which was introduced in Northern America by 
Noffsinger and Scott in 1996 [7-9] can be an effective and efficient option. In a GMA, a 
group of 8-12 patients spends 90 minutes with their treating physician and other health-
care providers, rather than the usual 10 to 15 min during an individual appointment. In 
a GMA, all the components of an individual appointment are incorporated including 
patient interview and physical examination. However, it allows more time to discuss 
disease related topics by healthcare providers. In addition, information and social sup-
port from fellow-patients can greatly improve self-management and quality of life in 
participants [10, 11].
Various studies in adults with other diseases, such as diabetes, severe headaches, cardio-
vascular and urological problems have shown that participation in a GMA can enhance 
patient and physician satisfaction, patient self-management, quality of life, and may 
reduce hospital admissions and emergency visits [12-18]. To date, however, little has 
been reported on GMAs in chronically ill children. Two recent observational studies in 
paediatric diabetic care showed that GMAs had a positive effect [19, 20]; a randomized 
controlled trial of GMA effect in atopic dermatitis is ongoing (personal communication, 
study results available in 2012). To our knowledge, no studies on GMA in haemophilia 
care have been reported.
In 2008, our paediatric team successfully implemented the GMA. This report summarizes 
the characteristics of a GMA for patients with haemophilia and von Willebrand’s disease 
and the experiences within our patient group with this innovative method of patient-
doctor interaction.
The objective of this observational study was to compare participants’ experiences with 
GMA to Individual Medical Appointments (IMA), our usual standard of care. Outcome 
measures were patient and parent satisfaction, the social support experienced by par-
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ticipants, the team’s attentiveness to the individual, informative value of a GMA, privacy 
aspects and the time investment. The hypothesis of this study was that less experienced 
patients, defined as patients not on prophylactic home treatment, would benefit more 
from a GMA than experienced patients, defined as patients on prophylactic home treat-
ment. As this latter group has undergone an intensive on-site training programme and 
visits our Haemophilia Comprehensive Care Centre standardly every 3-4 months. Dis-
ease severity was taken into account, but not considered as most important to measure 
impact of GMA on measured endpoints.
MaTERIaLS anD METHODS
Patients
From October 2008 to December 2009, patients being treated for haemophilia and von 
Willebrand’s disease at the Haemophilia Comprehensive Care Centre in the Erasmus 
Medical Centre-Sophia Children’s Hospital were invited to participate in a GMA by letter 
and an informative brochure. Exclusion criteria to participate in a GMA were language 
problems, hearing loss or severe behavioural problems. Participants were subsequently 
asked to evaluate both the standard IMA and the GMA.
Less experienced patients were defined as patients with haemophilia or von Willebrand’s 
disease not on prophylactic home treatment. These patients visit our Haemophilia 
Comprehensive Care Centre once to twice a year. Experienced patients were defined as 
patients on prophylactic home treatment, which implies they have undergone an inten-
sive on-site training programme and standardly visit our Haemophilia Comprehensive 
Care Centre three to four times a year. Disease severity was taken into account, but not 
considered as most important to measure impact of GMA on measured endpoints.
Methods
Group Medical Appointment
The GMA was introduced to the Netherlands by the Dutch Institute for Healthcare Im-
provement (CBO) in collaboration with Noffsinger [20, 21]; it was implemented in our 
Haemophilia Comprehensive Care Centre in 2008 for all hemophilia and von Willebrand 
patients as a standard follow-up visit. We aimed to schedule six to eight patients for each 
90 minute GMA in a conference room during regular working hours (Table 1). A GMA 
was planned approximately once a month. We aimed to invite each patient at least once 
every 2 years.
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Table 1. Characteristics of Individual Medical Appointment (IMA) compared with Group Medical Appoint-
ment (GMA).
IMa GMa
Number of patients 1 6-8
Duration of appointment 20 minutes 90 minutes
Participation Obligatory Voluntary
Severity of disease One severity of disease Various severities of disease
Professionals Treating physician, haemophilia 
nurse, physiotherapist, social 
worker.
Treating physician, haemophilia 
nurse, physiotherapist, social 
worker, clinical geneticist, guests 
depending on availability and 
topics.
One medical caretaker functions as 
chairman.
Clinical examination In doctor’s office Behind a screen in conference room
Privacy Complete Confidentiality protected by group
Table 2. Structure of (Paediatric) Haemophilia Group Medical Appointment (GMA).
1 Measurement of weight and height of all participants and copying of treatment log.
2 Introduction by GMA chairman (in our case: hemophilia nurse or social worker) with special attention to 
procedure, privacy, and allotted time.
Introduction of patients and severity of disease in each individual patient.
3 Individual interview by treating physician focusing on: acute bleeds and joint function, therapeutic 
interventions, administration of prophylactic treatment, future surgical or dental interventions, medication, 
physical activities and lifestyle.
4 Physical examination at the end of each patient interview by physician and physiotherapist.
5 During the GMA disease-related topics are discussed, in accordance to patient questions or introduced by 
the chairman:
Disease and therapy
-  Pathophysiology of disease and mechanism of action of therapeutic interventions (a.o. clotting factor 
concentrate, anti-fibrinolytic agents, xylometazolin).
-  Identification of bleeds, aspects of prophylactic home treatment and vena puncture techniques, 
importance of treatment log, timing of prophylactic medication with regard to physical activities, type 
and severity of bleeds with special attention to head trauma.
-  In all bleeding disorders: Subcutaneous instead of intramuscular vaccinations. Avoidance of pain- and 
other medication influencing haemostasis (acetylsalicylic acid, non-steroidal anti-inflammatory drugs, 
heparin / low molecular weight heparin, coumarin derivatives).
Lifestyle
-  Importance of physical activities for muscle tone and prevention of bleeds as well as psychosocial 
development.
- Safety measures such as SOS bracelets/ medallions.
-  Education and informing of environment (day care/ school, family, friends, dentist, other medical 
specialists).
- Future job and career choice.
-  How to cope with the disease during holidays.
Genetics and other family members
- Inheritance of the disease and importance of genetic counseling.
- Clinical consequences of carriership in X-linked diseases.
6 At the end of the GMA diagnostic vena punctures and more private individual consultations are performed, 
if necessary.
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All haemophilia professionals were trained by the CBO in different aspects of GMA 
management, including GMA setting and practical aspects (Table 2). Within a GMA, the 
physician proceeds as in an individual appointment under supervision of a chairman, 
in the presence of other patients, parents and other haemophilia caretakers. The chair-
man hosts the session and facilitates the group process, while monitoring the allotted 
time. At the beginning of each GMA, the chairman emphasizes the confidentiality of 
the shared experiences and explicit oral informed consent of participants is obtained. 
General disease topics are discussed collectively under supervision of the chairman.
Questionnaires
The CBO provided a standardized and validated questionnaire (QUOTE-communication 
questionnaire) as used in similar surveys in different patient groups [21-23]. Before the 
GMA, all parents received a questionnaire concerning their expectations and experi-
ences with an IMA and a similar questionnaire on their expectations of a GMA. After 
the GMA attendance they received a questionnaire concerning their experiences with 
a GMA. Children aged 12-18 years (adolescents) received only the latter questionnaire 
concerning their experiences with a GMA. Younger children did not receive a ques-
tionnaire. In the questionnaires, questions were asked regarding patient and parent 
satisfaction, the social support participants experienced, the team’s attentiveness to the 
individual, informative value of a GMA, privacy aspects and the necessary time invest-
ment. All surveys were confidential and sent anonymously. Treating physicians and 
other haemophilia caretakers were interviewed separately.
Statistical analysis
Differences in patient characteristics between the IMA and GMA were tested with 
Chi-square analysis in the case of categorical data and with the Mann-Whitney U-test 
in the case of continuous non-parametric data. A Chi-square analysis was performed 
to analyze the differences between topics during the IMA and the GMA. Differences 
between expectations and experiences of the IMA and the GMA were analyzed using 
the Wilcoxon signed rank test for non-parametric paired data. Differences between less 
experienced and experienced patients were analyzed by the Chi-square analysis. Level 
of significance was set at P ≤ 0.05. All analyses were performed using SPSS 17.0 (SPSS 
Inc., Chicago, IL, USA).
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RESULTS
Patients, Group Medical appointment and compliance
In 2008, 128 children from 103 families were treated in our hospital for haemophilia or 
von Willebrand’s disease. Three of these 103 families (with a total of 6 children) were 
excluded from participation in GMA due to language problems. The other 100 families 
(with a total of 122 children between 0 and 18 years) were approached to join the study 
by a personal letter with accompanying questionnaire (Figure 1). Forty-seven families 
did not take part in a GMA, due to practical reasons or lack of interest. Patients not par-
ticipating in a GMA did not diff er signifi cantly from the GMA participants with regard to 
baseline characteristics, and number of less experienced or experienced patients (Table 
3). Parents not participating in a GMA reported no signifi cant diff erences with regard to 
satisfaction of an IMA (only IMA median score 8.0 out of 10.0, IMA and GMA 9.0 out of 
10.0; P = 0.580), although they reported less expectations from a GMA (data not shown). 
 
figure 1. Flow diagram of patient inclusion.
Group Medical Appointment (GMA) in hemophilia
94
  C
ha
pt
er
 5
As a result of the unexpected non-attendance of patients, the average number of pa-
tients in a GMA was five (range 2-7), and the target of six to eight was not reached.
Seventy-six of the 100 families returned the questionnaire on expectations and experi-
ences with an IMA and 69 parents returned the questionnaire on the expectations of a 
GMA. Thereafter, 53 of these families participated in a GMA of which 38 families returned 
the questionnaire on their experiences (compliance 72%). Out of 17 children ≥ 12 years 
that had participated in a GMA, 14 (82%) returned their questionnaire (Figure 1).
Of GMA participants the less experienced group consisted of 28 families with 30 chil-
dren; 17 with haemophilia A [Factor VIII (FVIII) level range: 0.01-0.28 IU dL-1], 2 with hae-
mophilia B [both with Factor IX (FIX) level of 0.10 IU dL-1], and 11 with von Willebrand’s 
disease [von Willebrand Factor (vWF) antigen level range: < 0.10-0.28 IU dL-1; vWF activ-
ity level range: < 0.10-0.27 IU dL-1; FVIII level range: 0.03-0.59 IU dL-1]. The experienced 
group consisted of 10 families with 11 children; 10 with haemophilia A (FVIII level range: 
0.01-0.02 IU dL-1), and 1 with haemophilia B (FIX level: 0.01 IU dL-1).
Comparison of the Individual Medical appointment and Group Medical 
appointment
In this section, only results of patients ≥ 12 years (n = 14) and parents (n = 38) undergo-
ing both IMA and GMA are presented. Sequentially, we present our results on (i) patient 
and parent satisfaction, (ii) social support and the team’s attentiveness to the individual 
Table 3. Patient characteristics in Individual Medical Appointment (IMA) questionnaire and Group Medical 
Appointment (GMA) questionnaire category.
IMa GMa
Parents
(n = 76 families,
92 children)
Parents
(n = 38 families,
41 children)
Children ≥ 12 years
(n = 14 children)
Patient age, median (IQR) 8.0 (4.0-12.8) 9.0 (6-13.5) 14.0 (12.0-16.0)
Patient gender, n (% male) 78 (84.8) 37 (90.2) 14 (93.3)
Patient disease
Haemophilia A, n (%) 61 (66.3) 27 (65.9) 11 (78.6)
Haemophilia B, n (%) 8 (8.7) 3 (7.3) 1 (7.1)
Von Willebrand’s Disease, n (%) 19 (20.7) 11 (26.8) 2 (14.3)
Carrier Haemophilia A or B, n (%) 4 (4.3) . .
Experience (families)
Experienced, n (%) 21 (27.6) 10 (26.3) 4 (28.6)
Less experienced, n (%) 55 (72.4) 28 (73.7) 10 (71.4)
No significant differences were found between parents who only participated in an IMA and parents who 
also participated in a GMA.
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during GMA, (iii) informative value of a GMA, (iv) privacy, (v) time investment, and (vi) 
preference for a future GMA. Table 4 shows the extent of agreement of patients/ parents 
with nine specified statements regarding a GMA.
Patient and parent satisfaction
All parents (n = 38) were satisfied with the IMA (median score 9.0 of a score from 1-10; 
IQR = 8.0-9.0) and 83% (n = 30) were satisfied with the GMA (median score = 8.0; IQR = 
6.3-9.0). Less experienced parents were significantly more satisfied with the GMA than 
experienced parents (median score = 8.0; IQR = 7.0-10.0 versus median score = 5.0; IQR 
= 3.5-8.0; P = 0.006). The median satisfaction rate in children ≥12 years was 7.0 (IQR = 
5.8-7.3). Less experienced adolescents tended to be more satisfied than experienced 
adolescents (P = 0.159).
Table 4. Characteristics of Group Medical Appointment (GMA) reported by parents and adolescents.
GMa, parents
P
GMa, children ≥ 12 years
P
Less 
experienced
(n = 28)
Experienced
(n = 10)
Less 
experienced
(n = 10)
Experienced
(n = 4)
agree (n, %) agree (n, %) agree (n, %) agree (n, %)
Social support and attention
I felt supported by the other 
patients.
23 (82.1) 3 (30.0) 0.005* 5 (50.0) 3 (75.0) 0.580
I felt enough attention from the 
team members and the other 
parents for my situation.
27 (96.4) 10 (100.0) 1.000 . . .
Information
I learned from other patients and 
their questions.
18 (64.3) 0 (0.0) <0.001* 10 (100.0) 1 (25.0) 0.011*
Privacy
I did not mind discussing my child 
in a group setting.
28 (100.0) 6 (60.0) 0.003* . . .
I asked all relevant questions. 28 (100.0) 7 (70.0) 0.014* . . .
I did not mind that the physical 
examination took place behind a 
screen.
23 (82.1) 6 (60.0) 0.205 6 (60.0) 2 (50.0) 1.000
Time investment
The extra time investment in the 
GMA was worthwhile.
20 (74.1)† 3 (30.0) 0.023* 7 (70.0) 1 (25.0) 0.245
GMa in the future
I would choose for a GMA again. 22 (84.6)‡ 4 (40.0) 0.014* 5 (55.6)† 1 (25.0) 0.559
I would recommend participation 
in a GMA to others
25 (92.6)† 8 (88.9)† 1.000 . . .
Expectations fulfilled 27 (100.0)† 7 (70.0) 0.015* . .
* P-value < 0.05; † Missing = 1; ‡ Missing = 2.
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Social support and the team’s attentiveness to the individual during a GMA
Eighty-two percent of less experienced parents felt supported by other patients, ver-
sus 30% of experienced parents (P = 0.005). Support was specified by participants as 
‘feeling less of an outsider’ and as ‘hearing valuable experiences’ from fellow-sufferers. 
Contrastingly, only 50% of less experienced adolescents reported peer support, against 
75% of experienced adolescents (P = 0.580). Especially, younger patients and parents 
of recently diagnosed children reported increased understanding of the disease and 
disease-related topics. Attentiveness received from the haemophilia professionals was 
not perceived as different between an IMA and a GMA (96% of less experienced and 
100% of experienced parents; P = 1.000).
Informative value of a GMA
Sixty-four percent of less experienced patients acquired more knowledge in a GMA 
than in an IMA. They reported an increase in acquired knowledge with regard to 
disease-related topics (43%), health regimens (39%), side effects (32%), and therapeutic 
management (18%). None of the experienced patients reported an increase in acquired 
knowledge (P < 0.001). In children ≥12 years, all less experienced adolescents reported 
learning of new aspects of their disease, unlike the 75% of experienced adolescents who 
reported no learning effect (P = 0.011).
Privacy
After a GMA, none of the less experienced parents reported problems regarding privacy 
aspects, against 40% of the experienced parents (P = 0.003). However, whereas less 
experienced parents felt able to ask all questions, 30% of experienced parents reported 
avoidance of some questions due to privacy aspects (P = 0.014).
A physical examination behind a screen in the conference room was a problem in 18% of 
the less experienced parents and 40% of the experienced parents (P = 0.205). In children 
≥12 years, 40% of less experienced adolescents and 50% of experienced adolescents 
reported problems with this GMA-adapted physical examination (P = 1.000).
Time investment
The majority of parents (62%) did not regard the additional time investment for GMA as 
inconvenient (74% less experienced, 30% experienced; P = 0.023). In adolescents, 57% 
did not find the time investment problematic. Exceptionally, one adolescent rated the 
GMA as too short.
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GMA in the future
Sixty-six percent of parents returning the questionnaire would join a GMA in future (85% 
less experienced, 40% experienced; P = 0.014) and 87% would recommend a GMA to 
other patients (93% less experienced, 89% experienced; P = 1.000). Of the adolescents, 
46% would join a future GMA (56% less experienced, 25% experienced; P = 0.559).
With regard to satisfaction and efficiency, all haemophilia professionals were positive 
about GMA experiences in individual interviews. They reported it to be: challenging 
and enjoyable. They also observed increased peer support within the group, significant 
learning effects and more effective counseling of patients. All underlined the impor-
tance of the chairman during a GMA.
DISCUSSIOn
In this observational study, whose objective was to compare experiences with GMAs 
and IMAs, we measured patient and parent satisfaction, the social support experienced 
by participants, the team’s attentiveness to the individual, the informative value of a 
GMA, privacy aspects, and the time investment necessary.
Overall, parents and adolescents were very satisfied with both the GMA and with the 
IMA. In our opinion, the most important advantages of GMA in our study were the 
improvement in participants’ knowledge of the disease and the social support they 
reported. Both were significantly higher in less experienced than in experienced par-
ents and adolescents. A recent study on the value of GMA indicated that, due to the 
available time period and group interaction, disease-related topics are discussed more 
extensively during a GMA than an IMA [20]. Our results confirm prior studies on GMA 
that report high levels of participant satisfaction and advantages with regard to disease 
perspective, social support and therefore probably increased self-management abilities 
[19, 24-29].
An important characteristic of the GMAs are the group dynamics which acknowledge 
the individual patient and his family members as disease experts. Real-life experiences 
are strong advocates for behavioural changes and improved understanding of disease 
perspective and therapeutic interventions [30-32]. With regard to these aspects, a 
GMA could be superior to an IMA, especially in chronic patient care, which requires 
participants to deepen their knowledge of the disease and to improve adequate self-
management [17, 24, 33, 34]. It has been suggested that GMAs may be especially effec-
tive in adolescents when they are offered according to their needs and requirements, 
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as adolescents may be more sensitive to peers and group dynamics. In our study it is 
difficult to be conclusive on this subject due to the small case series. Strikingly, less 
experienced adolescents received less peer support than experienced adolescents. This 
may be explained by feelings of solidarity within the latter group due to the intensity of 
the required treatment.
Most participants in our study did not report problems with time investment, privacy 
aspects, or less team’s attentiveness to the individual. Less experienced participants 
reported fewer disadvantages of GMA than experienced patients. Notably, most of them 
felt free to discuss personal problems within the group. Almost half of the experienced 
parents and adolescents perceived the physical examination in the conference room 
as a problem. Therefore, it will be performed in a nearby consultation room in the near 
future. Despite their initial concerns, participants were positive about the introduction 
of the novel form of consultation. Most would join a GMA in the future and would rec-
ommend a GMA to other patients.
Possible reasons for the differences between less experienced and more experienced 
patients in our study include experienced patients’ increased knowledge of the disease 
due to prior home treatment training. Also, the fact that more experienced patients are 
used to frequent, short outpatient clinic visits and often have a close personal relation-
ship with the treating physician. This may lead to problems with the extra time invest-
ment involved in a GMA and with the need to adapt to a more distant setting.
A GMA should pursue a balance between individualized and witnessed interactions 
between patients and the treating physician, with focus on educational aspects. Accord-
ing to Thacker et al. there is no optimal standardized form for a GMA and healthcare 
providers should organize a GMA according to the needs of the patient population 
involved [28]. In our setting, we have now implemented the following adjustments. 
The heterogeneity of patients invited for GMA as recommended by Noffsinger was not 
feasible [35]. A complete lack of patient selection resulted in a lack of clarity between 
participants on patient diagnosis. Subsequently, we selected patients, differentiating 
between age, type and severity of disease. As participant involvement is essential for 
group dynamics, we were still careful to include both less experienced and experienced 
patients. Furthermore, results in our adolescent group led to a successful transitional 
GMA in which adolescents participated together with future adult haemophilia caretak-
ers. Practical aspects such as unexpected unattendance must be anticipated, and it is 
essential that a sufficient number of healthcare providers attends [28, 36]. In addition, 
to safeguard quality of care, the physical examination during GMA is best performed by 
a physiotherapist, in another consultation room. The number of invited patients recom-
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mended for GMA by Noffsinger (10-16) proved too large for our patient population [35]. 
As patients are accompanied by parents and siblings, we conclude that seven patients 
are optimal in our setting.
Limitations of our study were caused by the observational study design, patient num-
bers, and selection bias due to non-randomization. As the GMA was incorporated in 
standard haemophilia care, randomization was not feasible. Although, in the adolescent 
population, there were no significant differences between less experienced and expe-
rienced patients, most probably due to the small patient numbers. Also, it is difficult to 
assess whether respondent answers reflected their true opinion or were socially accept-
able answers. Nevertheless, we regard our findings as valuable for chronic (paediatric) 
patient care, and more specifically for haemophilia and von Willebrand caretakers in 
general.
In conclusion, we have shown that the GMA is a valuable addition in paediatric hae-
mophilia care, especially for less experienced patients, who compromise half of most 
Haemophilia Comprehensive Care Centres. In specific patient groups, it clearly improves 
satisfaction, peer support and informative value of a GMA of patients and parents. How-
ever, as not every patient may benefit from a GMA, a GMA will never be able to replace 
individual consultations. Ongoing research is required to further define the advantages 
of this new development in chronic patient care. Our team considers the GMA an impor-
tant asset in chronic patient care and will implement it in other haematological patient 
groups, such as sickle cell disease, thalassemia and hereditary spherocytosis.
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abSTRaCT
background Perioperative administration of factor VIII (FVIII) concentrate in hemophilia 
A may result in both underdosing and overdosing, leading to respectively a risk of bleed-
ing complications or unnecessary costs.
Objectives This retrospective observational study aims to identify the extent and 
predictors of underdosing and overdosing in perioperative hemophilia A patients (FVIII 
levels < 0.05 IU mL-1).
Patients and Methods One hundred-nineteen patients undergoing 198 elective, minor 
or major surgical procedures were included (median age 40 years, median body weight 
75 kg). Perioperative management was evaluated by quantification of perioperative 
infusion of FVIII concentrate and achieved FVIII levels. Predictors of underdosing and 
(excessive) overdosing were analysed by logistic regression analysis. Excessive overdos-
ing was defined as upper target level plus ≥ 0.20 IU mL-1.
Results Depending on postoperative day, 7-45% of achieved FVIII levels were under 
and 33-75% were above predefined target ranges as stated by National guidelines. A 
potential reduction of FVIII consumption of 44% would have been attained if FVIII levels 
had been maintained within target ranges. Blood group O and major surgery were 
predictive of underdosing (odds ratio (OR) = 6.3, 95%CI = 2.7-14.9; OR = 3.3, 95%CI = 
1.4-7.9). Blood group O patients had more bleeding complications in comparison to 
patients with blood group non-O (OR = 2.02, 95%CI = 1.00-4.09). Patients with blood 
group non-O were at higher risk of overdosing (OR = 1.5, 95%CI = 1.1-1.9). Additionally, 
patients treated with bolus infusions were at higher risk of excessive overdosing (OR = 
1.8, 95%CI = 1.3-2.4).
Conclusion Quality of care and cost-effectiveness can be improved by refining of dosing 
strategies based on individual patient characteristics such as blood group and mode of 
infusion.
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InTRODUCTIOn
Hemophilia A is an X-linked inherited bleeding disorder caused by a deficiency of 
coagulation factor VIII (FVIII). It is characterized by spontaneous bleeding or bleeding 
after minor trauma, typically in joints and muscles. In case of bleeding, patients are 
treated with intravenously administered factor replacement therapy. In severe (FVIII < 
0.01 IU mL-1) and some moderate severe (FVIII between 0.01 and 0.05 IU mL-1) cases, 
prophylactic treatment is administered to prevent spontaneous and frequent bleeding 
[1, 2]. In order to safeguard hemostasis in the perioperative setting, FVIII plasma levels 
are targeted according to guidelines for up to 2 weeks after surgery and consist of a FVIII 
bolus infusion of 50 IU kg-1, followed by either continuous infusion or intermittent daily 
infusions based on a clearance rate of 3-4 mL kg-1 h-1, and under daily monitoring of FVIII 
plasma levels (Table 1) [3]. Perioperative factor concentrate consumption is substantial 
and amounts to 15% of annual use in the hemophilia population [4-6]. To illustrate 
this, in the Netherlands > €100 million (> $109 million) is spent annually on total factor 
concentrate for 1600 hemophilia patients per year, including €15 million ($16.4 million) 
alone for perioperative replacement therapy[3, 4, 6]. Fortunately, treatment is extremely 
effective as perioperative bleeding is rare, in those cases where replacement therapy is 
adequately available[7, 8].
Previous studies evaluating perioperative dosing of FVIII concentrate in hemophilia A 
suggest that improvement is warranted as overdosing is widely reported [9-16]. This 
is attributed to current dosing strategies based on body weight and crude estimations 
of clearance, without taking into account other individual patient characteristics. Ad-
ditionally, the complexity of achieving targeted factor levels and fear of bleeding play an 
important role in overdosing. Strikingly, in reported studies, extent and timing of under-
Table 1. Target FVIII levels in the perioperative period*
Time Target fVIII level
(IU mL-1)Day Hours  
1 0 - 24   0.80 - 1.00
2-5 24 - 120 0.50 - 0.80
 ≥6 > 120   0.30 - 0.50
*The standard perioperative dosing regimen, as described by the consensus, consists of a factor VIII (FVIII) 
bolus dose directly before surgery of 50 IU kg-1, followed by either continuous infusion or intermittent 
daily bolus infusions. The rate of infusion (IU h-1) is obtained by multiplying the patient’s bodyweight (kg) 
with clearance (3-4 mL kg-1 h-1) and target FVIII level (IU mL-1). Subsequent FVIII clotting factor concentrate 
dosing will be based on daily monitoring of FVIII levels and adjusted according to the physician’s opinion, 
based on a standard clearance of 3-4 mL kg-1 h-1. Data are according to the National Hemophilia Consensus 
of the Netherlands [3].
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dosing and overdosing have not been specified. Moreover, risk factors for underdosing 
and overdosing have hardly been explored and are urgently required to individualize 
dosing in the near future.
We aim to quantify the extent and timing of underdosing and overdosing in the periop-
erative setting and to identify its predictors in severe and moderate severe hemophilia A 
patients. We believe that both underdosing and overdosing can be reduced by alterna-
tive dosing strategies that take into account individual patient characteristics, leading to 
optimization of care and a greater efficacy of consumption of costly factor concentrate.
MaTERIaLS anD METHODS
Patients
This is a retrospective multicenter observational cohort study. Eligible patients were 
male patients with severe or moderate-severe hemophilia A (FVIII levels < 0.05 IU mL-1) 
of all ages undergoing elective, minor, or major surgery (Table S1) [17] between 2000 
and 2013 under FVIII concentrate replacement therapy with monitoring of FVIII plasma 
levels. First surgical procedure was performed on January 7, 2000 and last surgical pro-
cedure on February 19, 2013. Patients were recruited from five Academic Hemophilia 
Treatment Centers in the Netherlands (Erasmus University Medical Center Rotterdam 
[n = 32]; Academic Medical Center Amsterdam [n = 32]; University Medical Center 
Groningen [n = 35]; Radboud university medical center [n = 12]; and Leiden University 
Medical Center [n = 8]). Exclusion criteria included: the perioperative presence of FVIII 
neutralizing antibodies, patients with severe infections during the perioperative period 
and patients lacking accurate perioperative documentation. The study was not subject 
to the Medical Research Involving Human Subjects Act, as patient data were analysed 
anonymously. Moreover, the study was approved by all local Medical Ethics Committees; 
one center requiring prior patient informed consent.
Objectives
The objectives of the study were to evaluate perioperative FVIII concentrate manage-
ment in patients with hemophilia A with regard to defined FVIII target ranges as stated 
by the National Hemophilia Consensus of the Netherlands and to identify potential 
predictors of underdosing and overdosing.
Methods
Data were collected on patient characteristics, type of surgical procedure, timing, dosing 
of FVIII administration and timing of blood sampling of FVIII plasma levels (in IU mL-1) 
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during the hospitalization period. FVIII plasma levels were generally monitored daily and 
were measured by one-stage clotting assays in all participating centers. Perioperative 
blood loss and hemostasis were evaluated according to the definitions of the International 
Society of Thrombosis and Hemostasis [18] and quantified by severity of complications 
and/or necessity of second surgical intervention, hemoglobin decrease of ≥ 1.24 mmol L-1 
and/or red blood cell transfusion necessity, or bleeding that prolonged hospitalization.
For our analysis, we defined severe bleeding complications as bleeding requiring a sec-
ond surgical intervention and/or the necessity of a red blood cell transfusion. Duration 
of hospitalization was defined by day of discharge minus day of surgical procedure and 
initiation of FVIII concentrate infusion. To increase data reliability, data were collected 
and checked by two individual researchers.
To acquire accurate insight into achieved FVIII plasma levels with regard to the target 
ranges stated in guidelines, only steady state FVIII plasma levels were included when 
replacement therapy was administered by continuous infusion and only FVIII trough 
plasma levels in case of administration via bolus infusion. Steady state FVIII plasma lev-
els were defined as perioperative FVIII measurements sampled when FVIII concentrate 
substitution is equal to clearance and FVIII trough plasma levels as FVIII measurements 
before FVIII concentrate bolus infusion. FVIII peak levels after FVIII bolus infusion were 
not included in this analysis.
Statistical analysis
For comparison of FVIII concentrate consumption between groups, the non-parametric 
Mann-Whitney U test was used. P for trend analysis using one-way ANOVA was per-
formed to evaluate trends in FVIII consumption on consecutive days. Calculations were 
performed only on the first surgical procedure in each individual patient. Descriptive 
statistics are presented as median and interquartile range (IQR) for continuous variables 
and as number and percentages for categorical variables. Comparison between propor-
tions was done by means of Pearson Chi-Square test.
A hypothetical reduction of FVIII concentrate consumption, if national guidelines for 
perioperatieve target ranges had been maintained, was calculated by comparing the 
difference of achieved FVIII plasma level in each individual at different time points to the 
prescribed lowest and highest target range level at that time point. First-order elimina-
tion curves were used to calculate the actual amount of FVIII concentrate underdosed 
or overdosed for the total population. The percentage of FVIII concentrate which could 
have been saved was calculated after subtraction of the amount of FVIII concentrate 
that was underdosed.
Perioperative treatment in hemophilia A
108
  C
ha
pt
er
 6
Prediction model for underdosing and overdosing
Underdosing was defined as all FVIII plasma levels below the lowest predefined target 
range level, and overdosing as all FVIII plasma levels above highest predefined target 
range level. Excessive overdosing was arbitrarily defined as the upper target range level 
with a deviation of ≥ 0.20 IU mL-1 to overcome the logistic delays caused by laboratory 
monitoring and adjustment of treatment. Potential predictors of underdosing in the first 
24 hours after surgery, as well as overdosing and excessive overdosing, were analyzed 
by a backward stepwise logistic regression analysis with elimination of variables with 
P > 0.10. Potential predictors of underdosing or overdosing were defined before analysis 
on the basis of their potential effect on the pharmacokinetic (PK) parameters: clearance 
and/ or volume of distribution of infused FVIII concentrate. The following variables were 
collected: first: patient characteristics of age, body weight [19], blood group [20-22], 
historical values of von Willebrand Factor (VWF) antigen and VWF activity [23], history of 
FVIII neutralizing antibodies [8], type and brand of factor concentrate (recombinant or 
plasma-derived) [24] and mode of infusion (continuous or bolus infusion) [25]. Secondly, 
surgical characteristics were colected: type and severity of surgical procedure catego-
rized according to Koshy et al. [17].
Data management and statistical analysis were performed with IBM SPSS statistics for 
Windows, version 21.0 (IBM Corp, Armonk, NY, USA). A P-value of < 0.05 was considered 
statistically significant.
RESULTS
Patient and surgical characteristics
Our study population consisted of 119 patients undergoing a total of 198 surgical proce-
dures: 75 adults (140 surgical procedures, median age 48 years, median body weight 80 
kg) and 44 children (58 surgical procedures, median age 4 years, median body weight 19 
kg) (Table 2). The majority of patients were severe hemophilia A patients on prophylactic 
treatment (70%). Approximately half of all patients were known with blood group O 
(51%). In adults median VWF:antigen (Ag) level was 1.23 IU mL-1 and median VWF:activity 
(Act) level was 1.39 IU mL-1. In children, median VWF:Ag was 0.92 IU mL-1 and VWF:Act 
was 0.88 IU mL-1.
Forty-four patients underwent multiple surgical procedures; nine of these had more 
than four surgical procedures (Table 2). In adults, mainly major surgical procedures (n = 
86; 61%) were performed, which were most often orthopedic procedures (n = 91; 65%). 
Children mainly underwent minor surgical procedures (n = 47; 81%), most frequently 
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Table 2. General characteristics
  Total cohort adults Children
Patient characteristics
No. of patients 119 75  44
Age (y) 40 [9-54] 48 [37-60]  4 [2-8]
Height (cm) 175 [162-182] 178 [173-182.0]  114 [89-136]
Body weight (kg) 75 [35-85] 80 [73-90]  19 [12-29]
Body mass index (kg m-2) 23 [17-26] 25 [23-28]  16 [14-18]
Severe hemophilia, FVIII levels <0.01 IU mL-1 83 (70) 49 (65)  34 (77)
Prophylaxis 84 (71) 51 (68)  33 (75)
Blood group O* 51 (51) 34 (50)  17 (52)
Neutralizing antibody titer
No. 131 (66) 82 (59)  49 (85)
Historically 67 (34) 58 (41)  9 (15)
Maximum titer (BU)  0.3 [0.2-0.7] 0.3 [0.2-0.5] 0.2 [0.2-2.4]
Historical VWF levels (IU mL-1)
Antigen# 1.1 [0.9-1.4] 1.2 [1.0-1.4] 0.9 [0.7-1.2]
Activity$ 1.1 [0.9-1.6] 1.4 [1.1-1.7] 0.9 [0.7-1.2]
Chronic hepatitis C  57 (48) 55 (73)  2 (5)
Surgical characteristics
No. of surgical procedures 198 140 58
Total No. of patients undergoing:
1 procedure 75 (63.0) 43 (57.3) 32 (72.7)
2 procedures 26 (21.8) 15 (20.0) 11 (25.0)
3 procedures 9 (7.6) 9 (12.0) 0 (0.0)
> 4 procedures 9 (7.6) 8 (10.7) 1 (2.3)
Major surgical procedure 97 (49.0) 86 (61.4) 11 (19.0)
Type of surgical procedure
General 6 (3.0) 6 (4.3) NA NA
Colorectal 5 (2.5) 4 (2.9) 1 (1.7)
Vascular 1 (0.5) 1 (0.7) NA NA
Cardiothoracic 1 (0.5) 1 (0.7) NA NA
Orthopedic 94 (47.5) 91 (65.0) 3 (5.2)
Urology 12 (6.1) 4 (2.9) 8 (13.8)
Maxillofacial 2 (1.0) 2 (1.4) NA NA
Ear-nose-throat 11 (5.6) 6 (4.3) 5 (8.6)
Eye 3 (1.5) 3 (2.1) NA NA
(Re)placement central intravenous 
catheters
32 (16.2) 1 (0.7) 31 (53.4)
Miscellaneous 31 (15.7) 21 (15.0) 10 (17.2)
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an insertion or removal of a central venous device (n = 31; 53%) (Table 2). In 115 (58%) 
surgical procedures, FVIII replacement therapy was given by continuous infusion; these 
patients were mainly adults (n = 88; 63%). In 83 (42%) surgical procedures, patients 
were treated via bolus infusion (Table 2). In 152 surgical procedures (77%) patients were 
treated with recombinant factor concentrates. Duration of hospitalization was similar in 
both adults and children treated via continuous infusion as compared with bolus infu-
sion (adults: 9 [IQR 6-15] vs. 8 [IQR 4-13] days, P = 0.09; children: 7 [IQR 6-10] vs. 7 [IQR: 
6-10] days, P = 0.99).
achievement of fVIII target range levels
Most perioperative FVIII plasma concentrations were outside the predefined target 
range in both adults and children. Achieved FVIII plasma concentrations in relationship 
to defined target ranges on consecutive days are depicted in Figure 1. In summary, on 
consecutive days deviations of FVIII levels with regard to predefined target range levels 
were increasingly significant (P for trend < 0.01). The overall median deviation of FVIII 
plasma concentrations below the lowest required target range level varied from 0.17 to 
0.11 IU mL-1 for consecutive postoperative days and above the highest required target 
Table 2. General characteristics (continued)
  Total cohort adults Children
Replacement therapy with factor 
concentrate, hospitalization and blood loss
Mode of infusion
Continuous 115 (58) 88 (63) 27 (47)
Bolus 83 (42) 52 (37) 31 (53)
Product type
Plasma derived 46 (23) 41 (29) 5  (9)
Recombinant 152 (77) 99 (71) 53 (91)
Duration of hospitalization (days) 9 [5-12] 9.0 [5-14] 7 [6-10]
Complications during the perioperative period
No. of patients with a complication
Bleeding 48 (24) 45 (32) 3 (5)
Re-operation 6 (3) 6 (4) NA NA
Hemoglobin drop >1.24 mmol L-1 and/
or RBCTF
38 (19) 36 (26) 2 (3)
Bleeding with prolonged 
hospitalization
5 (3) 4 (3) 1 (2)
    Thrombosis NA NA NA NA NA NA
Values given in No. (%) or median [interquartile range 25-75%]. FVIII, clotting factor VIII; BU, Bethesda Units; 
VWF, von Willebrand factor; NA, not applicable; RBCTF, red blood cell transfusion. * Blood group available 
in 101 patients (172 surgical procedures). # VWF antigen available in 67 patients (118 surgical procedures). 
$ VWF activity available in 57 patients (98 surgical procedures).
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range level from 0.23 to 0.31 IU mL-1 for consecutive postoperative days (Table 3). In 
the fi rst 24 h after surgery, 45% of measured FVIII levels were below lowest target range 
level with a median deviation below the lowest required target level of 0.17 IU mL-1. 
After 6 days of postsurgical hospitalization, 75% of the FVIII levels were above highest 
target range level with a median deviation of 0.31 IU mL-1. No evidence was found with 
regard to changes in dosing regimen over time during the overall study period as the 
proportion of underdosed and overdosed patients did not diff er for surgical procedures 
Table 3. Achieved FVIII levels after clotting factor replacement therapy
 
Total cohort adults Children
no. Samples 
(%)
Median
 deviation [IQR]
no. Samples 
(%)
Median 
deviation [IQR]
no. Samples 
(%)
Median 
deviation [IQR]
Preoperative: only 
peak levels
111 1.15 [0.9-1.41] 80 1.23 [0.94-1.50] 31 1.00 [0.82-1.18]
Day 1 (0-24 h) 308 (100.0) 0.83 [0.65-1.10] 237 (100.0) 0.87 [0.69-1.14] 71 (100.0) 0.76 [0.51-1.09]
FVIII levels outside 
target range
283 (77.3) . 181 (76.4) . 57 (80.2) .
Above 101 (32.7) 0.23 [0.10-0.40] 81 (34.2) 0.24 [0.10-0.43] 20 (28.2) 0.20 [0.12-0.29]
Below 137 (44.5) 0.17 [0.08-0.33] 100 (42.2) 0.16 [0.08-0.29] 37 (53.6) 0.27 [0.08-0.46]
Day 2-5 (24-120 h) 510 (100.0) 0.88 [0.69-1.08] 389 (100.0) 0.92 [0.76-1.10] 121 (100.0) 0.66 [0.51-0.93]
FVIII levels outside 
target range
339 (66.5) . 270 (69.4) . 69 (57.0) .
Above 303 (59.4) 0.23 [0.12-0.41] 262 (67.4) 0.24 [0.12-0.41] 41 (33.8) 0.19 [0.13-0.41]
Below 36 (7.1) 0.17 [0.07-0.24] 8 (2.1) 0.12 [0.03-0.23] 28 (23.1) 0.17 [0.08-0.24]
Day >6 (> 120 h) 471 (100.0) 0.68 [0.48-0.87] 422 (100.0) 0.70 [0.52-0.89] 49 (100.0) 0.44 [0.26-0.69]
FVIII levels outside 
target range
383 (81.3) . 347 (82.2) . 36 (73.5) .
Above 343 (74.7) 0.31 [0.15-0.45] 321 (76.1) 0.30 [0.16-0.45] 22 (44.9) 0.19 [0.10-0.30]
Below 40 (8.7) 0.11 [0.05-0.16] 26 (6.2) 0.09 [0.05-0.14] 14 (28.6) 0.12 [0.09-0.20]
No., number; IQR, interquartile range.
figure 1. Achieved FVIII levels in adults and children receiving clotting factor replacement therapy.
Achieved factor VIII (FVIII) levels in adults and children receiving clotting factor replacement therapy. Achieved 
FVIII levels in hemophilia patients treated via continuous infusion (blue) and via bolus infusions (red). Pre-
defi ned target levels as stated by the National Hemophilia Consensus are depicted as green boxes [3].
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performed before 2005 and after 2005 (Table S2). In addition, specific treatment center 
was not associated with proportion of underdosing or overdosing (data not shown).
Predictors of underdosing and (excessive) overdosing
In our logistic regression model, blood group O and major surgery were predictive of 
underdosing (respectively, odds ratio [OR] = 6.3, [95% confidence interval (95%CI) = 
2.7-14.9] and OR = 3.3 [95%CI = 1.4-7.9]) (Table 4). Complementary, blood group non-O, 
increasing age (per year) and replacement therapy with a plasma derived product and 
via bolus infusion were predictive of overdosing (Table 4). Replacement therapy with a 
plasma derived product and via bolus infusion and increasing age (per year) were as-
sociated with excessive overdosing.
Clotting factor VIII concentrate consumption
For the first surgical procedure in each individual, the median total amount of infused 
FVIII concentrate per kilogram per day during hospitalization was significantly higher 
in children when compared with adults (children: 93 IU kg-1 day-1 [IQR 75-119 IU kg-1 
day-1] and adults: 57 IU kg-1 day-1 [IQR 41-77 IU kg-1 day-1]; P < 0.001) (Table 5). Mode of 
infusion, type of concentrate (plasma derived or recombinant), and severity of surgical 
procedures were not associated with the amount of FVIII consumption for both children 
Table 4. Predictors of underdosing and (excessive) overdosing
OR 95% Confidence interval
Underdosing
Age (per year)# 1.03 0.99 - 1.07
Blood group O† 6.30 2.65 - 14.93
Major surgical procedure$ 3.30 1.38 - 7.90
Overdosing
Age 1.02 1.02 - 1.03
Blood group O† 1.47 1.13 - 1.91
Product type (recombinant) $$ 0.52 0.38 - 0.72
Mode of infusion (bolus)‡ 1.78 1.34 - 2.37
Excessive overdosing
Age 1.02 1.01 - 1.02
Product type (recombinant)$$ 0.48 0.37 - 0.63
Mode of infusion (bolus)‡ 1.92 1.45 - 2.54
Stepwise backward logistic regression analysis. OR, odds Ratio; CI, confidence Interval; # Increasing age (per 
year) † vs. blood group non-O; ‡ vs. continuous infusion; $ vs. minor surgical procedure; $$ vs. plasma derived 
clotting factor concentrate.
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and adults. As expected, an overall decrease was observed in infused FVIII concentrates 
over consecutive postoperative days, both in adults and children, as set target range 
values also decrease accordingly (P for trend < 0.001) (Figure S1).
Total FVIII concentrate consumption of the whole study cohort during the entire periop-
erative period amounted to a total of 6,800,000 IU. If predefi ned FVIII target ranges had 
been maintained according to the national guidelines, this would have led to a reduction 
of consumption of FVIII concentrate of 44% (Figure 2). This percentage was calculated by 
subtracting the total amount of FVIII concentrate under lowest target range level (e.g. 
491 000 IU) from FVIII concentrate consumed above highest target range level (e.g. 3 510 
000 IU) and dividing it by total consumption as defi ned earlier.
Perioperative blood loss and haemostasis
Forty-fi ve (32%) of the surgical procedures in adults and three (5%) surgical procedures 
in children were complicated by perioperative bleeding. In patients with blood group O, 
overall more bleeding complications were observed than in patients with blood group 
non-O (blood group O, n = 29 [64%]; blood group non-O, n = 16 [36%]; P = 0.047; OR 2.02, 
95%CI 1.01-4.09) (Figure 3). These patients also experienced more severe bleeding; 15 
(33%) severe bleeding complications were observed in patients with blood group O in 
comparison to 8 (18%) in blood group non-O patients. Overall, with regard to severity of 
bleeding, 6 of the 45 bleeding complications in adult patients and none of the bleeding 
complications in pediatric patients required a reoperation (Table S3 and S4). These six 
reoperations encompassed fi ve for intra-articular bleeding in a total knee replacement 
and one for bleeding after drain removal. Bleeding complications were overall more 
common in patients undergoing an orthopedic surgical procedure.
Overall, we did not fi nd an association between bleeding complications and actual FVIII 
plasma level at the time of the bleeding episode in adults (median FVIII level for patients 
figure 2. Total amount of FVIII consumption underdosed and overdosed in the perioperative setting.
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with a bleeding complication or without a bleeding complication: 0.81 IU mL-1 [0.65-0.99 
IU mL-1] or 0.82 IU mL-1 [0.62-1.07 IU mL-1]; P = 0.92) and children (median FVIII level for 
patients with a bleeding complication or without a bleeding complication: 0.66 IU mL-1 
[0.43-0.92 IU mL-1] vs 0.72 IU mL-1 [0.46-0.92 IU mL-1]; P = 0.66). No thrombotic complica-
tions and no deaths were reported.
DISCUSSIOn
This is presently the largest study evaluating perioperative FVIII concentrate dosing in 
hemophilia A patients. Our data illustrate the challenges of maintaining FVIII target lev-
els in current perioperative dosing and the magnitude of underdosing and overdosing 
when targeting prescribed FVIII ranges according to guidelines in a resource-rich coun-
try. In this study, depending on postoperative day, 7-45% of achieved FVIII plasma levels 
were under the lowest predefi ned target range level recommended by national guide-
lines and 33-75% above the highest predefi ned target range level [3]. If target ranges 
had been adequately maintained, an impressive overall reduction of FVIII consumption 
of 44% would have been possible. Patients with blood group O were at increased risk of 
underdosing and had a higher rate of both overall bleeding and severe bleeding com-
plications. In this retrospective analysis, we were not able to demonstrate an association 
between an actual lower FVIII plasma level at the time of a bleeding episode, as FVIII 
levels were often not available directly during the event. The data do, however, suggest 
that patients with blood group O may have a higher perioperative bleeding risk due to 
overall lower FVIII levels. Most probably, this is explained by lower VWF levels in patients 
with blood group O. Unfortunately, VWF:Ag and VWF:Act levels were only sporadically 
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available in this study, as perioperative VWF testing is currently not common practice, 
making it difficult to analyze this association. Previous studies have reported that 
lower VWF levels lead to shorter FVIII half-life as VWF protects FVIII against proteolytic 
degradation in the circulation [20-23]. Inversely, in this study, overdosing was predicted 
by blood group non-O and older age. This also may be explained by VWF levels, which 
are generally higher in blood group non-O and higher with increasing age [26]. Further 
supportive of this hypothesis are data collected by Kahlon et al. in healthy individuals, 
describing a decrease of VWF levels 30 min after incision and higher VWF levels 1 day 
after surgery [27]. If patients with lower baseline VWF levels decrease according to this 
principle at initiation of surgery and are not able to subsequently increase VWF levels, 
this may coincide with a higher perioperative bleeding risk. Further predictors of over-
dosing, other than blood group non-O and older age, were replacement therapy with 
plasma derived clotting factor concentrates and treatment via bolus infusion.
Strengths and limitations
Strengths of the study are the large number of included patients and surgical proce-
dures, not documented before, as well as the fact that patients were included from 
numerous treatment centers all work dedicatedly according to one national guideline 
[3]. The guideline was developed and approved by all hemophilia treatment centers 
collaborating within the Hemophilia Doctors Organization in the Netherlands. In the 
study, actual dosing regimens and subsequent FVIII plasma samples during the past 10 
years were collected thoroughly, and complications were extensively documented. Data 
were collected and checked by two independent researchers. The cohort is therefore 
representative of severe and moderate hemophilia A patients undergoing surgery in a 
resource-rich country.
Study limitations include the retrospective nature of the data. Therefore, not all periop-
erative patients were monitored as intensively, and analyses of modifiers of consump-
tion were difficult as data were not collected prospectively according to protocol. Major 
surgical procedures may be overrepresented in the study as these were, of course, 
monitored more intensely than minor surgical procedures. However, earlier reports 
show a similar prevalence of surgical procedures in other hemophilia populations [28, 
29]. In addition, quantification and documentation of blood loss is notoriously difficult, 
especially in retrospective studies. Therefore, criteria were applied for blood loss as de-
fined by the ISTH [18], leading to possible overreporting of blood loss as this definition 
is quite sensitive. We additionally reported clinically relevant, severe bleeding as defined 
simply and reliably by necessary red blood cell transfusion and/or reoperation.
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Potentially, the use of one-stage laboratory assays to measure FVIII plasma levels may 
lead to biased results with regard to achieved FVIII plasma levels. This is especially a 
concern as these assays generally lead to higher FVIII levels in higher FVIII ranges than 
do two-stage (chromogenic) assays [30-32], with the exception of the measured FVIII 
levels after infusion of one specific B domain-deleted FVIII concentrate, which was also 
administered in this study. In this B domain-deleted FVIII concentrate, one-stage assays 
lead to measurement of lower FVIII plasma levels, potentially leading to overdosing 
specifically in these patients. Due to the latter, consumption was analyzed extensively 
according to product type in our study cohort. However, no association was found 
between consumption of FVIII concentrate and specific product type. Prospective stud-
ies in perioperative hemophilia A patients are required to verify the data with regard 
to FVIII levels and type of FVIII assay. Currently, the one-stage assay remains the most 
often applied assay, and study results depict daily practice in the majority of hemophilia 
treatment centres.
fVIII consumption and mode of infusion of replacement therapy
In our study, median total amount of infused FVIII concentrates per kilogram per day 
during hospitalization was comparable to that in previous reports, both in adults and 
children [13, 33-38]. As expected, the amount of infused FVIII concentrate per kilogram 
was higher in children compared with adults, which is explained by a higher clearance 
of FVIII in young children resulting in a shorter half-life [19] and due to a larger volume 
of distribution in children in comparion with adults [39]. Consequently, variables associ-
ated with FVIII consumption were analyzed separately for children and adults.
The extent and timing of FVIII underdosing and overdosing in the perioperative pe-
riod have not been reported earlier. Both underdosing, most significant directly after 
surgery, and (excessive) overdosing, most significant > 6 days after surgery, can clearly 
be improved. During the entire study period, clinical practice in participating centers 
with regard to perioperative management of replacement therapy did not change as 
guidelines were not altered. Patients with preoperative or perioperative FVIII levels that 
were lower than expected, received additional bolus infusion(s) of FVIII concentrate to 
achieve target ranges as set by the consensus. Discrepancies between target ranges 
and actual FVIII plasma levels increased consecutively during the perioperative period, 
suggestive of a focus on prevention of bleeding and not on prevention of overdosing.
In two prospective studies by Batarova et al. and Bidlingmaier et al., savings of 30-36% of 
FVIII concentrate consumption were calculated for continuous versus intermittent bolus 
infusion [9, 16]. Our data, however, do not support continuous dosing as more cost 
reductive compared with intermittent bolus infusion. This may be due to the following 
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factors. In our study, the total amount of FVIII concentrate was corrected for duration of 
hospitalization, not only for body weight as in previous studies. Further, confounding by 
indication, for example, severity of surgical procedure, may have influenced outcome, as 
continuous infusion was more often used in more severe procedures. Moreover, when 
intermittent bolus infusion was applied in our study, it was often dosed more frequently 
per day in lower doses, thereby mimicking continuous dosing. All of these factors may 
have led to smaller differences in FVIII concentrate consumption between modes of 
administration of therapy. Last, type of concentrate and severity of surgical procedure 
were not associated with the overall amount of FVIII consumption in both children and 
adults, probably due to collinearity between these specific variables.
Complications
In this cohort, representative for surgical patients in hemophilia treatment centers 
in resource-rich countries [28, 29] bleeding complications were seen in 32% of adult 
patients and 5% of pediatric patients. This high percentage seems due to the broad 
ISTH definition applied in our study for bleeding, which was not used in comparable 
studies [29, 33, 35, 40]. Cases were mainly defined by the decrease of hemoglobin of ≥ 
1.24 mmol L-1 included in the definition, which was not accompanied by hemodynamic 
problems or low FVIII plasma levels in study patients. Severity of bleeding was similar 
to earlier reports, as the percentage of study patients requiring a reoperation (3%) was 
comparable to a previous study, which reported a percentage of 2.7% [33]. We could not 
demonstrate that FVIII plasma levels were under lowest target range levels in patients 
with bleeding complications [33], although this may be due to a lack of FVIII testing at 
the bleeding occurrence and FVIII plasma levels measured after acute FVIII concentrate 
administration.
Theoretically, in our study, optimal maintenance of predefined target FVIII levels by 
refined dosing would have led to a reduction of FVIII consumption of maximally 44%, 
with a concomitant reduction of treatment costs. However, when using a strategy of 
optimal target value maintenance, it is, of course, not possible to completely eliminate 
underdosing and overdosing as the logistic delays caused by laboratory monitoring, and 
assessment of FVIII values and adjustment of treatment will persist. Although currently 
not yet available due to the lack of perioperative PK population models, we believe 
more optimal treatment will consist of individually dosed FVIII concentrate based on 
an individual FVIII PK profile with adaptive dosing according to a perioperative FVIII PK 
population model. Until recently, most studies on PK-guided dosing were performed in 
the prophylactic setting [41-43]. In the few studies in which perioperative PK profiling 
is mentioned it was solely used to establish a preoperative PK- guided loading dose [9, 
11, 13].
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Conclusion
Our findings demonstrate significant underdosing and (excessive) overdosing of FVIII 
concentrate and identify its predictors during the perioperative period with current 
dosing strategies based on body weight and crude estimations of clearance. Blood 
group O proved to be predictive of underdosing and was associated with a higher risk 
of bleeding complications; blood group non-O was demonstrated to be a predictor of 
overdosing. With regard to excessive overdosing, older age and replacement therapy via 
bolus infusion were shown to be predictive. Currently available PK population models 
for FVIII replacement therapy in the prophylactic setting support that age influence FVIII 
plasma concentrations significantly [20, 41]. These data underline that quality of care 
and cost-effectiveness can be improved by future refining of dosing strategies based on 
individual patient characteristics such as the predictors blood group and mode of infu-
sion. However, we also believe that not all variables of influence on dosing and clearance 
of FVIII concentrate have yet been defined. Therefore, novel developments with regard 
to PK-guided dosing based on PK population models and Bayesian analysis, taking both 
known and unknown modifying factors into account as proposed by Bjorkman et al. 
[41], are more than promising.
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figure S1. Amount of infused FVIII clotting factor concentrate.
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Table S1. Classification of included surgical procedures*.
Surgical Type High Risk** Major Minor
General
Laparotomy Major
Liver Biopsy Major
Cholecystectomy and exploration of common duct Major
Colorectal Surgery    
Excision of anal fistula Minor
Gastro duodenoscopy (biopt) Major
Diagnostic laparoscopy Major
Vascular
Amputation of limb Major
Cardiothoracic Surgery
Insertion of defibrillator Major
Coronary Angioplasty High    
Coronary Artery Bypass Graft (CABG) High    
Excision of mediastinal mass High    
neurosurgery
Craniotomy High    
Meningioma High    
Shunt procedures High    
Orthopedics
Arthroscopy (shoulder/knee)   Major  
Foot or ankle surgery     Minor
Incision drainage     Minor
Internal fixation of tibia or fibula   Major  
Revision of total hip and knee replacement   Major  
Scoliosis surgery High    
Total joint replacement (elbow, hip, shoulder, knee)   Major  
Hand or wrist surgery Minor
Urology
Circumcision Minor
Vasectomy Minor
Prostatectomy   Major  
Urethroplasty   Major  
Urerthrolithotomy   Major  
Maxillofacial
Bimaxillary osteotomy   Major  
Craniofacial Surgery High    
EnT (Ear-nose-throat)
Adenoidectomy     Minor
Adenoido-tonsillectomy   Major  
ENT: insertion of stents     Minor
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Table S1. Classification of included surgical procedures*. (continued)
Surgical Type High Risk** Major Minor
Tonsillectomy   Major  
Eye Surgery
Orbital surgery   Major  
Cataract/Virectomy/Retinal surgery     Minor
Miscellaneous
Dental surgery     Minor
Drainage of abscess     Minor
Excision burns scars     Minor
Excision of lipoma     Minor
Hernia repair (inguinal/umbilical)     Minor
Central venous catheter removal/insertion     Minor
* Surgical risk score according to Koshy et al. 1995; ** Excluded
Table S2. Frequency of underdosing and overdosing in the perioperative period before 2005 and after 
2005.
2000 - 2013 < 2005 > 2005
Underdosing (%)
0-24 hours 45 38 47
24-120 hours 7 10 4
>120 hours 8,5 12 8
Overdosing (%)
0-24 hours 33 36 31
24-120 hours 59 58 58
>120 hours 73 64 73
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Table S3. Characteristics of patients with a severe bleeding complication requiring a reoperation.
Patient
Surgical 
procedure
Day of 
occurrence of 
the bleeding 
complication Description
fVIII 
level 
(IU mL-1)
Mode of 
infusion
Other 
medication
blood 
group
1 Total knee 
replacement
Day 5 Intra-articular 
bleed
0.99 Bolus Heparin Non-O
2 Total knee 
replacement
Day 5 Intra-articular 
bleed
1.03 Continuous Heparin O
3 Total knee 
replacement
Day 4 Intra-articular 
bleed
0.68 Continuous Tranexamic 
acid
O
4 Fixation of hip/
humerus
Day 2 Bleed after 
removal of a 
drain
0.99 Continuous Tranexamic 
acid
O
5 Total knee 
replacement
Day 7 Intra-articular 
bleed
0.50 Continuous Tranexamic 
acid, heparin
O
6 Total knee 
replacement
Day 9 Intra-articular 
bleed
0.64 Continuous Tranexamic 
acid, heparin
O
Table S4. Surgical and patient characteristics of all bleeding complications and severe bleeding complica-
tions.
bleeding complication*
Severe bleeding 
complication
no Yes Reoperation RbCTf
Type of surgical procedure
 General 4 2 0 0
Colo-rectal 4 1 0 1
Vascular 0 1 0 1
Cardio-thoracic 0 1 0 0
Orthopedic 64 30 6 12
Urology 10 2 0 1
Maxillofacial 1 1 0 1
Ear-Nose-Throat 7 4 0 1
Eye 3 0 0 0
(Re)placement central intravenous catheters 32 0 0 0
Miscellaneous 25 6 0 1
Mode of infusion
 Continuous 83 32 5 12
 Bolus 67 16 1 6
blood group
 O 60 29 5 10
 Non-O 67 16 1 7
* According to the ISTH definition; RBCTF = red blood cell transfusion
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abSTRaCT
background The role of pharmacokinetic-guided dosing of factor concentrates in 
hemophilia is currently subject of debate and focuses on long-term prophylactic treat-
ment. Few data are available on its impact in the perioperative period.
Objective In this study, a population pharmacokinetic model for currently registered 
factor VIII concentrates was developed for severe and moderate adult and pediatric 
hemophilia A patients (FVIII levels < 0.05 IU mL-1) undergoing elective, minor or major 
surgery.
Methods Retrospective data was collected on FVIII treatment, including timing and dos-
ing, time point FVIII sampling and all achieved FVIII plasma concentrations (trough, peak 
and steady state), brand of concentrate, as well as patient and surgical characteristics. 
Population pharmacokinetic modeling was performed using nonlinear mixed-effects 
modeling.
Results Population pharmacokinetic parameters were estimated in 75 adults undergoing 
140 surgeries (median age: 48 years, median weight: 80 kg) and 44 children undergoing 
58 surgeries (median age: 4.3 years, median weight: 18.5 kg). Pharmacokinetic profiles 
were best described by a two-compartment model. Typical values for clearance, inter-
compartment clearance, central and peripheral volume were 0.15L/h/68 kg, 0.16L/h/68 
kg, 2.81L/68 kg and 1.90L/68 kg. Inter-patient variability in clearance and central volume 
was 37% and 27%. Clearance decreased with increasing age (P < 0.01) and increased in 
case of blood group O (26%, P < 0.01). In addition, a minor decrease in clearance was 
observed when a major surgical procedure was performed (7%, P < 0.01).
Conclusion The developed population model describes the perioperative pharmaco-
kinetic of various FVIII concentrates, allowing individualization of perioperative FVIII 
therapy for severe and moderate hemophilia A patients by Bayesian adaptive dosing.
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InTRODUCTIOn
Hemophilia A is an X-linked hereditary bleeding disorder characterized by a deficiency 
of coagulation factor VIII (FVIII). Current management of hemophilia patients consists of 
replacement therapy with plasma derived or recombinant factor concentrates in case 
of acute bleeding (“on demand”) or to prevent spontaneous or perioperative bleeding 
(“prophylaxis”). The aim of long-term prophylactic treatment is to prevent severe joint 
damage and subsequent long term invalidity by raising FVIII trough plasma concentra-
tions to at least > 0.01 IU mL-1 [1, 2]. To acquire adequate hemostasis in the surgical set-
ting, normalization of coagulation factor levels is advocated for 7-14 days after surgery 
in most perioperative protocols [3].
Treatment with factor concentrates is costly. In the Netherlands, total annual costs of 
replacement therapy are estimated at more than €130 million and include costs for 
prophylactic and on demand treatment [4-7]. In the Canadian Hemophilia registry, peri-
operative consumption amounts to 1-3% of the total annual amount administered [8].
As we have reported earlier, coagulation factor plasma concentrations as recommended 
by National and International Guidelines are often exceeded in the perioperative setting 
to avoid lower plasma concentrations and a possibly higher bleeding risk with additional 
costs [9, 10]. In a retrospective analysis of hemophilia A patients undergoing surgery, 
45% of FVIII plasma concentrations were below the target range during the first 24 hours 
after surgery and 75% of the plasma concentration were above the target range after six 
days of hospitalization. In addition, a reduction of 44% in factor concentrates could have 
been reached if plasma concentrations had been maintained within target levels in the 
perioperative setting [9].
In the prophylactic setting, Carlsson et al. have shown that FVIII consumption can be 
significantly reduced by application of pharmacokinetic (PK) modeling to individual-
ize dosing regimens [11-14]. In the perioperative setting, Longo et al. have reported 
excessive FVIII consumption and clearance in 50% of surgical hemophilia patients 
due to unidentified factors [15]. This suggests mechanisms of increased clearance 
due to hemostatic challenges during surgery. Although an initial preoperative factor 
concentrate bolus dose may be individualized by individual PK parameters obtained 
after an individual PK profile based on a prophylactic population PK model, this may not 
be applicable as soon as a surgical procedure is initiated. A perioperative population 
PK model, however would make PK-guided iterative adaptive Bayesian dosing with a 
potential concomitant decrease of factor concentrate consumption possible. During 
this procedure individual PK parameters are iteratively updated by combining PK in-
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formation (e.g. dose, concentration, time) from the individual patient with a priori PK 
information (e.g. average clearance, variability) from the population. The latter does not 
currently exist and has therefore never been performed.
In order to construct such a perioperative population PK model facilitating Bayesian 
adaptive dosing in severe and moderate hemophilia A, we collected detailed retrospec-
tive FVIII infusion data in patients who had undergone surgery under replacement 
therapy with various similar FVIII concentrates, from five hemophilia treatment centers.
METHODS
Patients and data collection
Severe and moderate hemophilia A patients of all ages with FVIII plasma concentration 
< 0.05 IU mL-1 who had undergone elective, minor or major surgical procedures between 
2000 and 2013 from five Academic Hemophilia Treatment Centers in the Netherlands 
were included [9]. Patients received replacement therapy consisting of various recom-
binant factor concentrates (Kogenate FS (Bayer, Berkely, Ca, USA], Helixate FS (CSL 
Behring, Marburg, Germany], Advate and Recombinate [Baxter Bioscience, Thousand 
Oaks, CA, USA], and Refacto AF [Pfizer, New York, NY USA]) or plasma derived factor 
concentrates (Aafact [Blood Transfusion council of the Netherlands Red Cross], Hemofil 
M [Baxter Bioscience, Thousand Oaks, CA, USA]) to achieve target FVIII plasma concen-
trations as set by the National Hemophilia Consensus. This guideline recommends peak 
and trough FVIII plasma concentrations on consecutive postoperative days (Table 1): 
0-24 hours 0.80-1.00 IU mL-1; 24-120 hours 0.50-0.80 IU mL-1 and >120 hours 0.30-0.50 IU 
mL-1 [3]. The following retrospective data were collected: FVIII dosages, detailed timing 
of administration and timing of FVIII blood sampling, mode of infusion (continuous or 
bolus infusion), all achieved FVIII plasma concentrations (both trough, peak and steady 
state plasma concentrations), patient and surgical characteristics, and concomitant 
medication with a possible effect on hemostasis (i.e. tranexamic acid, heparin, desmo-
pressin and nonsteroidal anti-inflammatory drugs). Patient characteristics included: 
weight, length, lean body mass [16, 17], body mass index (BMI) [18], blood group, 
Table 1. Prevalence of under- and overdosing in the perioperative period*
Time (hours) 0-24 24-120 >120
Consensus 0.80-1.00 IU mL-1 0.50-0.80 IU mL-1 0.30-0.50 IU mL-1
% above 33% (>1.00 IU mL-1) 59% (>0.80 IU mL-1) 75% (>0.50 IU mL-1)
% below 45% (<0.80 IU mL-1) 7% (<0.50 IU mL-1) 9% (<0.30 IU mL-1)
* According to the National Hemophilia Consensus
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von Willebrand Factor (VWF) antigen and VWF activity (historically measured), liver 
and renal function, clinical bleeding phenotype, history of FVIII inhibiting antibodies, 
intensity of prophylactic dosing regimen, brand of concentrate, and treatment center. 
Surgical characteristics included: type and severity of surgical procedure categorized 
into minor, major and high risk according to Koshy et al [19]. In all centers, FVIII plasma 
concentrations were measured by one-stage clotting assays. The study was not subject 
to the Medical Research Involving Human Subjects Act, as patient data were analysed 
anonymously. Moreover, the study was approved by all local Medical Ethics Committees; 
one center requiring prior patient informed consent.
Pharmacokinetic modeling
Population pharmacokinetics (PK) is defined as the study of sources of variability in drug 
concentrations after dosing that occurs within and between patients [20]. In the present 
population analysis, all plasma concentration time points were analyzed simultaneously 
using non-linear mixed-effects modelling software (NONMEM (version 7.2.0), Globomax 
LLC, Ellicott City, Maryland, USA) [21]. All PK related abbreviations and terminology 
are described in Table S1. More specifically, first-order conditional estimation (FOCE) 
method with interaction was applied, allowing interaction between structural and re-
sidual variance components. The statistical package R, version 2.14.2 (The R Foundation 
for Statistical Computing) and Xpose version 4 [22] were used for data set checkout, 
exploration and model diagnostics. Pirana software was used as an interface between 
NONMEM, R and Xpose [23].
Model diagnostics included the evaluation of the goodness of fit plots, the objective 
function value (OFV), the precision of the parameter estimates and the shrinkage of 
estimated random parameters. The OFV is a measurement of goodness of fit of the 
model and is proportional to minus two times the logarithm of the likelihood (-2log 
likelihood) of the data. Competing hierarchical models were compared by calculating 
the difference between their OFV. This ratio is assumed to be χ2 distributed. Therefore, 
if models differ by one parameter, a decrease in OFV of 3.84 corresponds to P = 0.05 (1 
degree of freedom). And OFV decreases of 6.63 and 10.8 correspond to P-values of 0.01 
and 0.001, respectively.
Structural model development
FVIII plasma concentrations were described by a two-compartment PK model. Estimated 
(fixed) parameters were clearance (CL), volume of distribution of the central compart-
ment (V1), intercompartment clearance (Q) and volume of distribution of the peripheral 
compartment (V2). The structural model also accounted for the individual endogenous 
baseline FVIII plasma concentration. PK parameters were allometrically scaled to account 
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for the wide range of body weights of both adult and pediatric patients. An allometric 
power model was used with power exponents fi xed at 0.75 for clearances and 1.0 for 
volumes of distribution [24], as described in the following equations:
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for a subject with a body weight of 68 kilogram.
The random parameters inter-individual variability (IIV) and inter-occasion variability 
(IOV) of the PK parameters were estimated using an exponential function according to:
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where ηi and κi represent the IIV and IOV, respectively, and are assumed to be symmetri-
cally distributed with a mean of 0 and an estimated variance of ω2 and π2. IIV and IOV 
were included in the model if shrinkage was less than 20% [25]. The structural model 
also accounted for under prediction of plasma concentrations of a B-domain deleted 
product (Refacto®) due to known discrepancies and infl uence of one-stage laboratory 
assays on plasma concentrations [26, 27], as described:
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Where Cpred,bdp and Cpred are the predicted concentrations of the B-domain deleted prod-
uct (bdp) and other products, respectively, and θ is the fractional decrease in concentra-
tion.
Residual variability in FVIII concentration was described using a combined error model.
Covariate search
After obtaining the structural model individual empirical Bayesian estimates were ob-
tained for all PK parameters. Correlations between these parameters and patient and 
surgical characteristics, and the use of concomitant medication were explored graphi-
cally. All covariates were tested in a univariate analysis. The most clinically relevant and 
statistically signifi cant covariate was retained in the model: a stepwise forward approach 
was used to determine clinical and statistically signifi cant covariates with P-values < 
0.05. Backward elimination was performed to confi rm that all included covariates in the 
fi nal model were statistically signifi cant with P < 0.01. As the occurrence of a bleeding 
complication could not be related to actual FVIII plasma concentrations [9], occurrence 
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of a bleeding complication was not included in the fi nal model. Moreover, only a limited 
diff erence in clearance was observed between patients with and without a bleeding 
complication (7%). Also, time dependent changes in clearance were tested during the 
perioperative period.
final model and model evaluation
The stability and performance of the fi nal model was checked using an internal 
validation procedure via the bootstrap resampling technique in which 1000 bootstrap 
datasets were generated by random sampling with replacement [28]. Visual predictive 
check plots obtained after Monte Carlo simulations of the study population were used 
to evaluate if the fi nal model adequately described observed data [29].
RESULTS
Patients and treatment in the perioperative setting
Our cohort consisted of 119 hemophilia A patients undergoing a total of 198 surgical 
procedures as described previously [9]. Patients were treated for up to two weeks af-
ter surgery according to the National Hemophilia Consensus (Table 1) [3]. Treatment 
consisted of a preoperative bolus infusion of approximately 50 IU kg-1 followed by a 
treatment scheme with either bolus infusions or continuous infusion therapy based on 
a clearance rate of 3-4 mL kg-1 hour-1. General characteristics of these included patients 
are shown in Table 2. Seventy-fi ve patients underwent only one surgical procedure. Half 
of all patients had blood group O (51%). In three percent of all surgical procedures a se-
vere bleeding complication occurred, defi ned as necessity of a red blood cell transfusion 
(RBCT) and/or necessity of a second surgical intervention, which could not be related to 
FVIII plasma concentrations. In total 1389 FVIII measurements were obtained, equally 
distributed on consecutive days in the perioperative setting (Figure 1). Approximately 
7 samples per patient were taken in the perioperative period. In summary, 45% of FVIII 
plasma concentrations were below the target range in the fi rst 24 hours and 75% were 
above the tvarget range after six days of hospitalization (Table 1).
Pharmacokinetic modeling
Structural model development
Time profi les of FVIII plasma concentrations were best described by a two-compartment 
model with allometric scaling for body weight (Figure 2). By allometric scaling, all 
estimated PK parameters were normalized for a body weight of 68 kg. Model building 
steps that resulted in signifi cant decrease of the OFV and consequently a better fi t of the 
model are shown in Table 3. In the structural model, typical values for CL and V1 were 
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Table 2. Population characteristics
 
Total cohort adults Children
no. (%); or Median [minimum; maximum]
Patient characteristics
No. of patients 119 75 44
Age (years) 40 [0.2-78] 48 [19-78] 4 [0.2-17.3]
Weight (kg) 75 [5-111] 80 [45-111] 19 [5-85]
Severe hemophilia
(FVIII levels <0.01 IU mL-1)
83 (69.7) 49 (65.3) 34 (77.3)
On prophylaxis 84 (70.6) 51 (68.0) 33 (75.0)
Blood group O* 51 (50.5) 34 (50.0) 17 (51.5)
Historical VWF levels
Antigen 1.1 [0.3-2.5] 1.2 [0.3-2.5] 0.9 [0.5-2.3]
Activity 1.1 [0.2-2.7] 1.4 [0.2-2.7] 0.9 [0.4-1.7]
Surgical characteristics
Total no. of surgical procedures 198 140 58
No. of patients undergoing:
1 procedure 75 (63.0) 43 (57.3) 32 (72.7)
2 procedures 26 (21.8) 15 (20.0) 11 (25.0)
3 procedures 9 (7.6) 9 (12.0) 0 (0.0)
> 4 procedures 9 (7.6) 8 (10.7) 1 (2.3)
Major surgical procedure 97 (49.0) 86 (61.4) 11 (19.0)
Type of surgical procedure
General 6 (3.0) 6 (4.3) 0 0
Colorectal 5 (2.5) 4 (2.9) 1 (1.7)
Vascular 1 (0.5) 1 (0.7) 0 0
Cardio-thoracic 1 (0.5) 1 (0.7) 0 0
Orthopedic 94 (47.5) 91 (65.0) 3 (5.2)
Urology 12 (6.1) 4 (2.9) 8 (13.8)
Maxillofacial 2 (1.0) 2 (1.4) 0 0
Ear-nose-throat 11 (5.6) 6 (4.3) 5 (8.6)
Eye 3 (1.5) 3 (2.1) 0 0
(Re)placement of central 
intravenous catheters
32 (16.2) 1 (0.7) 31 (53.4)
Miscellaneous 31 (15.7) 21 (15.0) 10 (17.2)
Replacement therapy with factor 
concentrate, hospitalization and 
blood loss
Mode of infusion
Continuous 115 (58.1) 88 (62.9) 27 (46.6)
Bolus 83 (41.9) 52 (37.1) 31 (53.4)
Product type
Recombinant 152 (76.8) 99 (70.7) 53 (91.4)
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Table 2. Population characteristics (continued)
 
Total cohort adults Children
no. (%); or Median [minimum; maximum]
Plasma derived 46 (23.2) 41 (29.3) 5 (8.6)
Duration of hospitalization (days) 9 [1-50] 9 [1-50] 7 [1-16]
Complications during the 
perioperative period
No. of patients with a complication
Bleeding 48 (24.2) 45 (32.1) 3 (5.2)
Re-operation 6 (3.0) 6 (4.3) 0 0
Hemoglobin drop >20 gL-1
and/or erythrocyte transfusion
38 (19.2) 36 (25.7) 2 (3.4)
Bleeding with prolonged 
hospitalization
5 (2.5) 4 (2.9) 1 (1.7)
    Thrombosis 0 0 0 0   0 0
fVIII data
FVIII measurements (trough, peak 
and SS)
1389 1124 265
Prior to surgery 158 (11.4) 114 (10.1) 44 (16.6)
Day 1 (0 - 24 h) 323 (23.2) 246 (21.9) 76 (28.7)
Day 2 - 5 (24 - 120 h) 473 (34.0) 363 (32.3) 110 (41.5)
Day > 6 (>120 h) 436 (31.4) 401 (35.7) 35 (13.2)
No., number, %; percentages; kg, kilogram; FVIII, coagulation factor VIII; IU mL-1, international units per mil-
liliter; BU, Bethesda Units; VWF, von Willebrand factor; mmol L-1, millimolar per liter; g L-1, gram per liter; 
* Blood group known of 101 patients.
figure 1. Perioperative FVIII plasma concentrations and visual predictive check for observed FVIII plasma 
concentrations.
Perioperative FVIII plasma concentrations consists of trough, peak and steady state concentrations for both 
modes of therapy (continuous infusion and bolus infusion therapy); Visual predictive check for the ob-
served FVIII plasma concentrations, given the final model; observed FVIII plasma concentrations and mean, 
5th percentile and 95th percentile observed and simulated FVIII plasma concentrations. 
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190 ml/hour/68 kg and 3030 ml/68 kg (Table 4). It was possible to estimate IIV for CL and 
V1 whereas estimates for IIV of Q and V2 were imprecise and accompanied by a large 
shrinkage of > 40% [25]. Although this may suggest that inter-patient variability in Q 
and V2 is absent, this is due to the fact that available data was not informative enough. 
The IIV for CL and V1 were respectively 45% and 29%, underlining the importance of 
individualization of therapy. Estimation of IOV on CL and V1 resulted in high shrinkage 
values for both parameters (respective value 34% and 46%); consequently IOV was not 
included in the model. Inclusion of individual endogenous baseline FVIII plasma concen-
trations and inclusion of a structural under prediction of plasma concentrations using a 
B-domain deleted product improved the model. A proportional under prediction of 0.34 
(34%) in FVIII plasma concentration was estimated for this product. The residual error 
was described using a combined error model.
Covariate search
In the univariate analysis, significant covariates of clearance were age (P < 0.001), blood 
group (P < 0.01), severity of surgical procedure (P < 0.01), lean body mass (P < 0.01), use 
of tranexamic acid and heparin (P < 0.05), historically measured VWF antigen and activ-
ity levels (P < 0.05). Treatment center and type of product were not significant covariates. 
After the step forward analysis only age, blood group, and severity of surgical procedure 
were significantly associated with clearance. After the inclusion of age in the model, 
VWF antigen and activity levels were no longer statistically significant. Age was also as-
sociated with V1 (Table 3). Different models were used to test possible time dependent 
changes in clearance during the perioperative period; no differences were observed 
however. Differences in residual error were detected for the different centers.
figure 2. Visualization of NONMEM analysis and outcomes.
Allometric scaling based on body weight was applied with an allometric exponent of 0.75 for the clearance 
parameters and 1 for the volume terms; Age in years; IIV= inter-individual variability.
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covariates. IIV of V1 decreased from 29% to 27%. The PK parameter estimates of the final 
model are presented in Table 4. Typical PK parameter estimates were described with the 
equations presented in Table 5.
According to the equation, clearance was 214, 169, 150 and 142 ml/h/68 kg for a typical 
patient (with blood group non-O undergoing a minor surgical procedure) with an age 
of 5, 20, 40 and 55 years, respectively. In case of a major surgical procedure, a small de-
crease in CL was observed of 7% (Table 4). Interestingly, individual post-hoc clearances 
were higher in patients with a major surgical procedure (Figure 3B). This was however 
explained by collinearity between covariates; older patients underwent more major sur-
gical procedures (Figure 4). Clearance increased by 26% in patients with blood group O. 
CL and elimination half-life are depicted as functions of age and body weight in Figure 5.
The adequacy of the derived final model is shown in Figure 6. Population and indi-
vidually predicted concentrations for all patients were plotted against the measured 
concentrations in Figure 6. A good agreement was observed between FVIII concentra-
tions predicted by the model and those assessed by laboratory measurements. Overall, 
Table 3. Model-building steps resulting in significant decreases in objective function value (OFV)
Model nOP OfV
Structural model#
1 One compartment with IIV on V1 and CL 7 -2604.5
2 Two compartment with IIV on V1 and CL 9 -2799.3
3 Inclusion of individual endogenous baseline FVIII plasma concentrations 9 -2816.1
Covariates on CL (added to model 3)
4 Age 10 -2851.8
5 Age, blood group 11 -2862.3
6 Age, blood group, bleeding complication 12 -2886.7
7 Age, blood group, bleeding complication, severity of surgical procedure 13 -2895.2
Covariates on V1 (added to model 7)
8 Age 14 -2911.8
Error model (added to model 8)
9 Center (two categories) 16 -2930.6
# Allometric scaling based on body weight was applied with an allometric exponent of 0.75 for the clear-
ance parameters and 1 for the volume terms; under prediction of FVIII plasma concentrations of a B-domain 
deleted product was implemented NOP = number of estimated parameters, OFV = objective function val-
ue, IIV = inter-individual variability, V1 = volume of the central compartment, CL = clearance.
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Table 4. Parameter estimates for the final model and bootstrap analysis
Parameter
Structural model final model
bootstrap analysis 
final model
Mean (%RSE) Mean (%RSE) Mean (%RSE)
Structural model
θ1 - Clearance (CL; ml/h/68 kg) 190 (5) 150 (8) 160 (5)
θ2 - Volume of central compartment (V1; ml/68 kg) 3030 (3) 2810 (4) 2810 (3)
θ3 - Inter-compartmental clearance (Q; ml/h/68kg) 170 (17) 160 (20) 170 (15)
θ4 - Volume of peripheral compartment (V2; ml/68 kg) 1930 (12) 1900 (11) 1890 (8)
Β-domain deleted product 0.32 (11) 0.34 (13) 0.33 (10)
Covariate parameters
θ5 - CL – Age (change with increasing age) -0.17 (22) -0.16 (13)
θ6 - CL – Blood group O (% difference) 26 (7) 27 (22)
Θ7 - CL – Major surgical procedure (% difference) -7 (6) -7 (34)
Θ8 - V1 – Age (change with increasing age) -0.09 (28) -0.09 (18)
Inter-individual variability
Clearance (% CV) 45 (13) 37 (14) 36 (10)
Volume of central compartment (% CV) 29 (13) 27 (14) 26 (11)
Residual variability
Additive residual error (SD; IU mL-1)
 Center 1,2,3 0.15 (12) 0.14 (9)
 Center 4,5 0.05 (28) 0.05 (20)
Proportional residual error (% CV)
 Center 1,2,3 0.18 (15) 0.18 (9)
 Center 4,5 0.23 (9) 0.23 (7)
RSE indicates relative standard error; and CV coefficient of variation.
Table 5. Model equations describing the perioperative population PK model
CL CL (ml/h) = 150 x ((body weight / 68) ^ 0.75) x ((age / 40) ^ -0.17) x (1.26 ^ blood group) x (0.93 ^ severity 
of surgical procedure)
V1 V1 (ml) = 2810 x (body weight / 68) x ((age / 40) ^ -0.09)
Q Q (ml/h) = 160 x ((body weight / 68) ^ 0.75)
V2 V2 (ml) = 1900 x (body weight / 68)
Body weight (kilograms); Age (years); Blood group equals one in case of blood group O and zero in case of blood group 
non O; Severity of surgical procedure equals one in case of a medium risk surgical procedure and zero in case of a low 
risk surgical procedure.
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standardized weighted residuals revealed a random distribution around zero, within -2 
to +2 range indicative of an unbiased estimation (Figure 6C).
Model evaluation
A good agreement was found between parameter estimates of the final model and 
parameter estimates of the bootstrap analysis (Table 4). A visual predictive check was 
conducted by 1000 simulations based on the final model as shown in Figure 1. It con-
firmed, adequateness of the model, as seven percent of the measured concentrations 
were calculated above the 95th percentile of the simulated concentrations and nine 
percent of the measured concentrations were found to be below the 5th percentile of 
the simulated concentrations.
figure 3. Graphical visualization of variability of the clearance and covariates.
Visualization of variability of the clearance; a. as a function of blood group O versus blood group non O; b. 
as a function of risk of surgical procedure.
A perioperative population pharmacokinetic model for FVIII concentrate
142
  C
ha
pt
er
 7
DISCUSSIOn
In this study, a population PK model was constructed describing the perioperative PK of 
several currently used FVIII concentrates. These factor VIII concentrates were in majority 
FVIII recombinant products (77% of surgical procedures), of which 14% were a B-domain 
deleted FVIII concentrate, as well as plasma-derived FVIII concentrates (23% of surgical 
procedures). In the population PK model, a difference in results due to the B-domain 
deleted FVIII concentrate (Refacto AF®) was accounted for. No other differences were 
observed between products. As this difference is incorporated into the population PK 
model, this perioperative FVIII population PK model can be used for all described FVIII 
concentrates. The developed model will facilitate Bayesian adaptive dosing, allowing 
individualization of FVIII dosing during the entire perioperative period. Earlier, only a 
few studies have reported application of PK-guided dosing during the perioperative 
period. Unfortunately, in all studies only the FVIII loading dose was based on an indi-
vidual PK-profile derived several days before surgery [30-35]. Iterative perioperative FVIII 
dosing-adjustments after first loading dose could not be performed as a population PK 
figure 4. Clearance of FVIII in major and minor surgical procedures after stratification for age.
Post-hoc estimates of FVIII clearance, normalized for total body weight, and stratified for age (<4 years or 
>4 years) were categorized according to severity of surgical procedure. *A Spearman’s correlation test was 
performed to test for clearance differences between major and minor surgical procedures. The median 
age of children included in the study was used as cut-off value for analysis. This was supported by results 
of figure 5A.
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model was lacking . The perioperative population PK model presented, will now make 
Bayesian adaptive dosing in this setting possible. Moreover, it will take all important 
patient characteristics associated with clearance in the surgical setting into account.
figure 5. Clearance and elimination half-life as functions of age and body weight.
a. Clearance of FVIII, normalized for total body weight, as a function of age; b. Clearance of FVIII as a function 
of body weight; c. The elimination half-life of FVIII as a function of age; d. The elimination half-life of FVIII as 
a function of body weight. Eta shrinkage was 10% and 20% respectively for the estimates of inter-individual 
variability of clearance and volume of the central compartment.
figure 6. Observed and model-predicted FVIII plasma concentrations.
NONMEM model diagnostic plots, observed and model predicted FVIII plasma concentrations plotted 
against each other; a. population predicted FVIII plasma concentrations; b. individually predicted FVIII plas-
ma concentrations; c. conditionally weighted residuals versus time
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The presented model consists of a two-compartment model with allometric scaling 
of the PK parameters for body weight. Both increasing age and increased severity of 
surgical procedure were overall significantly associated with a lower FVIII clearance, 
although individual clearance rates showed that patients with a major surgical proce-
dure did demonstrate higher clearance rates. This contradiction may be due to the fact 
that included covariates in the PK model were confounders e.g. older patients with a 
decreased CL of FVIII concentrate underwent major risk surgical procedures more often 
than younger patients. Also, increased consumption of concentrates due to blood loss 
and activation of coagulation are other possible modifying factors. In addition, blood 
group O was associated with higher FVIII clearance, which will be discussed in following 
sections. Although it should be underlined that this population PK model is an important 
development, it is important to realize that it does not account for pharmacodynamic 
outcome measures, as the occurrence of a bleeding complication could not be related to 
actual FVIII plasma concentrations due to scarcity of FVIII plasma concentrations during 
an acute bleeding.
As in most resource rich countries, current perioperative replacement therapy in hemo-
philia A in the Netherlands, consists of a FVIII loading dose followed by either continuous 
FVIII infusion or treatment with FVIII bolus infusions, while targeting predefined peak 
and trough FVIII plasma concentrations as stated in the National Hemophilia Consensus 
[3]. The retrospective study performed to collect data for this PK model, has been de-
scribed earlier [9]. Results show the challenges of current perioperative dosing of FVIII 
replacement therapy in daily clinical practice when targeting prescribed FVIII plasma 
concentrations as significant underdosing and overdosing were demonstrated. More-
over, it underlines the necessity of alternative, more individualized dosing strategies in 
the perioperative setting as is possible when PK-guided dosing based on a population 
PK model is applied.
PK-guided dosing based on population PK models has mainly been studied in the long-
term prophylactic setting. However, to be able to apply Bayesian adaptive dosing, it is 
necessary to utilize a population PK model appropriate for the individual patient and 
the specific setting concerned. In analyses preceding the construction of this periop-
erative population PK model, it was confirmed that the mean estimated PK parameters 
for prophylactic dosing, as reported by Björkman et al. [12], did not reliably predict 
observed perioperative FVIII plasma concentrations. Using the prophylactic model, 
calculations showed an under prediction of perioperative FVIII concentrations < 1.00 IU 
mL-1 as well as an overprediction of FVIII concentrations > 1.00 IU mL-1. In other words, 
actual FVIII plasma concentrations were higher and respectively lower than predicted 
by prophylactic population PK model (data not shown). Therefore, it was concluded that 
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prophylactic population PK models cannot be applied in the perioperative setting. Use 
of the prophylactic model in this setting would generate a bias of predicted periopera-
tive FVIII plasma concentrations.
In the prophylactic setting, a similarly constructed population PK model has been ap-
plied earlier [12]. CL, V1 and Q were actually in accordance when a comparison was made 
between perioperative and prophylactic PK population model (CL: 150 versus 222 ml/
hr/68 kg; V1: 2810 versus 3520 ml/68 kg; and Q: 160 versus 256 ml/h/68 kg, respectively). 
However, in the present perioperative model, a value of 1880 ml/68 kg was found for V2 
in contrast to a value of 240 ml/68 kg found in the prophylactic situation, suggesting a 
rapid redistribution of FVIII concentrate following intravenous administration [12]. Due 
to increased V2, calculated distribution half-life and elimination half-life are significantly 
larger (as half-life is a derivative of the distribution volume) in the perioperative setting 
in comparison with the prophylactic state (respectively 4 hours and 25 hours versus 
0.6 hours and 12 hours). These calculated half-lifes are in accordance with previously 
described half-life observed immediately after surgery and half-life observed at steady 
state of 10 surgical patients described with a surgical model (respectively 9.6 and 17.8 
hours) in comparison to 10 surgical patients described with an estimated half-life of 10.1 
hours described with a non-surgical model [15]. Unfortunately, the rapid redistribution 
was not quantifiable, due to minimal data of laboratory assessment after infusion. Previ-
ously, it has been suggested that V2 may reflect the FVIII distribution into extravascular 
spaces or within an intravascular compartment, more specifically as a reflection of adhe-
sion to the vessel wall or that it may reflect the process of a rapid initial elimination 
[36,37]. We hypothesized that an extra intravascular component resulting in a large V2, 
may be the result of the high affinity and stoichiometry of FVIII to VWF [38], combined 
with the significant increase of VWF after surgery due to inflicted endothelial damage 
and its role in the acute phase reaction [39]. In addition, Deitcher et al. have shown that 
volume of distribution increases after desmopressin administration, which of course 
results in an overall increase in VWF levels [40].
Moreover, we believe that VWF may play a crucial role in the perioperative setting with 
regard to FVIII PK parameters, as previous studies have demonstrated a clear association 
between VWF plasma concentrations and FVIII half-life [41, 42]. This is not surprising, 
as VWF protects FVIII against proteolytic degradation by expression of ABH antigens 
on N-linked glycans and the uptake of the copper-binding protein ceruloplasmin [43, 
44]. Additionally, it has been shown that in healthy individuals undergoing orthopedic 
surgery, VWF decreases significantly intraoperatively and rises immediately after sur-
gery [39]. Therefore, we suspected a time-dependent FVIII clearance in the presented PK 
model, with an increased clearance during the surgical procedure itself and a decrease 
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in clearance directly after surgery. However, no time-dependent clearance could be 
established. Unfortunately, it was not possible to investigate the role of VWF plasma 
concentrations in our analyses in more detail, as VWF measurements are currently not 
routine practice in the perioperative setting and only historically measured VWF plasma 
concentrations were available in half of the study population. However, a 26% higher 
clearance rate was observed in blood group O patients in the perioperative setting, 
underlining the potential importance of measurement of VWF plasma concentrations 
in the perioperative setting if PK-guided dosing is implemented. This is supported by 
earlier reports that blood group O patients have around 25% lower VWF levels in com-
parison to patients with blood group non-O [43]. Strikingly, this effect of blood group 
on clearance was not significant in the prophylactic population PK model as shown 
by Bjorkman et al [12]. However, we are not informed if VWF levels were available for 
those analyses. Contrastingly, higher VWF levels may also help explain the unexpected 
overall lower clearance found in patients undergoing major surgical procedures. In the 
ongoing prospective randomized controlled “OPTI-CLOT” trial (RCT), which is described 
in more detail elsewhere [45], insight will be gained into the pathophysiology of VWF 
in hemophilia patients during the perioperative setting and the relationship between 
VWF levels and estimates of FVIII PK parameters, among others. These data will further 
validate the now presented perioperative PK population model, refining its applicabil-
ity and further defining the influence of possible modifying factors of PK parameters. 
Moreover, extension of this population PK model, in combination with extended half-life 
(EHL) products in the near future, could be of great value. However, firstly, studies are 
needed to extensively document associations between clearance of current FVIII prod-
ucts and EHL products within individuals.
Clinically in the perioperative setting, adaptive Bayesian dosing can be used to optimize 
and individualize dosing in order to obtain desired target FVIII plasma concentrations 
with increased certainty. Bayesian analysis combines individual PK information with 
information from an available population PK model. Such a population PK model is 
constructed from PK data of many individuals, and not only embodies defined patient 
characteristics known to influence clearance and other PK parameters, but also currently 
unidentified patient characteristics which cannot be quantified. Individual patient in-
formation that is entered into the model must include dose and time point of factor 
concentrate administration as well as achieved FVIII plasma concentrations. Incorpora-
tion of the patient’s weight, blood group, age and severity of surgical procedure will 
improve estimation of the individual clearance of factor concentrate. In clinical practice, 
individual clearance and other PK parameter estimates can be made by a clinical phar-
macologist with experience with this methodology and iteratively updated, leading to 
calculated dose adjustments. Currently, we are planning to develop a PK tool to imple-
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ment this perioperative population PK model in daily clinical practice. The first dose of 
FVIII concentrate, still in steady state, will be based on individual PK parameters deducted 
from an individual PK profile constructed according to the prophylactic population PK 
model. As we were not able to demonstrate time dependent changes in PK parameters 
during the perioperative setting, the perioperative population PK model described here 
can be applied to the complete perioperative period with varying target FVIII plasma 
concentrations as described by National guidelines.
In conclusion, we have constructed a perioperative population PK model facilitating it-
erative dose-adjustments by Bayesian analysis. We believe this model will prove its value 
as it will lead to optimization of current dosing strategies by a decrease of underdosing 
and overdosing, and therefore both a decrease of bleeding risk and an expected overall 
reduction of factor concentrate consumption with concomitant cost reduction.
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Table S1. Terminology and definitions used to develop population PK models.
Terminology Definitions
NONMEM® Non-linear mixed-effects modelling software to construct a population analysis, 
where all plasma concentration time points are analyzed simultaneously
OFV Objective function value; a measurement of goodness of fit of the model. OFV is 
proportional to minus two times the logarithm of the likelihood (-2log likelihood) of 
the data
PK parameters Pharmacokinetic parameters (e.g. CL, V1, Q, V2)
CL Clearance
V1 Volume of distribution of the central compartment
Q Intercompartment clearance
V2 Volume of distribution of the peripheral compartment
Allometric scaling PK parameters are allometrically scaled to account for the wide range of body weights 
of both adults and pediatric patients
IIV Inter-individual variability; variability between patients
IOV Inter-occasion variability; variability within patients
 CHaPTER 8
Facilitating implementation of 
pharmacokinetic-guided dosing of 
prophylaxis in hemophilia care by 
Discrete Choice Experiment
J Lock, EW de Bekker-Grob, G Urhan, M Peters, K. Meijer, P Brons, FJM van der Meer, 
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abSTRaCT
Introduction Patients’, parents’ and providers’ preferences with regard to medical in-
novations may have a major impact on their implementation.
aim To evaluate barriers and facilitators for individualised pharmacokinetic (PK)-guided 
dosing of prophylaxis in haemophilia patients, parents of young patients, and treating 
professionals by discrete choice experiment (DCE) questionnaire.
Patients and Methods The study population consisted of patients with haemophilia 
currently or previously on prophylactic treatment with factor concentrate (n = 114), 
parents of patients aged 12-18 years (n = 19), and haemophilia professionals (n = 91). 
DCE data analysis was performed, taking preference heterogeneity into account.
Results Overall, patients and parents, and especially professionals were inclined to opt 
for PK-guided dosing of prophylaxis. In addition, if bleeding was consequently reduced, 
more frequent infusions were acceptable. However, daily dosing remained an important 
barrier for all involved. ‘Reduction of costs for society’ was a facilitator for implementa-
tion in all groups.
Conclusions To achieve implementation of individualised PK-guided dosing of prophy-
laxis in haemophilia, reduction of bleeding risk and reduction of costs for society should 
be actively discussed as they are motivating for implementation; daily dosing is still 
reported to be a barrier for all groups. The knowledge of these preferences will enlarge 
support for this innovation, and aid in the drafting of implementable guidelines and 
information brochures for patients, parents and professionals.
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InTRODUCTIOn
Patients’, parents’ and providers’ preferences with regard to medical innovations may 
have a major impact on their implementation, often delaying initiation significantly [1]. 
Therefore, it is of importance to thoroughly investigate existing barriers and facilitators 
with regard to the targeted intervention in all involved.
In haemophilia, prophylactic treatment with regular infusion of factor concentrate 
aims to convert the bleeding pattern of severe haemophilia patients to a milder phe-
notype. Replacement therapy with factor concentrate thus prevents morbidity due to 
haemophilic arthropathy and mortality due to lethal bleeds [2]. As early as 1997, it was 
suggested by Carlsson et al. that a 30% reduction of factor concentrate consumption in 
prophylaxis could be attained by dosing based on an individual pharmacokinetic (PK) 
profile in relationship to a PK population model (PK-guided dosing) with adjustment of 
dose and frequency of dosing, with concomitant reduction of costs of this expensive 
treatment [3, 4]. Moreover, PK-guided dosing may also optimize care as inappropriately 
low or infrequent dosing is corrected before bleeding occurs [5].
To date, PK-guided dosing has still not been implemented in routine haemophilia care, 
due to different reasons such as: the long-time absence of PK population models; lack 
of knowledge of PK in haemophilia professionals; lack of belief in the cost-effectiveness 
of PK-guided dosing due to studies hampered by small sample size; and lack of financial 
motives in resource rich countries to improve cost-effectiveness of treatment [2, 6]. 
However, routine PK-guided dosing of prophylaxis may now become within reach, due 
to the PK population models developed by Björkman et al. [7, 8] and a recent global 
initiative for a web-based portal for PK consultation by Iorio and Hermans [9]. Therefore, 
practical insights into successful implementation of this most probably cost-effective 
approach are urgently required.
Barriers and facilitators with regard to certain interventions can be quantified by discrete 
choice experiment (DCE) [10]. A technique that is increasingly applied with regard to the 
implementation of healthcare innovations [11, 12]. Thus far, only a limited number of 
studies have investigated preferences with regard to haemophilia treatment [13-18]. No 
studies have focused on preferences with regard to PK-guided dosing of prophylaxis.
We performed a DCE to quantify preferences towards PK-guided dosing of prophylaxis 
in haemophilia patients, parents of young patients and professionals, using it as a diag-
nostic tool to rank barriers and facilitators. In our opinion, increased insight into these 
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mechanisms will generate wider support for this innovation and will help develop suc-
cessful implementation strategies.
PaTIEnTS anD METHODS
Study population
Patients older than 12 years with severe and moderate severe haemophilia currently 
or previously on prophylactic treatment, parents of patients between 12 and 18 years, 
and haemophilia professionals from throughout the world, were invited to participate 
in the study. All subjects were required to speak either Dutch or English. Patients and 
parents were recruited from five Dutch Haemophilia Treatment Centres. Professionals 
were included during the World Federation of Haemophilia Congress, 2012. Patients 
and parents received a study information brochure and a questionnaire in the home 
setting. A reminder was sent in case of non-response. The study protocol was approved 
by a Medical Ethical Committee (MEC-2011-456) with written informed consent from pa-
tients and parents. Oral informed consent was obtained from haemophilia professionals.
Survey
A cross-sectional self-completion DCE questionnaire assessing a range of barriers and 
facilitators regarding PK-guided dosing was used [6]. Individuals were presented with a 
questionnaire that consisted of a sequence of choice sets with two (hypothetical) hae-
mophilia treatment scenarios that varied along several characteristics (i.e. attributes). 
Attributes were further specified by varying choice levels of that attribute (i.e. attribute 
levels) (see Table 1 and Appendix S1). It was assumed that attribute levels determined 
the value for each healthcare intervention, and that individuals will select the preferred 
healthcare intervention with the highest benefit according to their opinion within each 
choice set [19]. Within a DCE, it is possible to consider both health and non-health 
outcomes simultaneously [20]. As the study population must choose between different 
options and make trade-offs between several attributes and their levels, DCE can be 
used as a diagnostic tool to prioritize potential barriers and facilitators and to specify 
implementation strategies [10, 21, 22]. To assess the internal consistency of responses, a 
rationality test was added consisting of a choice set where one of the two options was 
clearly superior at all levels.
The proposed attributes with regard to PK-guided dosing of prophylaxis were deduced 
from literature and from face to face interviews with professionals. They were asked to 
comment on proposed attributes and to rank them to make an a priori selection of the 
five most relevant attributes. These were: ‘number of blood samples necessary to con-
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struct an individual PK-profile’, ‘advised frequency of prophylactic infusions’, ‘frequency 
of repetitive PK-profiling’ (especially applicable in the paediatric population), ‘risk of 
bleeding’, and estimated ‘cost reduction of treatment with benefit for society’ (Table 1). 
Attributes were evaluated in a pilot study (n = 10) to study the feasibility and accept-
ability, time investment, intelligibility, and validity of the questionnaire. Questionnaire 
answering took 15 min. The first 15 study patients were contacted by the treating team 
to assure understanding of study design and questionnaire. No changes were made as 
requirements were met in all respondents.
The attributes and levels chosen, resulted in 2628 potential choice sets (see Supporting 
Information). As it is not feasible to present this number of choice sets to a single re-
spondent, a subset of scenarios was generated by maximizing D-efficiency using Ngene 
Table 1. Attributes and attribute levels for pharmacokinetic (PK)-guided dosing of prophylaxis with factor 
concentrate compared to current treatment.
attributes# Levels
Current treatment$
1. Number of blood samples necessary to construct PK-profile No blood samples
2. Advised frequency of prophylactic infusions Two to three times weekly
3. Frequency of repetitive PK-profiling No PK-profile
4. Risk of bleeding No reduction
5.  Estimated cost reduction of treatment with benefit for 
society (%)
0
PK-guided dosing regimen
1. Number of blood samples necessary to construct PK-profile At 1 time point (reference level)
  At 3 time points
2. Advised frequency of prophylactic infusions† Two to three times weekly (reference level)
Every other day
  Daily
3. Frequency of repetitive PK-profiling Every other year (reference level)
  Once
4. Risk of bleeding No reduction (reference level)
  Decreased
5.  Estimated cost reduction of treatment with benefit for 
society (%)
0, 15, 30
# Attributes 1,2, 3, and 4 entered the analyses as categorical variables. The attribute ‘Estimated cost reduc-
tion of treatment with benefit for society’ entered the analyses as a numerical variable; $ Attribute levels for 
‘current treatment’ entered the analyses as fixed variables; † For haemophilia B patients current treatment 
consisted of prophylactic infusions one to two times weekly due to the longer half-life of factor IX concen-
trates.
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software (version 1.1.1, http://www.choice-metrics.com/), leading to a DCE design con-
taining 24 choice sets. To further reduce respondent burden, a blocked design was used, 
which resulted in two questionnaire versions [23, 24]. Study participants were randomly 
allocated to one questionnaire version.
Characteristics of patients, parents and professionals were collected. For level of educa-
tion the International Standard Classification of Education division was used [25]. In 
addition, as an internal control, all respondents were asked to rank attributes of the DCE 
(Appendix S4), to rate their experience with the DCE questionnaire (five-point scale), 
satisfaction with current treatment (three-point scale), willingness to modify treat-
ment (three-point scale), and willingness to increase frequency of infusions on a visual 
analogue scale of 10 centimetre (cm) with 0 cm: ‘very willing’ and 10 cm: ‘not willing’. 
The questionnaire ended with an open question in which respondents were given the 
opportunity to record comments.
Sample size calculation
Sample size calculation of the study was impeded due to the small number of eligible 
haemophilia patients, and available health care professionals in this rare disease. The 
power of the study was explored a priori using a parametric sample size method ap-
proach as a well-considered survey instrument with an experimental design was present 
(see Supporting Information).
Statistical analyses
State-of-the-art analyses of the discrete choice data were performed by use of a panel 
latent class model, allowing identification of different utility functions (i.e. taking prefer-
ence heterogeneity into account) across unobserved subgroups [26]. These unobserved 
subgroups are known as classes. Class membership of respondents is latent because it is 
based on a modelled probability and not assigned by the analyst a priori. To determine 
the number of classes, the model with the best fit based on the Akaike information 
criterion was selected. See Appendix S2 for detailed information on the utility functions 
that were used for estimation of the model. For the class coefficients, the sign (positive 
or negative) of a coefficient reflects whether the attribute has a positive or negative 
effect on the utility of the alternative to PK-guided dosing of prophylaxis. In other words, 
individuals feel positive or negative with regard to this aspect of treatment and its influ-
ence on implementation. The value of a coefficient indicates the relative importance of 
the corresponding attribute (level). The statistical significance of a coefficient (P ≤ 0.05) 
indicates that the respondent underlines the importance of the attribute within the 
options in the DCE. Beforehand, it was expected that all attributes would be significant, 
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and that the attributes ‘decrease risk of bleeding’ and ‘estimated cost reduction of treat-
ment with benefit for society’ would have a positive effect (i.e. a positive sign) [27, 28].
Importance scores and trade-offs
Preference coefficients of all attributes were translated to importance scores (IS) and to 
trade-offs that the respondents were willing to make between the attributes [29]. This 
method gives more insight into which attribute is most important (IS of 1) and quanti-
fies the willingness to trade different attribute levels. In our DCE, we set out to quantify 
the willingness to trade between attributes when taking ‘estimated cost reduction of 
treatment with benefit for the society’ into account. This willingness was calculated by 
taking the ratio of a coefficient of a different attribute with ‘estimated cost reduction 
of treatment with benefit for the society’ as the dominator. This value represents how 
much ‘cost reduction for society’ is required, before respondents accept a unit change in 
the attribute of interest (e.g. higher ‘advised frequency of prophylactic infusions’). Con-
fidence intervals of this trade-off were estimated using the Krinsky and Robb procedure 
[30].
To compare mean age of non-respondents with mean age of respondents, an indepen-
dent-samples t-test was used. Age of non-respondents was calculated with median date 
that questionnaires returned.
We used NLogit 4.0 Software (Econometric Software, Plainview, NY, USA) to estimate the 
latent class model. All other statistical analyses were performed with IBM SPSS statistics 
for Windows, version 21.0 (IBM Corp, Armonk, NY, USA).
RESULTS
Participants
Between December 2011 and January 2014, 176 haemophilia patients and 33 parents 
of young patients were invited to participate in the study. Of these, 114 patients and 19 
parents filled out the questionnaire (response rate 64%). Table 2A and 2B summarize 
the characteristics of all participants. Patients had a mean age of 38.0 years (SD = 18.5), 
which was significantly older than non-respondents [mean age 30.8 years (SD = 19.1); P 
< 0.01]. In addition, 91 haemophilia professionals from both the Netherlands (37%) and 
other countries (63%) participated. Participants were equally distributed across each 
questionnaire version.
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Table 2a. Characteristics of haemophilia patients and parents of young patients.#,$
Characteristics Patients (n = 114) Parents (n = 19)
Mean age (years) (SD) 38 (18.5) 44 (5.8)
Male gender 112 (100.0) 14 (73.7)
Type of haemophilia  
  A (clotting factor VIII deficiency) 92 (82.1) 15 (78.9)
  B (clotting factor IX deficiency) 20 (17.9) 4 (21.1)
Severity of haemophilia  
  Severe (clotting factor VIII or IX <1 IU mL-1) 102 (91.1) 18 (94.7)
  Moderate (clotting factor VIII or IX 1-5 IU mL-1) 8 (7.1) 1 (5.3)
  Mild (clotting factor VIII or IX >5 IU mL-1) 2 (1.8) .
Actual haemophilia treatment
  On demand, prophylactic treatment in the past 11 (9.8) .
  Prophylactic infusions: two to three times weekly 81 (72.3) 17 (89.5)
  Combination of periods of prophylactic infusions alternating 
with on demand treatment
20 (17.9) 2 (10.5)
Educational level  
  Lower 27 (24.8) 2 (11.8)
  Intermediate 48 (44.0) 8 (47.1)
  Higher 34 (31.2) 7 (41.2)
# Numbers are n and % unless stated otherwise; $ Baseline characteristics of two patients were not available, 
and in three other patients educational level was not available.
Table 2b. Characteristics of haemophilia professionals.#
Characteristics Professionals (n = 91)
Age (years)  
  18-29 12 (13.2)
  30-49 53 (58.2)
  50-64 22 (24.2)
  ≥65 years 4 (4.4)
Country$  
  High income countries with high standard haemophilia care 69 (75.8)
  Low income countries lacking high standard haemophilia care 22 (24.2)
Profession
  Nurse 29 (31.9)
  Haematologist 47 (51.6)
  Other 15 (16.5)
Clinic employed  
  Academic Hospital 74 (81.3)
  Haemophilia Treatment Centre 15 (16.5)
  Regional Hospital 1 (1.1)
  Other 1 (1.1)
Ability to determine clotting factor plasma levels in laboratory 77 (95.1)
# Numbers are n and % unless stated otherwise; $ Country and Lending Groups | Data. Data.worldbank.org. 
Retrieved on 2013-07-12.
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Overall satisfaction with actual treatment and willingness to change
Of the patients and parents, 99% were satisfied or very satisfied with current treatment 
(see Appendix S4). When asked in general, 92% were willing to change the current 
treatment, of which 36% were willing to change under certain conditions such as no 
increase in frequency of infusions, improvement of clinical outcome and feasible and 
reliable PK-profiling. Of the professionals, 75% were satisfied or very satisfied with cur-
rent treatment and 98% was willing to change the current treatment (of which 34% 
were only under certain conditions). These percentages correspond with the DCE choice 
sets in which a majority of 64% of patients and parents of young patients, and 80% 
of the professionals preferred a PK-guided dosing regimen over the current treatment 
regimen. On a visual analogue scale of 10 cm, patients and parents scored a mean of 6.3 
cm (SD = 3.1) and professionals scored a mean of 6.1 cm (SD = 2.4), indicating they were 
not willing to increase frequency of prophylactic infusions if there were no additional 
facilitating factors (P = 0.74).
Results from DCE
Of the respondents, 98% passed the rationality test that was included in the question-
naire, and 83% of the respondents did not find the DCE questionnaire difficult.
Haemophilia patients and parents of young patients
Overall, patients and parents were willing to opt for PK-guided dosing of prophylaxis. 
However, preference heterogeneity was substantial. Two latent classes of preferences 
were identified (Appendix S3). Respondents belonging to latent class 1 were generally 
more willing to choose for PK-guided dosing of prophylaxis than those belonging to 
latent class 2, e.g. the value of the constant ‘current treatment’ vs. ‘new treatment’ was 
-0.99 for latent class 1 and 0.26 for latent class 2 (Appendix S3). The average probability 
that someone within the sample population belongs to latent class 1 was 41% and to 
latent class 2 was 59%. We found no evidence that the probability of belonging to a 
specific class depended on age, severity of haemophilia or educational level. This sug-
gests the fact that it is important to actually discuss reasons to opt for PK-guided dosing 
as patients and parents are willing to change, but sometimes hesitate.
In the final model, all coefficient directions were as expected (Appendix S3). The im-
portance scores (IS) based on the relative importance of the attributes (Figure 1A and 
Appendix S3) showed that respondents’ choices were influenced most strongly by the 
attributes higher ‘advised frequency of prophylactic infusions’ (barrier; overall IS = 1) and 
reduction of ‘risk of bleeding’ (facilitator; overall IS = 2). Also, ‘estimated cost reduction of 
treatment with benefit for society’ was considered highly important (facilitator; overall 
IS = 3).
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In Figure 2, three alternatives of PK-guided dosing of prophylaxis are compared with cur-
rent treatment that only differ with regard to ‘advised frequency of weekly prophylactic 
infusions’ and ‘risk of bleeding’. As depicted, respondents belonging to latent class 1 
preferred a PK-guided treatment programme as defined in column 1 above current treat-
ment (choice probability = 0.61). When frequency of ‘advised prophylactic infusions’ was 
reduced to two to three times weekly, it only slightly influenced their choice probability 
(0.60). However, when a PK-guided treatment programme led to a reduction in ‘risk of 
bleeding’ their choice probability for PK-guided dosing increased to 0.84, with only 0.16 
preferring current treatment. In contrast, respondents belonging to latent class 2 did 
not prefer a PK-guided treatment programme above current treatment (choice prob-
ability = 0.49). However, when a the ‘advised frequency of prophylactic infusions’ was 
lower or a reduction in ‘risk of bleeding’ was added the majority was also positive about 
a PK-guided treatment programme (choice probability, respectively, 0.64 and 0.55).
Trade offs
Patients and parents required an ‘estimated cost reduction of treatment with benefit for 
society’ of at least 12% (CI = 7 – 20) to consent to a PK-profile with blood samples at three 
time points instead of one time point (Table 3A). Willingness to increase prophylactic 
infusions to every other day instead of two to three times weekly was stated, if a cost re-
duction for society was reached of at least 25% (CI = 16 – 38). Patients and parents were 
only willing to consent to daily prophylactic infusions if a reduction in bleeding risk was 
achieved. Solely a cost reduction was not sufficient as more than 100% cost reduction 
was required (104%; CI: = 75 – 151). The wide range of CIs shows that the difference in 
willingness to trade different attribute levels for ‘estimated cost reduction of treatment 
with benefit for the society’ was considerable, supporting preference heterogeneity 
between groups.
Haemophilia professionals
Haemophilia professionals had an even more positive attitude towards implementing 
PK-guided dosing than patients and parents of young patients (see Figure 1B and Ap-
pendix S3). Within haemophilia professionals two latent classes were also identified (Ap-
pendix S3), with an average class probability of 26% for latent class 1 and 74% for latent 
class 2. Professionals belonging to latent class 1 were most positive towards PK-guided 
dosing of prophylaxis. Overall importance scores of the attributes were the same as in 
patients and parents of young patients. As depicted in Figure 2, professionals preferred 
a PK-guided approach over the current treatment (choice probabilities for latent class 1: 
0.56 and for latent class 2: 0.73; see Appendix S2, equation (1) and Figure 2).
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Trade offs
Based on the expressed preferences, professionals required an ‘estimated cost reduc-
tion of treatment with benefit for society’ of 1% (CI = -3 – 5) to perform a PK-profile 
with blood samples at three time points instead of at one time point (Table 3B). They 
were willing to prescribe infusions every other day instead of two to three times weekly 
Table 3a. Willingness of haemophilia patients and parents of young patients to trade-off among attributes 
of PK-guided dosing of prophylaxis dosing to achieve cost reduction for society.
Trade-offs
Patients/parents of patients are willing 
to…..
If this will lead to a 
cost reduction for the 
society of …% (CI)
Number of blood samples necessary 
to construct PK-profile
…get a PK-profile with blood sample at 
three time points instead of one time point
12.2 (7.0 - 20.0)
Advised frequency of prophylactic 
infusions
…get infusions every other day instead of 
two to three times weekly
24.6 (15.9 - 38.1) 
  …get infusions daily instead of two to 
three times weekly#
104.4 (75.3 - 151.4) 
Frequency of repetitive PK-profiling …get a PK-profile once instead of every 
other year
0.7 (-3.1 - 4.4) 
Risk of bleeding …get no additional reduction in risk of 
bleeding instead of additional reduction
62.2 (45.0 - 90.1) 
CI = Confidence Interval. CI, 95% confidence interval based on the Krinsky Robb method adjusted for class 
probabilities. The average values of the interactions are taken into account; (i.e., costs = […]); # For haemo-
philia B patients current treatment consists of prophylactic infusions one to two times weekly due to the 
longer half-life of factor IX concentrate.
Table 3b. Willingness of haemophilia professionals to trade-off among attributes of PK-guided dosing of 
prophylaxis to achieve cost reduction for society.
Trade-offs Professionals are willing to…..
If this will lead to a 
cost reduction for the 
society of …% (CI)
Number of blood samples necessary 
to construct PK-profile
…get a PK-profile with blood sample at 
three time points instead of one time point
1.2  (-2.5 - 4.7)
Advised frequency of prophylactic 
infusions
…get infusions every other day instead of 
two to three times weekly
16.9  (8.7 - 27.0)
  …get infusions daily instead of two to three 
times weekly#
51.7  (37.0 - 75.7)
Frequency of repetitive PK-profiling …get a PK-profile once instead of every 
other year
1.4  (-2.3 - 5.2)
Risk of bleeding …get no additional reduction in risk of 
bleeding instead of additional reduction
55.3  (39.8 - 80.6)
CI = Confidence Interval; CI, 95% confidence interval based on the Krinsky and Robb method adjusted for 
class probabilities. The average values of the interactions are taken into account; (i.e., costs = […]); # For 
haemophilia B patients current treatment consists of prophylactic infusions one to two times weekly due 
to the longer half-life of factor IX concentrate.
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when a cost reduction was reached of at least 17% (CI = 9 – 27) and they required a cost 
reduction of 52% (CI = 37 – 76) to prescribe patients daily prophylactic infusions if no 
reduction of bleeding was achieved.
DISCUSSIOn
Our DCE study reveals that the majority of patients, parents of young patients and pro-
fessionals have an overall positive attitude towards changing their current haemophilia 
treatment and towards implementation of PK-guided dosing of prophylaxis. However, 
the preference heterogeneity is substantial and there is a group of slower adapters, that 
may be willing to change treatment under certain conditions.
In general, more frequent infusions were acceptable if bleeding was consequently 
reduced. Prioritization of preferences, revealed that the most important barrier was 
daily ‘advised frequency of prophylactic infusions’. Illustrated by a requirement of a cost 
reduction of more than 100% as a trade-off to consent to daily prophylactic infusions 
without reduction of bleeding. It is important to realize that daily prophylactic dos-
ing is only considered by professionals in the presence of frequent bleeding or when 
resources for replacement therapy are minimal. On the other hand, it is also important 
to underline that PK-guided dosing does not always lead to more frequent dosing, as in 
some cases, especially in older patients, it may even lead to less frequent dosing due to 
lower clearance rates [31]. Overall, the most important facilitators for implementation 
of PK-guided dosing of prophylaxis in this study, were reduction of ‘risk of bleeding’ and 
‘estimated cost reduction of treatment with benefit for society’. The attributes ‘number 
of blood samples necessary to construct PK-profile’ and ‘frequency of repetitive PK-
profiling’ did not influence patient’s, parent’s and professional’s preferences and should 
not be regarded as important with regard to acceptance of this medical intervention.
Implications of results
Prevention of bleeding and subsequent complications is the ultimate goal in haemo-
philia treatment. Prophylaxis with intravenous infusions of factor concentrate on a 
regular basis, with dosage based on patient weight and clinical bleeding phenotype, 
is currently the best approach to prevent bleeds and subsequent arthropathy. The 
majority of patients and professionals seem satisfied with current prophylactic treat-
ment. However, all involved are conscious of the fact that treatment is expensive 
and that breakthrough bleeds do still exist, leading to pain, (joint) damage, and life-
threatening situations. Some may be caused by increased individual clearance rates of 
factor concentrate or trough levels not appropriate for the individual patient due to 
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bleeding phenotype, target joints or high activity level. Dosing of factor concentrate 
according to an individual PK profile in relationship to population PK data may lead to 
both optimisation of care in these cases as well as cost reduction of treatment in some 
patients. However, the true impact of large scale PK-guided dosing outside of a clini-
cal trial setting is still to be demonstrated. It is important to keep in mind that Lindvall 
et al. [32] demonstrated increased bleeding in a small patient sample after PK-guided 
decrease of dosing. Although it may be discussed that PK-guided dosing may lead to 
increase of costs due to increased dosing in under dosed patients, we believe that even 
then, PK-guided dosing will lead to an overall cost reduction. This, as we hypothesize 
that the majority of overdosed patients will be adult, leading to a large reduction of 
factor concentrate consumption due to greater body weight, and those under dosed 
will be mainly children, with a small increase in consumption due smaller body weight.
Results of this study will increase the likelihood of effective implementation of PK-guided 
dosing of prophylaxis as a medical intervention that may optimize haemophilia patient 
care. They will provide professionals with motivational factors to persuade patients to 
opt for PK-guided dosing and additionally lead to feasible guidelines and appealing pa-
tient brochures. Its implications are also of importance in the light of the development 
of the longer acting factor VIII and IX concentrates [33]. This, as the cost per unit of these 
novel factor concentrates will be significantly higher, making overdosing unacceptable 
and individualized replacement therapy a necessity. In addition, infrequent dosing 
schemes will lead to increased inter-individual variation in clearance and therefore 
increased variation in dosing frequency. Naturally, calculated costs of an individual PK-
profile to initiate PK-guided dosing of prophylaxis dosing are minimal when compared 
to possible long-term cost reduction of PK-guided dosing in both current products and 
longer acting products.
Although six prior DCE studies have been performed in haemophilia patients [13-18], 
none have been performed on preferences with regard to PK-guided dosing of pro-
phylaxis. Literature in other diseases demonstrates that DCE is a valuable method to 
tailor implementation strategies to specify barriers and facilitators in an implementation 
process [21, 34, 35].
Although a DCE gives more insight in considerations of patients and professionals, a 
drawback of the DCE methodology is the modelling based exercise with hypothetical 
scenarios. It may therefore not depict what the individual will actually do when con-
fronted with these choices in daily life, and may lack a link between the proposed 
choices and the individual’s health status or current clinical practice [21]. It has also been 
suggested that subjects may employ simplification of decision making [36]. In our study, 
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it is conceivable that subjects have focused on the avoidance of frequent prophylactic 
infusions (19% of patients and parents and 1% of professionals) or on a decrease of 
bleeding risk (17% of patients and parents and 26% of professionals) and therefore may 
ignore other information. Gigerenzer et al. however conclude in a review that simplifica-
tion of decision making does not necessarily lead to judgmental biases [36].
Strengths and limitations
As all involved with the implications of PK-guided dosing of prophylaxis, were included 
in our study, conclusions seem valid for all groups. This is of importance as groups may 
express different opinions and possibly conflicting interests, illustrated by different 
preferences. Secondly, Discrete Choice tasks and the concept of PK-guided dosing were 
introduced thoroughly as most respondents (> 80%) did not find the concept of the 
study and the questionnaire difficult to understand. Thirdly, our DCE model demon-
strated good theoretical validity, as all coefficients had the expected positive or negative 
value sign. Fourthly, 98% of the respondents passed the rationality test, included in the 
questionnaire. We therefore believe that the inclusion of numbers and rates in our DCE, 
which may have caused interpretation problems with regard to the choice tasks, cannot 
have influenced results to a large extent.
This study also has some limitations. Firstly, the response rate for this clinical study was 
low in comparison with other questionnaire studies in a clinical setting e.g. 64% instead 
of an optimal 80% [36]. Secondly, although the attributes have been carefully selected 
and generated by face to face interviews with professionals with subsequent ranking 
of attributes, the DCE could have been even more valid if focus groups had been used. 
This, as recent literature recommends this methodology for formulating such ques-
tions. Thirdly, selection bias cannot be excluded as respondents and non-respondents 
(mean age = 38.8 vs 30.8 years) differed significantly with regard to age. However, no 
covariates, including age, significantly influenced the probability of belonging to one of 
the two specific latent classes. Fourthly, unfortunately no data was collected on actual 
bleeding phenotype, presence of arthropathy, availability of venous access, the indi-
vidual responsible for administration of prophylaxis and detailed information of current 
prophylactic dosing regimen. These characteristics may have provided insight into the 
differences between groups more inclined to implement PK-guided dosing of prophy-
laxis and those less inclined to confer. Lastly, patients and parents of young patients 
were all inhabitants of the Netherlands, therefore data may reflect Dutch values and may 
not be extrapolated. However, professionals were from both developing and resource 
rich countries and analyses did not reveal any influence of country of origin on results.
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Conclusions
Our study is an important documentation of heterogeneity of opinions around PK-
guided dosing, recognizing decisions are complex and multifactorial. PK-guided dosing 
of prophylaxis may be successfully implemented in haemophilia care if all involved, 
weigh the pros and cons in each individual patient. And when PK-guided prophylaxis 
is thought to be beneficial realize the impact of daily dosing of factor concentrate and 
motivate patients and parents of young patients by underlining the potential reduced 
‘risk of bleeding’ and the ‘estimated cost reduction of treatment with benefit for society’ 
as quantified in this DCE analysis. The knowledge acquired through this study may facili-
tate the long-awaited implementation of PK-guided dosing of prophylaxis as a potential 
strategy to individualize and optimize dosing in the haemophilia population.
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SUPPORTInG InfORMaTIOn
appendix S1. Example of a choice set.
 
appendix S1. Example of a choice set.
* For haemophilia B patients current treatment consists of prophylactic infusions one to two times weekly 
due to the longer half-life of factor IX concentrate.
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appendix S2. Utility functions and sample size calculation.
Utility functions
DCE is a methodology which aims to quantify individual’s preferences, as choices are 
made within a sequence of choice sets with two or more hypothetical treatment sce-
narios. It is assumed that individuals act rationally and will choose the alternative with 
the highest level of benefit. DCE modelling is based on Lancaster’s economic theory of 
value and on the random utility theory.
In our study each treatment scenario be made up of five attributes and their levels, 
which resulted in 72 (23 X 32) potential scenarios. Assuming two scenarios per choice set, 
2,628 different choice sets could be created (i.e. 2,558 (72 X 71 / 2) choice sets containing 
two PK-profiling treatment scenarios, plus 72 choice sets containing a PK-guided treat-
ment scenario and a non-PK-guided or current treatment scenario). As it is not feasible 
to present this number of choice sets to a single respondent, a subset of scenarios was 
generated using Ngene software by maximizing D-efficiency (version 1.1.1, http://www.
choice-metrics.com/), leading to an efficient DCE design containing 24 choice sets.
The following utility functions were used to model DCE data:
The utility functions were:
VPK-profiling_nsj|c = β0|c + β1|cblood samples_at three pointsnsj|c + β2|c infusion_dailynsj|c +
β3|c infusion_every other daynsj|c + β4|cfrequency PK-profiling_oncensj|c +
β5|crisk of bleeding_decreasednsj|c + β6|ccost reductionnsj|c
Vcurrent treatment _nsj|c = 0
Where:
Vnsj|c  represents the observable utility (i.e., preference score) that respondent ‘n’ 
belonging to class segment ‘c’ has for alternative ‘j’ in choice set ‘s’;
β0|c represents an alternative-specific constant for a certain class;
β1-6|c  are class-specific parameter weights (coefficients) linearly associated with each 
attribute (level) of the DCE
Hence, the cost attribute acted as a linear attribute, whereas all other attributes were 
categorical. The reference levels for ‘blood sample’, ‘infusion’, ‘frequency PK-profiling’, and 
‘risk of bleeding were respectively: ‘at one time’, ‘two to three times weekly’, ‘every other 
year’, and ‘no reduction’.
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In addition to the utility function, the final DCE model allowed for several covariates 
such as age, severity of disease, type of disease, level of education to enter into the class 
assignment model [37]. This gives insight into the composition of the different latent 
classes.
Sample size calculation
To explore the power of the study a priori a parametric sample size method approach 
as a well-considered survey instrument with an experimental design was present. The 
following method was applied [38]: assuming a sample size of 90-100 respondents, a 
significance level α = 0.05, and using the outcome of the pilot study as initial estimates 
of the true parameter values, (except for the attribute ‘frequency of PK-profiling’ - the 
most critical parameter – for which we assumed a value of 0.2 as clinically relevant), a 
statistical power of at least 0.8 was estimated that all attribute (level) values were not 
equal to zero.
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appendix S3. Latent class regression coefficients.
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appendix S4. Ranking of attributes and overall satisfaction with actual 
treatment and willingness to change.
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DISCUSSIOn
In the following chapter the main findings of this thesis are summarized and discussed. 
We will also elaborate on methodological issues and gaps in described studies. Subse-
quently, suggestions are given to further refine strategies to improve hemophilia patient 
outcome. Ultimately, future studies will be proposed in the respective areas of research.
The first part of this thesis focuses on improvement of adherence to treatment in order 
to enhance quality of hemophilia care and therefore patient outcome. Adherence to 
treatment was approached in different ways: by evaluation of the effects of transmural 
support of patients and their parents by specialized nurses, by implementation and 
validation of questionnaires to evaluate and monitor both adherence and self-efficacy 
and by analysis of alternative outpatient clinic approaches to increase the impact of 
contact moments with the hemophilia treatment center. The main finding of the first 
study was that transmural support has a positive effect on perceived support by he-
mophilia patients and/or parents and communication with the hemophilia treatment 
center. However, it did not improve other outcome measures, including adherence to 
prescribed treatment, overall quality of life, behavior, total clotting factor consump-
tion, annualized bleeding rate and capacity towards self-efficacy. We did demonstrate 
that outpatient care for hemophilia and von Willebrand patients can be improved by 
implementation of Group Medical Appointments. We revealed that this setting leads 
to improvement in participant’s knowledge of the disease and also to improved per-
ceived support, especially for patients with less disease experience due to a milder 
bleeding phenotype. We translated and validated the VERITAS-pro adherence scale to 
measure and monitor adherence for application in the Netherlands and constructed and 
validated the Hemophilia-specific Self-Efficacy scale (HSES) to measure capacity towards 
self-efficacy. This is a capacity needed to develop adequate self-management abilities. 
Both scales proved to be reliable and valid tools to assess adherence and self-efficacy in 
pediatric hemophilia patients on prophylactic home treatment.
In the second part of this thesis, we verified that quality of care and cost-effectiveness 
can be improved by refining of FVIII dosing strategies perioperatively based on individual 
patient characteristics such as blood type and mode of infusion. Moreover, based on the 
retrospective data collected in order to evaluate current perioperative management in 
moderate and severe hemophilia A, we constructed a population pharmacokinetic (PK) 
model. This model describes the PK of various FVIII concentrates in the perioperative 
setting. Such a model, will make it possible to individualize perioperative replace-
ment therapy with FVIII concentrate in moderate and severe hemophilia A patients 
by Bayesian adaptive dosing. To facilitate future implementation of these promising 
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treatment innovations, we performed a Discrete Choice Experiment to look at barriers 
and facilitators for PK-guided prophylactic dosing. An important conclusion was that to 
be able to achieve implementation of individualized PK-guided dosing of prophylaxis 
in hemophilia, reduction of bleeding risk and reduction of cost for society should be 
actively discussed with patients. Both were proven to be motivating for implementa-
tion. Importantly, daily dosing was reported to be a barrier for all groups. The latter was 
shown to only be acceptable when other aspects of care, such as risk of bleeding could 
be significantly influenced by daily dosing.
1. IMPROVEMEnT Of aDHEREnCE TO TREaTMEnT
Measurement of adherence and self-efficacy
The most important goal in hemophilia care is the prevention of bleeding in joints and 
muscles. This is of utmost importance as this ultimately leads to progressive degen-
erative arthropathy and chronic pain, with functional impairment [1]. To safeguard joint 
function, adherence to prophylactic treatment is essential in patients with hemophilia. 
When optimal joint function is maintained, hemophilia patients are able to pursue an 
active daily lifestyle with a high degree of quality of life and life fulfilment. To achieve 
optimal adherence, it is necessary to have tools to monitor adherence, as well as the pos-
sibility to optimize adherence and self-management skills by training and educational 
programs. In our opinion, the latter should include strategies to ensure active patient 
involvement, improve self-efficacy, train patient’s problem-solving skills, and to enhance 
perceived interpersonal support, besides more traditional approaches such as patient 
education and lifestyle recommendations [2-4].
As no validated adherence scale was available in the Netherlands, we translated and 
validated the VERITAS-Pro scale (chapter 3). The adequate psychometric properties 
shown by our data confirm that this scale is a reliable and feasible tool to quantify 
adherence in a pediatric population in the Netherlands. The strength of this scale lies in 
the fact that it scores in different domains related to adherence e.g.: ‘Time’, ‘Dose’, ‘Plan’, 
‘Remember’, ‘Skip’, and ‘Communicate’. Therefore, it provides specific information to dis-
cuss issues related to non-adherence and causal mechanisms with patient and parents 
during outpatient clinic visits. The scale is valuable to quantify and monitor adherence 
and is currently the most reliable self-reported adherence measure in hemophilia. The 
VERITAS-Pro was developed by Duncan et al. in the United States [5] and is currently 
applied in 17 countries worldwide (personal communication). In our study population, 
the applicability was somewhat limited due to the high adherence at baseline described 
by pronounced floor effects (> 50%) of domains ‘Dose’ and ‘Skip’. Moreover, our pediatric 
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population may not have been the most optimal to test the scale, as it is widely known 
that adult populations are much less adherent with regard to prophylactic treatment 
[6, 7]. We conclude that the scale may be more applicable in less adherent populations, 
such as adolescents or adults, and therefore promote a wider application in the Dutch 
hemophilia population.
We do have some suggestions to improve the scale. Firstly, it may be relevant to evalu-
ate the contribution of domains ‘Time’ and ‘Dose’, as both showed low Cronbach’s alpha 
scores (respectively 0.38 and 0.01) in our study compared with respectively 0.86 and 0.67 
in the original study by Duncan et al. [5]. Specifically, in our study, this may have been 
due to high floor effects and small random variance caused by the homogenous Dutch 
pediatric population as well as the different cultural context of our study population. But 
this finding does imply that these domains may be less applicable in different popula-
tions. A shorter scale with revision of less valid domains, would improve overall validity 
and make it more efficacious. Naturally, a drawback of a novel version of the scale, is 
that it must be validated once again in all populations in which it has now been imple-
mented. Another aspect which could be improved, is the fact that it remains difficult to 
associate a lower total scale score with higher adherence to treatment. Furthermore, the 
VERITAS-Pro scale does not take alterations of weekly prophylactic dosing into account. 
These are often applied to support intensive sporting activities or physiotherapy, and 
may be necessary after a large bleed, or postoperatively. And lastly, the VERITAS-Pro 
unfortunately evaluates adherence to prescribed prophylactic regimen retrospectively, 
which of course leads to less reliable patient reporting.
There is controversy in hemophilia research which level of non-adherence leads to re-
duced patient outcomes. This limits the establishment of normative values for example 
the VERITAS-Pro score and respective subscale scores [5, 6]. Recently, Schrijvers et al. 
conducted a Delphi procedure to define non-adherence according to a hemophilia 
professional’s opinion [submitted, [8]]. Unfortunately, results of this Delphi procedure 
were based on expert opinion, and not on a large longitudinal study in which treatment 
adherence and patient outcome were objectively measured and compared by validated 
outcome measures. However, it is a first and important step in concordance of defini-
tions of non-adherence. Conclusions were that patients should be considered adher-
ent when < 15% of prescribed infusions is missed, when there are < 10% dosage (IU) 
changes, and when there is < 30% deviation in timing of infusions. Patient outcome and 
non-adherence were evaluated longitudinally in another single-center observational 
cohort (n = 66) study by Nijdam et al., which compared joint outcomes in patients with 
a median age of 34.4 years, who stopped prophylaxis at own initiative with patients 
on prophylaxis (median age: 32.3 years) [9]. Strikingly, self-reported bleeding rate and 
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functional limitations were similar in both groups. However, objective assessment of 
joint status after 10-year study follow up, revealed a decreased joint status in patients 
who discontinued prophylaxis compared to those still on prophylaxis. The authors con-
cluded that these results support long-term continuation of prophylaxis in adults. In our 
opinion, it also underlines the necessity of a clear definition of non-adherence as well as 
long term follow up studies on the effects of different levels of non-adherence and its 
association with joint outcome.
Until now, most reports on adherence have been performed in patients with moderate 
or severe hemophilia, as we have also done. However, we also underline the importance 
of evaluation of non-adherence in more mildly affected hemophilia patients. We suspect 
that other mechanisms may play a role in these patient populations as several studies 
and reviews in other diseases have suggested [7, 10, 11]. Studies report a relationship 
between lesser disease symptoms and a decreased belief of necessity of treatment. 
The long awaited arrival of extended half-life (EHL) coagulation factor products and 
increased availability of gene therapy will lead to a hemophilia population that is 
overall, less severely affected. Potentially this may lead to non-adherence and loss of 
self-treatment abilities especially in severe hemophilia B. Contrastingly, the hemophilia 
community overall expects more optimal adherence to novel products as current pi-
lotstudies show adherence levels of ≥ 76% and lower bleeding rates in the first studies 
performed [18]. It is of great importance to study the impact of these innovations on 
both patient outcome measures and adherence to treatment, to be able to analyze the 
long term impact at patient level.
General agreement between patients, parents and hemophilia professionals with 
regard to acceptable treatment goals and dosing regimens leads to the best long-term 
patient outcomes [12]. This concept of mutual agreement is named concordance and it 
is increasingly mentioned as the ultimate goal in the treatment of chronic diseases. We 
support this concept as it describes the ultimate setting of personalization of treatment. 
The term encompasses the feasibility of a specific treatment for the individual patient 
in his or her personal, ever changing life cycle. Concordance has not yet been applied in 
current studies in hemophilia but will be relevant for both somatic outcome measures 
as well as more subjective measures such as quality of life.
To understand non-adherence in the individual patient, it is crucial to uncover underlying 
problems and challenges in treatment adherence and self-management of the disease. 
Self-management refers to the ability of an individual to manage disease symptoms, 
treatment of symptoms, physical and psychosocial consequences of the disease as well 
as the implementation of lifestyle alterations necessary to cope with the specific chronic 
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disease involved [13]. One of the capabilities needed for adequate self-management is 
self-efficacy, which encompasses an individual’s confidence in the ability to carry out 
necessary tasks or procedures to manage their or their child’s personal health or health 
care [14, 15]. In order to quantify and monitor the capacity towards self-efficacy, we 
developed and validated the Hemophilia-specific Self-Efficacy Scale (HSES; chapter 4). 
The psychometric properties of the scale as illustrated by our data, confirm that it is a 
reliable and feasible method in a pediatric population in the Netherlands. Confirming 
earlier studies, we found high self-efficacy levels in our population [16]. This is most 
likely due to the intensive educational program given by hemophilia staff prior to initia-
tion of home treatment. In addition, we showed that high self-efficacy was correlated 
with higher quality-of-life. This was supportive of our hypothesis that self-efficacy is 
an important condition to achieve higher quality of life. In contrast, we did not find a 
correlation between self-efficacy and higher levels of adherence. Unfortunately, high 
self-efficacy levels at baseline in our study limited the measurable positive effect of 
the intervention of a hemophilia nurse in the home setting. We believe that capacity 
towards self-efficacy may be an important measure, especially in patients with milder 
disease e.g. moderate severe and mild patients, who’s ability to judge a possible bleed 
and to contact the hemophilia treatment center is of more importance than knowledge 
of appropriate dosing.
Home based intervention and Group Medical appointment intervention
To improve hemophilia patient outcome by enhancement of patient empowerment, 
we conducted two interventions. The first study described effects of home visits by a 
hemophilia nurse on adherence to treatment, health-related quality of life, behavior, 
total clotting factor consumption, number of joint bleeds, and self-efficacy in children 
with hemophilia on prophylactic home treatment (chapter 2). Extra transmural care 
did not lead to improvement of adherence to treatment, but did lead to improved 
communication and an increase of perceived support by parents. This is important as 
communication with regard to (atypical) disease symptoms and barriers for adherence 
results in more effective treatment and therefore more optimal joint status. Outcome 
measures of generic quality of life scale CHQ, self-efficacy scores, total clotting factor 
consumption, and number of joint bleeds however did not change after intervention.
Critically, a number of factors should be taken into account. Firstly, overall scores on 
these outcome measures were already high at baseline in our cohort, making it difficult 
to achieve a visible effect. Secondly, a study period of two years may have been too short 
to establish an effect on joint bleeds. Study results of our small study however do confirm 
an extended recent Cochrane review by Nieuwlaat et al. [17] that reviewed 182 random-
ized controlled trials on interventions aiming to improve treatment adherence. Of these 
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182 trials, 17 studies (range n= 38-2097 patients) were selected with adequate study 
design. Interventions studied included tailored support from health care professionals 
by educational interventions, counseling by motivational interviewing or cognitive 
behavioral therapy or daily treatment support. General conclusions of the systematic 
review were that interventions to improve adherence are complex and laborious and 
not always associated with increased adherence and improvement of patient outcome. 
Therefore, it was stated that these interventions are often not cost-effective and should 
not be implemented without critical evaluation of effects.
The second intervention was the group medical appointment (GMA), which aimed 
to improve effectiveness of outpatient clinic visits (chapter 5). Aspects studied were: 
patient’s and parent’s satisfaction, social support experienced by participants, team’s 
attentiveness to the individual, informative value of a GMA, privacy aspects and time 
investment. We established that GMA visits show high levels of participant satisfaction 
and advantages with regard to patient’s disease perspective, social support, and en-
hanced information transfer. Therefore, a GMA probably leads to an increased patient 
and parent empowerment with increased self-management abilities and self-efficacy 
[18-25]. Strikingly, best results were documented in patients with less experience with 
their disease. Moreover, these results were achieved in a more cost-effective setting 
as 8-10 patients and parents were seen within a time span of 90 minutes. Although, 
an important conclusion, we must state that outcome was self-reported by patients 
and parents. Moreover, in the study design no direct measurements on quality of care 
outcomes, health care costs, and self-efficacy were actually measured. In future studies, 
addition of these outcome parameters would be valuable with regard to this interven-
tion [25].
In both interventions studied, patient outcomes were measured. However, these were 
not fully discriminative. Overall in hemophilia research, there is a need for more sensi-
tive patient outcome measures, e.g. early detection and quantification of joint disease, 
functional outcome measures, emotional problems related to self-esteem and body 
image and economic or cost-utility analyses evaluating the relationship between care 
investments and patient outcome [26, 27]. Moreover, these outcome measures should 
be developed in collaboration with hemophilia patients and representatives of patient 
societies as the opinion of health care professionals does not always reflect patient 
opinion [2, 27, 28]. Novel insights into value based care methodology as developed by 
Porter et al., may provide the measures valuable for hemophilia care [27, 29].
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Other strategies to improve treatment adherence
In recent years, other strategies to improve self-care have been developed within the 
hemophilia community as in other chronic diseases. Often ICT-based methodology was 
applied to achieve this goal, e.g. short message services (SMS), mobile applications to 
document factor concentrate infusion and to provide immediate treatment advice, or 
e-learning modalities, such as the recently developed Cyberpoli in the Netherlands 
by the Stichting Artsen voor Kinderen (www.cyberpoli.nl) and the e-learning module 
developed by Mulders et al. [16, 30-36]. Next to more conservative approaches, such 
as informative patient meetings and hemophilia camps for younger patients [33]. A 
valuable addition to current care is the web-based health-related quality of life (HRQoL) 
application developed by Grootenhuis et al. for chronically ill children, which is able 
to systematically monitor HRQoL in the outpatient care clinic and makes it possible 
to discuss outcome measures directly during the visit to the outpatient clinic [37]. In 
children with juvenile idiopathic arthritis this systematic monitoring of HRQoL through 
electronic patient-reported outcome measures, resulted in increased attention for psy-
chosocial topics during outpatient clinic visits [38].
2. TOwaRDS MORE PERSOnaLIZED TREaTMEnT
Pharmacokinetic-guided dosing of factor concentrates and its implementation
In general, medical treatment is increasingly tailored according to individual needs and 
patient characteristics. In hemophilia, this is illustrated by adaptions of the frequency 
and timing of doses according to daily (sporting) activities, bleeding phenotype, and 
joint status [39]. Moreover, it is known that a large interpatient variability exists in clear-
ance of factor concentrate between hemophilia patients [40]. This fact may be a patient 
characteristic and an aspect of treatment in which can be intervened. As other factors 
influencing phenotype and adequate treatment such as age, body weight, length, blood 
group, von Willebrand factor, presence of target joints, hyperlaxicity and activity level 
cannot or are difficult to be influenced.
Thanks to pioneering studies by Björkman and Collins, it is increasingly accepted that 
both prophylactic and on demand treatment with factor concentrates can be tailored 
according to individual patient pharmacokinetics (PK) [40-44]. This is possible, thanks 
to the development of population PK models for few FVIII and FIX concentrates [40, 
41, 43, 45-47]. The theoretical background of this principle is that when population 
pharmacokinetic data from a large population are available, the amount of IU per kilo-
gram necessary to achieve a certain plasma concentration of coagulation factor can be 
predicted based on the results of an individual PK profile with only a limited number 
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of sampling time points. To construct an individual PK profile, a standardized dose of 
factor concentrate is infused and achieved factor concentrations are measured at set 
time points to establish PK parameters in the individual patient [45]. PK modeling and 
simulation is based on Bayesian analysis and performed using non-linear mixed-effects 
modelling software (NONMEM® version 7.2.0, Globomax LLC, Ellicott City, Maryland, 
USA) [48].
In order to implement PK-guided dosing and to make it applicable in all individual pa-
tients, it is important to develop models that are representative for all patients, specific 
factor concentrates and under all different circumstances. In an optimal population PK 
model for dosing in a patient with a coagulation factor deficiency, these differences can 
be integrated into one single model with various covariates. Until recently, only popula-
tion PK models were available for the prophylactic setting and only for recombinant FVIII 
concentrate developed by Baxter/ Baxalta (Advate®), for recombinant FIX developed by 
Pfizer (Benefix ®), and for plasma derived FIX [40, 41, 43, 45-47].
Although the concept and cost-effectiveness of PK-guided dosing according to popula-
tion PK models for prophylactic treatment in hemophilia A was proven as early as 1993 
by Carlsson et al. [41, 43], this has still not led to implementation in daily standard hemo-
philia care. This can be explained by various reasons. Firstly, an overall lack of population 
PK models for different concentrates, made it difficult to practice sparse sampling PK-
guided dosing. Moreover, a wash out period for prophylaxis was necessary to perform an 
individual PK profile. Naturally, this principle put the patient at risk for bleeding, leading 
to reluctance of patients and hemophilia professions to perform such a profile and thus 
hampering implementation of PK-guided dosing. Secondly, early studies have been 
hampered by small sample size and selected patient populations using one single factor 
concentrate, leading to limiting generalization of results. Thirdly, lack of knowledge and 
practical insights into background of PK-guided dosing in hemophilia professionals may 
have played a role. As well as the lack of clinical pharmacologists practicing within a 
hospital setting. Lastly, lack of financial motives to improve cost-effectiveness of treat-
ment most certainly has most probably also played a role in its delay in implementation.
Implementation of medical innovations is notably difficult as has been extensively stud-
ied by Grol et al. [49]. Therefore, it is of utmost importance to develop these strategies in 
an early stage of innovation. Part of our implementation strategy was to define possible 
barriers and facilitators in patients, parents of young patients and hemophilia profes-
sionals for implementation of PK-guided prophylactic by discrete choice experiment. 
Discrete choice experiment analysis is a quantitative method to gain insight into how 
patients value selected attributes of an intervention by asking them to state their choice 
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over different hypothetical scenarios [50-52]. It is used to determine the significance 
of attributes and the extent to which patients are willing to trade one attribute for 
another [52, 53]. Our study results showed that most patients, parents and hemophilia 
professionals were inclined to opt for PK-guided dosing of prophylaxis. Both, reduction 
of bleeding risk and reduction of costs for society were facilitating attributes to achieve 
implementation of individualized PK-guided dosing. Importantly, daily dosing remained 
an important barrier for all involved. However, if bleeding was consequently reduced, 
more frequent infusions were acceptable.
These results are relevant to successfully implement PK-guided prophylactic dosing in 
the near future. However it is important to realize that DCE is a modelling based exercise 
with hypothetical scenarios and may therefore lack a link with individual’s current health 
status or current clinical practice [51]. Veldwijk et al. found the majority of participants 
are capable to adequately complete a DCE when provided information is understood 
and to employ the complex decision strategies associated with DCE choice tasks [54]. 
However, a smaller group of lower educated and less literate participants found it dif-
ficult to employ simplification of decision making. This group used less than three at-
tributes to motivate decisions and did not apply trade-offs between attributes to make a 
choice [55]. Although, Gigerenzer et al. concludes that simplification of decision making 
does not necessarily lead to judgmental bias, Veldwijk et al. do recommend researchers 
to certify that participants understand choice tasks adequately [54, 55].
Critically, our DCE analysis would have been more valid when patient focus groups were 
organized to determine attributes, besides the face to face interviews with professionals 
that were performed. This was done subsequently by Reerds et al. (unpublished data) in 
a small study on implementation of a PK tool to support PK-guided dosing. Strikingly, 
results did not differ from our DCE analysis.
Collaborative interventions aimed to implement PK-guided dosing are currently embod-
ied by the Dutch “OPTI-CLOT” research group (patient-tailOred PharmacokineTIc-guided 
dosing of CLOTting factor concentrates in bleeding disorders) initiated in the Erasmus 
MC, a multicenter international initiative aiming to implement PK-guided dosing of 
clotting factor replacement therapy by initiating studies to prove the implications of 
PK-guided dosing, to construct perioperative and prophylactic PK population models 
and to evaluate the cost-effectiveness of a PK-guided approach [56]. But other initiatives 
are also currently ongoing, such as the web-based portal initiated by Iorio and Hermans, 
which aims to make PK-guided dosing accessible for all hemophilia professionals world-
wide [57]. In addition, development of easily applicable PK tools such as myPKFiT based 
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on Bjorkman’s prophylactic population PK model are valuable contributions to install 
PK-guided dosing in the hemophilia community in the near future [58].
Perioperative management and Pk-guided dosing based on a population Pk 
model
Annual costs of factor concentrate in the Netherlands are estimated around €130 mil-
lion, of which approximately 15% are consumed in the perioperative period [59-62]. 
In an era of increasing health care costs, it is clearly important to explore if PK-guided 
dosing may lead to both optimizations of treatment and cost-reduction by decrease of 
factor concentrate consumption.
To evaluate current perioperative management in (moderate) severe hemophilia A, 
retrospective data on FVIII concentrate infusions and achieved FVIII concentrations 
were collected (chapter 5). In this retrospective cohort study, aims were to identify the 
extent and predictors of underdosing and overdosing in this category of patients to 
quantify urgency of alternative dosing algorithms. The study population consisted of 
119 patients of all ages, undergoing 198 elective, minor or major surgical procedures. 
Results confirmed that perioperative management is challenging as both under dosing 
(up to 45% in the first 24 hours) and over dosing (up to 75% after 120 hours) were con-
siderable. Patients with blood type O were proven to be at increased risk of under dosing 
and had more bleeding complications in comparison to patients with a non-O blood 
type. Hypothetically, we concluded that this may have been caused by higher clearance 
rates in these patients due to lower VWF levels and concomitant lower FVIII levels due 
to decreased protection against proteolytic degradation in the circulation [63-68]. In 
addition, older patients and patients treated with bolus infusions, when compared to 
continuous infusion, were at higher risk of overdosing. Partly, this may be explained by 
confounding by indication. More specifically, as older patients underwent more severe 
surgical procedures, this may have led to maintenance of higher FVIII target levels by 
treating hemophilia professionals, due to a focus on prevention of bleeding by under-
dosing and less attention to avoidance of overdosing. In addition, as VWF levels increase 
with age, theoretically this may have also played a role in decrease of FVIII clearance due 
to higher VWF levels in these older patients [69]. Unfortunately, underlying mechanisms 
remain hypothetical as few VWF levels were measured in this retrospective study.
The retrospective data collected within this study, were used to construct a perioperative 
population PK model. With this population PK model, it is possible to iteratively perform 
dose adjustments of replacement therapy in the perioperative setting. Although a small 
number of studies has mentioned perioperative PK profiling, all studies only define a 
preoperative PK-guided loading dose [70-73].
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The perioperative PK of various FVIII concentrates in the (moderate) severe hemophilia 
patients described in our study, were best described by a two-compartment model, 
with following values for clearance (CL): 0.15L/h/68 kg, intercompartment clearance: 
0.16L/h/68 kg, central volume (V1): 2.81L/68 kg and peripheral volume (V2): 1.90L/68 kg. 
Compared to the prophylactic setting a larger V2 compartment was found, suggesting 
a more rapid redistribution of FVIII concentrates following intravenous administration 
in the perioperative setting [45]. We hypothesized that the significant increase of VWF 
after surgery due to the inflicted endothelial damage and its role in the acute phase 
reaction, combined with the high affinity and stoichiometry of FVIII to VWF may have 
resulted in a large V2 directly after surgery [78, 79]. Due to the retrospective nature of 
the data however, there were not sufficient samples of VWF plasma levels available to 
confirm this hypothesis. In addition, due to lack of FVIII samples at the acute occurrence 
of bleeding complications, it was not possible to reliably confirm FVIII plasma levels at 
time of bleeding. For that reason, this model cannot account for pharmacodynamical 
outcome measures.
Future prospective studies, such as the “OPTI-CLOT” trial mentioned, are necessary to un-
cover modifiers of FVIII clearance and to further refine this perioperative FVIII population 
PK model [56]. Subsequently, leading to more insight into the PK and pharmacodynamic 
(PD) parameters of FVIII, VWF pathophysiology during the perioperative period, and the 
complex relationship between VWF levels FVIII PK parameters.
Developments with regard to Pk-guided dosing in the near future
In an era of new treatment modalities, such as EHL coagulation factor products, gene 
therapy and new hemostatic products such as ACE910 (a bispecific antibody designed 
to replace FVIII by mediating the juxtaposition of FIXa and FX), monoclonal antibody 
2021 (an antibody against tissue factor pathway inhibitor), or ALN-AT3 (a RNA interfer-
ence agent against antithrombin), international data collection on PK and PD of these 
hemostatic agents are of importance to further individualize treatment for these novel 
therapies [74]. Moreover, as it is probable that not all products will be optimal for all 
patients. Therefore, the principle of transparent and accessible population PK and PD 
models as a basis for therapeutic approaches as stated by the “OPTI-CLOT” initiative is of 
great value [56]. These population PK and PD models will be able to take both individual 
patient characteristics as well as probable modifying factors such as endothelial activa-
tion and acute phase reaction, and unknown factors into account with regard to optimal 
dosing [75-78]. In addition, this principle will safeguard implementation of these new 
products for all different individuals.
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Conclusions
We have addressed a number of options to improve patient outcome in hemophilia 
care. Although transmural support seems promising, this intervention improved per-
ceived support and communication with the hemophilia treatment center, but did 
not increase adherence or other quality of life measures. Valuable questionnaires, able 
to quantify and monitor adherence and self-efficacy were developed and validated 
within this study. Initiation of Group Medical Appointments did lead to improvement 
of care as experienced by patients and parents. These effects were most significant in 
less experienced patients as this group benefited from knowledge and advice given by 
experienced patients and parents.
We have proven that both quality of care and cost-effectiveness can be improved by 
refining of perioperative dosing strategies based on individual patient characteristics 
such as blood group and mode of infusion. Moreover, the data from this retrospective 
study were used to construct a perioperative population FVIII PK model that describes 
the perioperative PK of various FVIII concentrates. This model will individualize periop-
erative FVIII replacement therapy in (moderate) severe hemophilia A patients by itera-
tive Bayesian adaptive dosing. To facilitate the implementation of PK-guided dosing, it 
is important to discuss possible positive effects on bleeding risk as well as a possible 
decrease of costs of treatment for society with patients and parents.
Overall, prospective systematic assessment of novel innovations such as studied within 
this thesis is important to establish which interventions are valuable and sustainable for 
patients, parents and professionals in the long run in hemophilia care.
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The aims of this thesis were to study strategies that may further improve patient out-
come in hemophilia, by optimization of both patient care by interventions in adherence 
as well as treatment innovations (Chapter 1). The first part of this thesis specifically 
described strategies to optimize patient care.
Part I: Improvement of patient outcome by optimization of hemophilia care
Patients with severe hemophilia and some patients with moderate severe hemophilia 
are treated prophylactically with factor concentrate to prevent (spontaneous) bleed-
ing. Most patients administer factor concentrate intravenously at home (or by parents) 
without direct medical supervision. Although home treatment has many advantages 
with regard to joint status and quality of life, it also has disadvantages. Previous studies 
have reported that it may lead to waning from prophylactic and on demand dosages 
and to parents and patients” insecurity with regard to treatment decisions and when to 
contact the hemophilia treatment center due to the increased responsibility. In chapter 
2, we conducted an intervention study in which the effects of transmural support by 
a hemophilia nurse on adherence to prophylactic treatment, health-related quality of 
life (HRQoL), prosocial behaviour and psychopathology, as well total factor concentrate 
consumption, capacity towards self-efficacy, and number of joint bleeds were evalu-
ated. Hemophilia nurses conducted four to seven home visits in 46 patients (mean age 
9.4 years) during a median time period of 22 months [Interquartile range (IQR = 21-23)]. 
Strikingly, before intervention (baseline), almost all parents of patients already reported 
a high level of adherence to treatment, high quality of life, and a high capacity for self-
efficacy, as well as a low number of joint bleeds. No difference in adherence to prescribed 
treatment was seen after the home visits when compared with baseline measurements. 
A decrease was observed over time on Child Health Questionnaire (CHQ) domains 
“Role functioning – Emotional/Behavioural” and “Parental Time Impact”. Improvement 
was observed with regard to disease-specific HRQoL on Haemo-QoL domains: “Fam-
ily”, “Friends”, and “Perceived support”. The domain “Communication” of the validated 
VERITAS-Pro scale also improved slightly.
No other outcome measures changed significantly after intervention. Parents, patients 
and nurses were satisfied with home visits and scored the intervention as valuable. 
Although effects are small, transmural care by a hemophilia nurse leads to improve-
ment of perceived support by parents and of communication between parents and the 
hemophilia treatment centre. Taking the lifelong relationship between patients with 
the hemophilia treatment centre this is an important finding to increase and maintain 
quality of care.
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Non-adherence in patients with a chronic disease is strongly associated with a decreased 
quality of life and reduction of cost-benefit of treatment. Therefore, it is crucial to be able 
to measure and monitor adherence with validated instruments. Duncan et al. (2010) 
developed and validated the VERITAS-Pro adherence scale for prophylactic treatment 
in a pediatric and adult hemophilia population in the United States. We translated this 
questionnaire in Dutch according to international guidelines and validated it in our 
pediatric population, which is described in chapter 3. The VERITAS-Pro consists of six 
subscales (“Time”, “Dose”, “Plan”, “Remember”, “Skip” and “Communicate”) each including 
four items. Lower scores reflect higher adherence. In total, 60 children with a mean 
age of 10 years [Standard deviation (SD) = 4] with hemophilia on prophylactic clotting 
factor replacement therapy for more than 1 year were included from three hemophilia 
treatment centers (response rate 85%). With regard to the quality of the questionnaire, 
internal consistency reliability, was adequate as mean Cronbach’s alphas were sufficient 
(> 0.70) for total score and the subscales “Skip” and “Communicate”. In addition, item-
own subscale correlations were stronger than most item-other subscale correlations 
and convergent validity analyses showed that total scores were higher for non-adherent 
participants compared with adherent participants according to patient infusion logs 
(n = 48; P < 0.05). Furthermore, test–retest correlations demonstrated significance for 
all scales except “Dose” (n = 58; P < 0.01). This study has demonstrated the applicability 
of VERITAS-Pro outside the United States, as total score and most subscales effectively 
quantified treatment adherence in a Dutch pediatric population on prophylactic thera-
py. Non-adherent respondents’ total scores were significantly higher, demonstrating the 
ability of VERITAS-Pro to identify non-adherent individuals.
Self-efficacy describes the actual confidence an individual feels for specific actions 
necessary to achieve certain results. Higher self-efficacy in chronic disease patients is 
associated with a higher level of self-management skills and an increased quality-of-life. 
Therefore, quantification and monitoring of self-efficacy is important. In general, self-
efficacy in hemophilia patients has received little attention due to lack of standardized 
scales. In chapter 4, we have described the development and validation of the novel 
Hemophilia-specific Self-Efficacy Scale (HSES) in patients on prophylactic home treat-
ment. Hemophilia patients aged 1–18 years on prophylactic treatment ≥ 1 year were 
included from three Dutch hemophilia treatment centers. The HSES consists of 12 items, 
relating to parent and patient’s perceptions of the ability to function on a day-to-day 
basis with hemophilia. Retest was performed in a subsample of the study population. 
Validity was proven by the General Self-Efficacy Scale and by the health-related quality 
of life assessment tool Haemo-QoL. Data were analysed in 53 children (response 75%), 
with a mean age of 9.8 years (SD = 4.0). Mean total scale score of HSES was 55.5 (SD = 
4.7; range: 38–60), with a ceiling effect of 17%. The HSES showed adequate internal con-
Summary
205
  C
ha
pt
er
 1
0
sistency (Cronbach’s alpha 0.72) and good test–retest reliability (Intra-Class-Correlation 
coefficient 0.75; P < 0.01; n = 37). The convergent validity was adequate as hemophilia-
specific self-efficacy correlated significantly with general self-efficacy (r = 0.38; P < 0.01). 
High HSES scores correlated significantly with quality-of-life as measured by the Haemo-
QoL (r = -0.42; P < 0.01). We therefore concluded that the novel HSES is a reliable and 
valid tool to assess self-efficacy in pediatric hemophilia patients on prophylactic home 
treatment.
In chapter 5, we describe the effects of Group Medical Appointments (GMA) as compared 
to Individual Medical Appointments (IMA), the usual standard of care in patients with 
hemophilia and von Willibrand disease. GMA is a consultation form in which patients 
undergo individual consultations in each other’s presence. We measured effects of GMA 
with regard to participant’s satisfaction, social support experienced, team’s attentive-
ness to the individual, informative value of a GMA, privacy aspects, and time investment 
necessary. Overall, parents and adolescents were very satisfied with both GMA and IMA. 
In our study, most important advantages of GMA were the improvement in participant’s 
knowledge of the disease and social support experienced by participants. Both were 
significantly higher in parents and adolescents with less experience with disease 
symptoms, thus those with a milder disease phenotype than in those with a significant 
experience with the disease symptoms. The results presented in this chapter therefore 
suggested that GMA is a valuable addition in hemophilia and von Willebrand care, 
especially for patients with less experience with disease symptoms, thus more mildly 
affected patients. It leads to improved patient and participant satisfaction, experienced 
social support and an improved transfer of information and therefore most probably 
leads to an increase in self-efficacy.
Part II: Improvement of patient outcome by optimization of hemophilia 
treatment
The second part of this thesis describes strategies to optimize hemophilia treatment 
itself. Several studies have reported on the challenges of targeting of clotting factor 
VIII (FVIII) levels during perioperative replacement therapy in hemophilia and mention 
both underdosing and overdosing with respectively a risk of bleeding complications or 
unnecessary costs. However, the extent of underdosing and overdosing is not specified 
in these studies. To identify the extent, timing and possible predictors of FVIII under and 
overdosing, we evaluated perioperative management in a large series of hemophilia A 
patients and discuss novel strategies towards more personalized treatment in hemo-
philia, in chapter 6. In this retrospective observational study, we included 119 moderate 
and severe hemophilia A patients (FVIII levels < 0.05 IU mL-1; median age 40 years [IQR = 
9-54]; median body weight 75 kilograms [IQR = 35-85]) undergoing 198 elective surgical 
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procedures. Perioperative management was evaluated by quantification of periopera-
tive infusion of FVIII concentrate and achieved FVIII levels. Predictors of under dosing 
and (excessive) overdosing were analysed by logistic regression analysis. Excessive 
overdosing was defined as an upper target level plus ≥ 0.20 IU mL-1. In summary, on 
consecutive days deviations of FVIII levels in relation to target range levels were increas-
ingly significant (P for trend < 0.01). In the first 24 hours after surgery, 45% of measured 
FVIII levels were below lowest target range level with a median deviation of 0.17 IU mL-1. 
Six days after surgery, 75% of the FVIII levels were above highest target range level with 
a median deviation of 0.31 IU mL-1. A potential reduction of FVIII consumption of 44% 
would have been attained if FVIII levels had been maintained within target ranges. 
Blood group O and major surgery were predictive of under dosing [Odds ratio (OR) = 6.3, 
95% Confidence interval (95%CI) = 2.7-14.9; OR = 3.3, 95%CI = 1.4-7.9]. Moreover, blood 
group O patients had more bleeding complications in comparison to patients with other 
blood groups (OR = 2.02, 95%CI = 1.0-4.1). Patients with blood group non-O were at 
higher risk of overdosing (OR = 1.5, 95%CI = 1.1-1.9). Additionally, patients treated with 
bolus infusions were at higher risk of excessive overdosing with upper target level plus 
≥0.20 IU mL-1 (OR = 1.8, 95%CI = 1.3-2.4). These results suggest that quality of care and 
cost-effectiveness can certainly be improved by refining of dosing strategies that in-
creasingly take individual patient characteristics into account, such as blood group and 
mode of infusion. The study also concluded, that pharmacokinetic (PK)-guided dosing 
may be an option to achieve this goal.
The role of PK guided dosing of factor concentrates in hemophilia is currently subject of 
debate and generally focuses on long-term prophylactic treatment. Few data are avail-
able on its impact in the perioperative period. In chapter 7, a population PK model was 
presented that describes the perioperative PK of various current FVIII concentrates for 
moderate and severe hemophilia A patients (FVIII levels < 0.05 IU mL-1) undergoing elec-
tive, minor or major surgery. The developed model was constructed on the basis of the 
retrospective data collection described in chapter 6 which included data on FVIII treat-
ment, time points of FVIII sampling and all achieved FVIII plasma concentrations. Popu-
lation PK modeling was performed using nonlinear mixed-effects modeling (NONMEM). 
Population PK parameters were estimated in a total of 119 patients undergoing a total 
of 198 surgeries, of which 75 adults underwent 140 surgeries (median age 48 years [IQR 
= 37-60]; median weight 80 kg [IQR = 73-90]) and 44 children underwent 58 surgeries 
(median age 4 years [IQR = 2-8]; median weight 19 kg [IQR = 12-29]). Individual PK was 
best described by a two-compartment model. Values for clearance (CL), intercompart-
ment clearance, central (V1) and peripheral volume were 0.15L/h/68 kg, 0.16L/h/68 kg, 
2.81L/68 kg and 1.90L/68 kg. Inter-patient variability in CL and V1 were respectively 37% 
and 27%. CL decreased with increasing age (P < 0.01) and was increased in case of blood 
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group O (26%, P < 0.01). In addition, a minor decrease in CL was observed when the 
surgical procedure was considered major (7%, P < 0.01). We concluded, that in the near 
future perioperative population PK models will lead to individualization of perioperative 
FVIII dosing and make iterative PK-guided dose-adjustments possible with subsequent 
optimization of care.
In chapter 8, we described strategies to facilitate the implementation of PK-guided 
prophylactic dosing in hemophilia care by identification of barriers and facilitators for 
this novel dosing strategy. This is of importance as patients’, parents’ and providers’ pref-
erences may have a major impact on implementation. We conducted a discrete choice 
experiment (DCE) to evaluate barriers and facilitators for individualized PK-guided 
dosing of prophylaxis in hemophilia patients, parents of young patients, and treating 
professionals. The study population consisted of patients with hemophilia currently 
or previously on prophylactic treatment with factor concentrate (n = 114), parents of 
patients aged 12–18 years (n = 19) and hemophilia treating professionals (n = 91). DCE 
data analysis was performed, taking preference heterogeneity into account. Overall, 
patients and parents, and especially professionals were inclined to opt for PK-guided 
dosing of prophylaxis. In addition, if bleeding was consequently reduced, more frequent 
factor concentrate infusions were acceptable. However, daily dosing remained an im-
portant barrier for all involved. Strikingly, reduction of costs for society’ was a facilitator 
for implementation in all groups. We concluded that to achieve implementation of 
individualized PK-guided dosing of prophylaxis in hemophilia, reduction of bleeding 
risk and reduction of costs for society should be actively discussed as they are motivat-
ing for implementation. The knowledge of these preferences will enlarge support for 
this innovation, and aid in the drafting of implementable guidelines and information 
brochures for patients, parents and professionals.
Finally, this thesis ends with a general discussion in chapter 9. Options to improve 
hemophilia patient outcome by optimization of patient care and hemophilia treatment 
are summarized and discussed. The importance of an increased insight into care and 
treatment innovations and the dynamics within these processes are underlined. Meth-
odological issues and gaps in described studies are highlighted, resulting in recommen-
dations and requirements to further refine these strategies. Ultimately, suggestions for 
future studies are proposed in the respective areas of research.
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In dit proefschrift worden studies beschreven die het optimaliseren van patiëntenzorg 
door interventies die gericht zijn op verbetering van therapietrouw (deel I) en de hemofi-
lie behandeling met stollingsfactor concentraten (deel II) als doel hebben. In hoofdstuk 
1 worden de achtergronden en doelstellingen van dit proefschrift beschreven.
Deel I: Verbetering van patiënten uitkomsten door het optimaliseren van de 
hemofilie zorg
Patiënten met ernstige hemofilie en sommige patiënten met matig-ernstige hemofilie 
worden profylactisch behandeld met stollingsfactorconcentraat om (spontane) bloedin-
gen te voorkomen. De intraveneuze toediening hiervan wordt meestal door patienten 
zelf of door hun ouders gedaan. Dit gebeurt in de thuissituatie zonder directe medische 
supervisie. Hoewel deze thuisbehandeling veel voordelen heeft voor de toestand van 
gewrichten en de kwaliteit van leven, heeft het ook nadelen. Eerder onderzoek heeft 
aangetoond dat thuisbehandeling kan leiden tot een vermindering van therapietrouw 
voor zowel de profylactische als on demand toedieningen van stollingsfactorconcen-
traat. De grote verantwoordelijkheid die patiënten en hun ouders voor hun behandeling 
hebben, kan ook leiden tot onzekerheid over het eventuele toedienen van medicatie 
en inschakelen van het hemofiliebehandelcentrum. In hoofdstuk 2 beschrijven we een 
interventiestudie met huisbezoeken door een hemofilie verpleegkundige. We evalueer-
den het effect hiervan op therapietrouw, gezondheids-gerelateerde kwaliteit van leven, 
pro-sociaal gedrag en psychopathologie, het verbruik van stollingsfactorconcentraat, 
de mate van zelf-effectiviteit en het aantal gewrichtsbloedingen. Hemofilie verpleeg-
kundigen bezochten 46 patienten (gemiddelde leeftijd 9,4 jaar) 4-7 keer gedurende een 
periode van mediaan 22 maanden (IQR = 21-23). Deze huisbezieken werden uitermate 
gewaardeerd door ouders, patiënten en verpleegkundigen. Opvallend was dat bijna alle 
ouders van patiënten al voor start van de interventie een hoge mate van therapietrouw, 
kwaliteit van leven en zelfeffectiviteit rapporteerden alsook een gering aantal bloe-
dingen. Na de periode met huisbezoeken werd geen verschil gezien in therapietrouw 
ten opzichte van de uitgangssituatie. Op de scores in de domeinen “Rol functioneren-
Emotioneel/ Gedrag” en “U en uw gezin- Tijdsbesteding” van de generieke gezondheids-
gerelateerde kwaliteit van leven vragenlijst CHQ werd een daling waargenomen. De 
ziekte-specifieke gezondheids-gerelateerde kwaliteit van leven die gemeten werd met 
de Haemo-Qol verbeterde op de domeinen “Familie”, “Vrienden” en “Ervaren steun”. Het 
domein “Overleg” van de gevalideerde VERITAS-Pro vragenlijst verbeterde ook enigszins. 
De andere uitkomst maten waren na de interventie periode niet significant verschillend. 
Alhoewel effecten klein zijn, werd geconcludeerd dat huisbezoeken door een hemofilie 
verpleegkundige leiden tot verbetering van de communicatie tussen patiënten en het 
hemofiliebehandelcentrum alsook tot een toename van de door ouders ervaren steun. 
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Dit is een belangrijke uitkomst gegeven de levenslange relatie tussen hemofiliepatiënt 
en het behandelcentrum.
Therapieontrouw bij patiënten met een chronische ziekte is sterk geassocieerd met 
een verminderde kwaliteit van leven en vermindering van de kosteneffectiviteit van de 
behandeling. Het is daarom cruciaal om therapietrouw te kunnen meten en vervolgen 
met gevalideerde instrumenten. Duncan et al. (2010) ontwikkelde en valideerde de 
VERITAS-Pro therapietrouw-schaal voor profylactische behandeling in een populatie 
van volwassenen en kinderen met hemofilie in de Verenigde Staten. Wij vertaalden deze 
vragenlijst volgens internationale richtlijnen in het Nederlands en valideerden deze 
in onze populatie kinderen (hoofdstuk 3). De VERITAS-Pro bestaat uit zes subschalen 
(“Tijd”, “Dosering”, “Planning”, “Onthouden”, “Overslaan” en “Overleg”), elk met vier items. 
Lagere scores komen overeen met een betere therapietrouw. We includeerden totaal 
60 kinderen met hemofilie uit drie behandelcentra, met een gemiddelde leeftijd van 10 
jaar (SD = 4) die al meer dan één jaar profylactisch behandeld werden met stollingsfac-
torconcentraat (respons 85%). De interne consistentie, als een maat voor de kwaliteit 
van de vragenlijst, was voldoende voor de totale score en de subschalen “Overslaan” 
en “Overleg” (gemiddelde Cronbach’s alfa scores > 0,70). Bovendien waren de meeste 
inter-item subschaal correlaties sterker dan de correlaties met items uit andere schalen. 
Analyse van de convergente validiteit toonde aan dat patienten die volgens infusielog-
boekjes therapieontrouw zijn, hoger scoorden dan patienten die therapietrouw waren 
(n = 48; P < 0,05). Test-hertest correlaties toonden het belang aan van alle schalen met 
uitzondering van de subschaal “Dosering” (n = 58; P < 0,01). Deze studie heeft de toepas-
baarheid van de VERITAS-Pro in hemofile patiënten met profylaxe buiten de Verenigde 
Staten aangetoond. De totale score en de meeste subschalen geven daadwerkelijk de 
mate van therapietrouw weer in een Nederlandse populatie kinderen die profylactisch 
worden behandeld met stollingsfactorconcentraat.
Zelf-effectiviteit beschrijft het vertrouwen van een individu in de eigen bekwaamheid 
voor specifieke acties die nodig zijn om bepaalde resultaten te bereiken. Hogere zelf-ef-
fectiviteit bij patienten met een chronische ziekte is geassocieerd met een hogere mate 
van zelfmanagement en een betere kwaliteit van leven. Het kwantificeren en vervolgen 
van zelf-effectiviteit is daarom belangrijk. Tot op heden is er weinig aandacht geweest 
voor zelf-effectiviteit bij hemofiliepatiënten vanwege het gebrek aan gestandaardiseerde 
meetinstrumenten. In hoofdstuk 4 wordt de ontwikkeling en validatie van een nieuwe 
hemofilie-specifieke zelf-effectiviteitsschaal (HSES) bij patiënten die thuis profylactisch 
worden behandeld beschreven. We includeerden hemofiliepatiënten van 1-18 jaar uit 
drie Nederlandse hemofiliebehandelcentra die sinds minstens 1 jaar thuis profylactische 
behandeld werden. De HSES bestaat uit 12 items, die de perceptie weergeven van 
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ouders van hemofiliepatiënten en de patiënten zelf, hoe zij met hemofilie omgaan in 
het dagelijks leven. In een subgroep van de studie populatie werd een hertest gedaan. 
De validiteit werd bevestigd middels de generieke zelf-effectiviteitsschaal GSES en de 
ziekte-specifieke gezondheids-gerelateerde kwaliteit van leven vragenlijst Haemo-Qol. 
De gegevens van 53 kinderen (respons 75%) met een gemiddelde leeftijd van 9,8 jaar 
(SD = 4,0) werden geanalyseerd. De gemiddelde totale score van de HSES was 55,5 (SD 
= 4.7; range: 38-60), met een plafond effect van 17%. De HSES vertoonde adequate in-
terne consistentie (Cronbach’s alpha 0,72) en een goede test-hertest betrouwbaarheid 
(Intra-klasse-correlatie coëfficiënt 0,75; P < 0,01; n = 37). De convergente validiteit was 
voldoende gezien de hemofilie-specifieke zelf-effectiviteit significant gecorreleerd was 
met de generieke zelf-effectiviteit (r = 0,38; P < 0,01). Hoge HSES-scores waren signifi-
cant gecorreleerd met de kwaliteit van leven gemeten met de Haemo-Qol (r = -0,42; P 
< 0,01). Wij concludeerden daarom dat deze nieuwe HSES een betrouwbaar en valide 
meetinstrument is om zelf-effectiviteit te meten bij kinderen met hemofilie die thuis 
profylactisch worden behandeld.
In hoofdstuk 5 beschrijven we de resultaten van een studie waarin groepsconsulten 
(GMA) worden vergeleken met de gebruikelijke individuele poliklinische afspraak voor 
patiënten met hemofilie en de ziekte van von Willebrand. Een groepsconsult is een 
bijeenkomst waarbij iedere patiënt een individueel consult heeft, in aanwezigheid 
van andere patiënten en ouders. Na ieder groepsconsult werd de tevredenheid van 
de deelnemer met de ervaren sociale steun, aandacht van het team voor de individu-
ele patiënt, de educatieve en informatieve inhoud, privacyaspecten en de benodigde 
tijdsinvestering gemeten. In het algemeen, waren zowel ouders als adolescenten zeer 
tevreden met zowel het groepsconsult als de individuele poliklinische afspraak. De 
belangrijkste meerwaarde van de groepsconsulten was de toename van kennis van de 
ziekte en de grote sociale steun die door deelnemers werd ervaren. Beide waren signi-
ficant hoger bij ouders en adolescenten met minder ervaring met hun ziekte, dus met 
een milder fenotype. De in dit hoofdstuk gepresenteerde resultaten suggereren daarom 
dat groepsconsulten een waardevolle aanvulling zijn bij de zorgverlening aan patiënten 
met hemofilie en de ziekte van von Willebrand, vooral wanneer er minder ervaring is 
met ziektesymptomen, zoals bij milder aangedane patiënten. Het groepsconsult leidt 
daarom tot verbetering van de tevredenheid van patiënten en behandelteam, meer er-
varen sociale ondersteuning en een verbeterde informatieoverdracht en waarschijnlijk 
ook tot een toename van zelf-effectiviteit.
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Deel II: Verbetering van patiënten uitkomsten door optimalisering van 
behandeling met stollingsfactorconcentraat
Het tweede deel van dit proefschrift beschrijft strategieën om de behandeling van 
hemofilie te optimaliseren. We laten de complexiteit zien van het bereiken van streef-
waarden van stollingsfactoren in de perioperatieve periode. Geconcludeerd wordt dat 
zowel onder- als overdosering van stollingsfactor VIII (FVIII) concentraat voorkomt, met 
respectievelijk een verhoogd risico op bloedingen en onnodige kosten. Om de mate, het 
tijdstip en mogelijke voorspellers van onder- en overdosering van FVIII te identificeren, 
evalueerden we de perioperatieve periode in een grote groep patiënten met ernstige 
en matig ernstige hemofilie A. De resultaten van deze studie hiervan beschrijven we 
in hoofdstuk 6. In deze retrospectieve observationele studie includeerden we 119 
patiënten met matige en ernstige hemofilie A (FVIII-niveau < 0,05 IU mL-1; mediane 
leeftijd 40 jaar [IQR = 9-54]; mediane lichaamsgewicht 75 kilogram [IQR = 35-85]) die 
198 electieve chirurgische procedures ondergingen. De perioperatieve aanpak werd 
geëvalueerd door het kwantificeren van perioperatieve infusie van FVIII-concentraat en 
de bereikte FVIII-niveaus. De voorspellers van onder- en (extreme) overdosering werden 
geanalyseerd door een logistische regressieanalyse. Extreme overdosering werd gedefi-
nieerd als een plasmaspiegel ≥ 0.20 IU mL-1 boven de bovengrens van de streefwaarde. 
Samenvattend blijkt dat in de dagen na de procedure de afwijking van FVIII ten opzichte 
van de streefwaarde steeds aanzienlijker wordt (P voor trend < 0,01). In de eerste 24 uur 
na de operatie is 45% van de gemeten FVIII-niveaus lager dan de ondergrens van de 
streefwaarde met een gemiddelde afwijking van 0,17 IU mL-1. Zes dagen na operatie is 
75% van de gemeten FVIII-niveaus hoger dan de bovengrens van de streefwaarde, met 
een gemiddelde afwijking van 0,31 IU mL-1. In potentie zou 44% reductie van de FVIII-
consumptie zijn bereikt als FVIII-niveaus binnen de streefwaarde waren gehandhaafd. 
Bloedgroep O en een grote operatie waren voorspellend voor onderdosering (OR = 6,3, 
95%CI = 2,7-14,9; OR = 3,3, 95%CI = 1,4-7,9). Daarbij hadden patiënten met bloedgroep 
O meer bloedingscomplicaties vergeleken met patiënten met een andere bloedgroep 
(OR = 2,02, 95%CI = 1,00-4,09). Patiënten met een niet-O bloedgroep hadden een gro-
tere kans op overdosering (OR = 1,5, 95%CI = 1,1-1,9). Bovendien hadden patiënten die 
behandeld werden middels bolus infusies een hoger risico op extreme overdosering 
(OR = 1,8, 95%CI = 1,3-2,4). Deze resultaten suggereren dat de kwaliteit van zorg en 
kosteneffectiviteit beslist kan worden verbeterd door een verfijnde aanpak van doseren 
die rekening houdt met individuele patiëntkarakteristieken zoals bloedgroep en wijze 
van infusie. Farmacokinetisch (PK) gestuurd doseren is een mogelijkheid om dit doel te 
bereiken.
De rol van het PK-gestuurd doseren van stollingsfactorconcentraten bij hemofilie is mo-
menteel onderwerp van discussie en in het algemeen vooral gericht op de langdurige 
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profylactische behandeling. Er zijn maar weinig gegevens beschikbaar over de effecten 
in de perioperatieve periode. In hoofdstuk 7 presenteren we een populatie PK-model 
voor patiënten met matige en ernstige hemofilie A (FVIII niveaus < 0,05 IU mL-1) die 
een electieve, chirurgische ingreep ondergaan. Het model beschrijft de perioperatieve 
farmacokinetiek van de FVIII concentraten die op dit moment beschikbaar zijn. Het 
model werd ontwikkeld met de retrospectief verzamelde gegevens zoals beschreven 
in hoofdstuk 6: De dosering FVIII concentraat, bereikte FVIII plasma concentraties en 
exacte tijdstippen van toedieningen en metingen. Het populatie PK-model werd 
geconstrueerd met behulp van non-lineair mixed-effects modeling (NONMEM). De 
populatie PK-parameters werden vastgesteld op basis van gegevens van 119 patiënten 
die in totaal 198 operaties ondergingen. Hiervan ondergingen 75 volwassenen 140 
operaties (gemiddelde leeftijd 48 jaar [IQR = 37-60]; mediaan gewicht 80 kg [IQR 73-
90) en 44 kinderen ondergingen 58 operaties (gemiddelde leeftijd 4 jaar [IQR = 2-8]; 
mediaan gewicht 19 kg [IQR = 12-29]). De individuele farmacokinetiek werd het best 
beschreven door een twee-compartimenten model. De waarde van de klaring (CL), de 
intercompartimentele klaring en het centraal (V1) en perifeer volume was respectieve-
lijk 0,15L/u/68kg, 0,16L/u/68kg, 2,81lL/68 kg en 1,90L/68kg. Verschillen tussen patiënten 
(inter-patiënt variabiliteit) in CL en V1 waren respectievelijk 37% en 27%. De klaring nam 
af met toename van de leeftijd (P < 0,01) en was verhoogd bij bloedgroep O (26%, P < 
0,01). Daarnaast werd een wat verminderde klaring waargenomen bij grotere chirurgi-
sche ingrepen (7%, P < 0,01). We concludeerden dat populatie PK-modellen ook voor 
de perioperatieve setting zullen leiden tot individualisering van de perioperatieve FVIII 
concentraat doseringen en tot PK-gestuurde dosisaanpassingen met een significante 
optimalisering van de zorg.
In hoofdstuk 8 beschrijven we strategieën om PK-gestuurd profylactisch doseren suc-
cesvol te implementeren. Dit werd gebaseerd op onderzoek waarbij de belemmerende 
en bevorderende factoren voor deze nieuwe doseringsmethode werden geïdentificeerd. 
Dit is van belang omdat de voorkeuren van patiënten, ouders en behandelaars grote in-
vloed kunnen hebben op de uiteindelijke invoering van een medische innovatie. Om de 
voorkeuren te inventariseren werd een “discrete keuze-experiment” (DCE) analyse uitge-
voerd naar mogelijke belemmerende en bevorderende factoren van geïndividualiseerde 
PK- gestuurde dosering van profylaxe. De onderzoekspopulatie bestond uit patiënten 
met hemofilie die nu of eerder profylactisch werden behandeld met factorconcentraat 
(n = 114), ouders van patiënten 12-18 jaar (n = 19) en hemofilie behandelaren (n = 91). 
In het algemeen waren patiënten en ouders, en vooral professionals geneigd te kiezen 
voor PK-gestuurde dosering van profylaxe. Bovendien was, als het risico op bloedingen 
werd gereduceerd, het frequenter toedienen van factorconcentraat aanvaardbaar. 
Dagelijkse doseren bleef echter een belangrijke barrière voor alle betrokkenen. Het 
Samenvatting
216
  C
ha
pt
er
 1
0
beperken van de kosten voor de maatschappij was opvallend genoeg in alle groepen 
een bevorderende factor voor implementatie. We concludeerden dat bij de invoering 
van geïndividualiseerd PK-gestuurd doseren van profylaxe bij hemofilie, het verlagen 
van het risico op bloedingen en de reductie van de kosten voor de samenleving actief 
besproken moet worden, omdat ze bevorderlijk zijn voor implementatie. De kennis van 
deze voorkeuren zal behulpzaam zijn bij het opstellen van richtlijnen en informatiefol-
ders voor patiënten, ouders en professionals.
Dit proefschrift eindigt tenslotte met een algemene discussie in hoofdstuk 9. Hierin 
worden de mogelijkheden om de uitkomsten van de patiëntenzorg en de behande-
ling van hemofilie te verbeteren samengevat en besproken. Het belang van een beter 
inzicht in zorg en toekomstige innovaties van behandeling, en de dynamiek van deze 
processen wordt hierin onderstreept. Methodologische vraagstukken en lacunes in de 
beschreven studies worden ook belicht, resulterend in aanbevelingen en voorwaarden 
om besproken strategieën te optimaliseren. Tenslotte worden suggesties gedaan voor 
toekomstig onderzoek.
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I LIST Of abbREVIaTIOnS
bMI Body Mass Index
bU Bethesda Units
bw Body Weight
CbO Dutch Institute for Healthcare Improvement
CHQ Child Health Questionnaire
CI Confidence Interval
CL Clearance
CM Centimeter
DCE Discrete Choice Experiment
fIX Coagulation factor IX
fOCE First-order conditional estimation
fVIII Coagulation factor VIII
GMa Group Medical Appointment
GSES General Self-Efficacy Scale
Haemo-QoL Haemophilia-specific Quality of Life
HSES Haemophilia-specific Self-Efficacy Scale
HTC Haemophilia Treatment Center
ICC Intra-Class-Correlation
IIV Inter-individual variability; variability between patients
IMa Individual Medical Appointment
IOV Inter-occasion variability; variability within patients
IQR Interquartile Range
IS Importance score
ISCED International Standard Classification of Education
ISTH International Society of Thrombosis and Hemostasis
IU International Units
IVR In vivo recovery
kG Kilogram
L Liter
MEC Medical Ethical Committee
ML Milliliter
MMOL Millimole
n Number
na Not Applicable
nOnMEM  Non-linear mixed-effects modelling software to construct a 
population analysis, in which all plasma concentration time 
points are analysed simultaneously
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OfV  Objective Function Value, a measure of goodness of fit of the 
model. OFV is proportional to minus two times the logarithm 
of the likelihood (-2log likelihood) of the data
OR Odds Ratio
Pk Pharmacokinetic
Pk-parameters Pharmacokinetic parameters (e.g. CL, V1, Q, V2)
Q Intercompartment clearance
QUOTE-questionnaire Questionnaire about quality of care
RbCT Red Blood Cell Transfusion
SD Standard Deviation
SDQ Strength and Difficulties Questionnaire
SE Standard Error
SPSS Statistical Packages for Social Sciences
V1 Volume of distribution of the central compartment
V2 Volume of distribution of the peripheral compartment
VERITaS-Pro  Validated Haemophilia Regimen Treatment Adherence Scale 
- Prophylaxis
Vwf Von Willebrand Factor
Vwf:act Von Willebrand Activity
Vwf:ag Von Willebrand Antigen
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IV DankwOORD
“Als het hoogste doel van de kapitein zou zijn om zijn schip te behouden, zou hij het 
voor altijd in de haven houden” 
(Thomas van Aquino, 1225-1274)
Er zijn momenten die je niet vergeet. Zoals het moment waarop Marjon Cnossen mij zes 
jaar geleden op de Intensive Care kinderen van het Erasmus na een visite aansprak. Of ik 
ook zo’n ANIOS was die nog op zoek was naar een onderzoek. Met het ideaal voor ogen 
een goede arts te worden, sprak een promotieonderzoek mij zeker aan. Wel in het besef 
dat het een harde leerweg zou worden, maar Marjon wist mij met haar enthousiasme te 
overtuigen. Er lagen ambitieuze plannen, dat sprak mij aan! Maar, zoals Marjon mij later 
ook meegaf, ”Onbereikbare doelen, die gaan zo lekker lang mee” (Loesje). Inmiddels is de 
derde promovenda bezig om de plannen van toen te realiseren en verder uit te bouwen. 
Deze dissertatie legt de basis voor die prachtige onderzoekslijnen. Velen hebben de 
afgelopen jaren deuren voor mij en voor het onderzoek geopend en direct of indirect 
meegeholpen aan dit resultaat. En daar wil ik in dit woord van dank bij stilstaan.
Allereerst wil ik alle patiënten en hun ouders/verzorgers bedanken die letterlijk hun 
deur hebben geopend of op een andere manier hun medewerking aan dit onderzoek 
hebben verleend. Medisch onderzoek gaat over mensen die patiënt zijn en dus in aan-
raking komen met de kwetsbare kant van het leven. Daarom vind ik het altijd bewon-
derenswaardig dat juist zij bereid zijn andere patiënten, die ze helemaal niet kennen en 
die misschien zelfs nog niet leven, te dienen door mee te werken. Daarbij is hemofilie 
een zeldzame ziekte. Dit betekent dat er weinig patiënten zijn die informatie kunnen 
aanleveren en dat ze regelmatig belast worden met de vraag (weer) aan een onderzoek 
te willen meedoen. Bedankt dat velen van jullie dit met veel geduld, passie en inzet 
hebben gedaan!
Geen promotie zonder promotoren. Prof. dr. F.W.G. Leebeek en prof. dr. H.A. Moll jullie 
steunden en stimuleerden mij en gaven mij keer op keer vertrouwen. Frank, als een 
leider heb je me door dit promotieonderzoek geloodst. Door je kritische vragen en 
jarenlange ervaring, wist je bij elke bespreking mijn geest te scherpen en het onder-
zoek weer een stap verder te brengen. Henriette, wat heb jij veel voor me betekend de 
afgelopen jaren. Je gaf me niet per se antwoorden, maar stelde met je voortreffelijke 
helikopterview altijd de goede vragen, zodat ik zelf de volgende stap kon zetten. Je bent 
er op cruciale momenten voor me geweest, waarbij je echt luisterde en me de ruimte gaf 
om mijn vleugels even op een andere manier uit te slaan. Frank en Henriette: bedankt!
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Dr. M.H. Cnossen, lieve Marjon, samen zijn we ruim 6 jaar geleden van start gegaan. Jij als 
co-promotor en ik als jouw eerste promovendus. We hadden veel mooie momenten en 
hoogtepunten: de goedgekeurde METC-aanvragen, de prachtige beurzen en subsidies 
die we binnenhaalden om het onderzoek te kunnen financieren, de discussies, koffiet-
jes, congressen, etentjes en wat al niet meer. Het was soms ook een zoektocht, want er 
is geen promotietraject zonder dat er ook deuren dichtgaan. Maar jouw enthousiasme, 
mensenkennis, en vooral jouw enórme doorzettingsvermogen zijn een inspiratiebron 
geweest om door te gaan. Met dit prachtige resultaat! En zelfs nog veel meer, want de 
zaadjes die we hebben geplant, zijn bijna allemaal tot ontwikkeling gekomen en een 
heel aantal staat volop in bloei!
Lieve Arja, ook jij hebt aan de wieg van deze dissertatie gestaan. Je hebt een enorm hart 
voor patiënten en jij bent de grondlegger geweest van het thuiszorgonderzoek. Met 
inzicht in de patiëntenzorg, gedegen kennis en eindeloze precisie, heb je mij de eerste 
anderhalf jaar van mijn promotie begeleid. Helaas, voor mij, ging je toen met pensioen. 
Het is prachtig te zien hoe jij in het leven staat. Arja, Henriette en Marjon, we delen onze 
roots in Indonesië en dat heeft toch wel iets speciaals!
Prof. dr. R.A.A. Mathôt, Dr. M. Peters en Prof. dr. H. Raat, dank voor het plaatsnemen in 
de leescommissie. Ron, ik ken weinig wetenschappers op jouw niveau die zoveel rust en 
aandacht hebben voor de mensen die zij begeleiden. Je brengt met passie en geduld 
je vak over aan jonge wetenschappers. Marjolein, met jouw leiderschapskwaliteiten, 
ideeën, enthousiasme, ondernemingszin en oog voor de patiënt en de organisatie daar-
omheen beteken je geweldig veel voor de hemofiliezorg en heb je ook veel betekend 
voor ons onderzoek. Hein, dank voor alle waardevolle discussies over het valideren 
van vragenlijsten en het thuiszorgonderzoek. Maar het meest heb ik genoten van het 
brainstormen over allerlei nieuwe onderzoeksvragen en -vormen.
Prof. dr. J.A. Hazelzet, beste Jan. Je hebt mij de beginselen van de bloedstolling en de 
magische verbinding met het immuunsysteem onderwezen tijdens mijn periode op de 
Intensive Care. Bijzonder dat je nu plaats neemt in de grote commissie. Prof. dr. V.W.V. 
Jadoe, beste Vincent. Je hebt me onderwezen tijdens de master Clinical Epidemiology 
en geïnspireerd door het onderzoek van Generation R. Prof. dr C.M. Zwaan, beste Michel. 
De laatste jaren heb je een stimulerende omgeving gecreëerd, waarin de Kinderhema-
tologie en de onderzoekslijnen binnen de afdeling zich goed hebben kunnen ontwikke-
len. Je maakt je onder andere sterk voor de beschikbaarheid van geneesmiddelen voor 
kinderen en daarmee ben je van grote waarde voor de kindergeneeskunde. Ik ervaar het 
als stimulerend dat jullie deel uitmaken van de promotiecommissie.
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Wat is de zorg en het onderzoek zonder verpleegkundigen. Jullie zijn de spil van de zorg. 
Zowel qua organisatie als in het intermenselijke contact met patiënten én collega’s. 
Fantastisch! Mariejan, je hebt een hart van goud. Wat zijn die jongens gek op je! Fijn 
dat je als ervaren hemofilieverpleegkundige het thuiszorgonderzoek wilde gaan doen. 
Je hebt mij wegwijs gemaakt in de hemofiliezorg én de leuke plekjes om iets te gaan 
eten. Annet, met passie voor het vak heb je ontzettend waardevol werk verricht voor 
het onderzoek naar de groepsconsulten. Het was fantastisch om dat onderzoek verder 
uit te mogen bouwen. Ook daarna stond je altijd klaar om te helpen of om een goed 
gesprek te voeren! Greta, Floor en Marlous, dank voor de waardevolle ondersteuning 
en betrokkenheid vanuit de volwassen hematologie! Ik heb warme herinneringen 
aan de congressen die we samen bezochten en jullie gezelligheid! Marlous, jij werkt 
inmiddels niet meer op de afdeling, maar jouw uitstraling, compassie, vrolijkheid en 
moed zijn een voorbeeld voor mij geweest en dat zal ik niet snel vergeten! Marlène, als 
researchverpleegkundige heb jij een belangrijke rol in het hemofilieonderzoek. Jij hebt 
onder andere het thuiszorgonderzoek in Amsterdam uitgevoerd. Geordend, rechtlijnig, 
gestructureerd én enthousiast en warm heb je het werk gedaan en kwaliteit aan het 
onderzoek toegevoegd. Dank! Marlies, wij zijn ongeveer tegelijkertijd met ons promo-
tieonderzoek gestart. Jij bent al een tijdje gepromoveerd en bent inmiddels (inter)nati-
onaal groots bezig met onderzoek naar adherence en personalized care. Dank voor de 
samenwerking en hopelijk komt er nog veel mooi onderzoek voort uit de samenwerking 
tussen de hemofiliecentra in Nederland!
Dank aan alle co-auteurs voor hun bijdrage aan het onderzoek. Auke, dank voor wat je 
voor me betekend hebt in het hemofilieteam. Als co-auteur met een scherp oog voor 
detail, en ook als hematoloog. Je bent daarin een voorbeeld voor me. Je staat naast 
mensen, zowel bij patiënten als bij collega’s. Je straalt rust uit, bent doortastend, luis-
tert en doorgrondt. Dear Natalie, thank you so much for being my co-author. It was so 
wonderful to work with you! Thank you! Esther, via je collega Suzanne kwam ik bij jou 
terecht. En het werd een succes! Dank voor de fijne en vruchtbare samenwerking en het 
vele werk dat je voor de “DCE-studie” hebt verricht.
Gamze en Hannan, ik heb jullie tijdens jullie keuze-onderzoek mogen begeleiden. En 
ondanks dat ik aan het einde van dit traject met zwangerschapsverlof ging, hebben 
jullie het onderzoek met succes afgerond! Inmiddels delen we de passie voor het huis-
artsenvak, wie had dat toen kunnen denken! Maurits en Arienne, dank voor jullie hulp 
bij het onderzoek. Heel veel succes met wat er nu op jullie pad komt.
Tijdens mijn onderzoeksjaren heb ik deel mogen nemen aan verschillende onderzoeks-
groepen. Dank aan de collega’s van de werkgroepen algemene kindergeneeskunde, 
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hematologie, farmacologie, en NONMEM. Het is bijzonder inspirerend om door de 
discussies over het onderzoek (van jezelf, maar ook van anderen!) nieuwe inzichten 
te verkrijgen, maar ook ontzettend verhelderend om de hiaten in je onderzoek te 
ontdekken. Deze werkbesprekingen hebben absoluut tot een betere kwaliteit van het 
onderzoek geleid.
Als promovendus heb je ook een werkplek nodig. De eerste jaren heb ik op de SP 
gezeten. Aangekondigd met een enorme bos bloemen, en ontvangen met verraste 
gezichten, heb ik geweldig warme herinneringen aan de SP-tijd. Inmiddels is bijna ie-
dereen uitgevlogen, maar de warme band die we nu nog hebben, geeft blijk van een 
onderzoeksgroep die elkaar wist te respecteren, naast elkaar stond, elkaar verder hielp; 
als mens en als collega. Ik waardeer dat zeer. Lieve Janneke, Nienke, Evelien, Thijs, Yvette, 
Idse, Marieke, Ruud, Dorien, Eefje, Iris, Myrthe en Joany, dank voor al de keren dat de 
deur openstond, en we met koffie/thee en chocolade de beste gesprekken hadden!
Na de SP-tijd, kwam er de overgang van de kindergeneeskunde naar de afdeling he-
matologie. Yvonne, Carolien, Carina, Michelle, Shiraaz, Jossi, Johan, Iris, Eva, Shirley en 
Marc, jullie hebben deze tijd onvergetelijk gemaakt. Ik wil een aantal mensen nog in 
het bijzonder noemen. Eva, jij hebt me in het vak ingewerkt, en wat was het gezellig in 
Buenos Aires! Carolien en Iris, jullie zijn de nieuwe OPTI-CLOTTERS. Het was bijzonder 
om samen te werken. Carolien, heel veel succes met de laatste loodjes en Iris succes 
met het vervolg van de OPTI-CLOT! Yvonne, wat bijzonder dat we in dezelfde jaargroep, 
onderwijsgroep en ook nog in dezelfde subgroep werden geplaatst. Dank voor je col-
legialiteit als onderzoeker en ook de laatste maanden als huisarts in opleiding! Carina, 
je was multi-inzetbaar en stond altijd voor iedereen klaar! Michelle, met jouw gestructu-
reerde manier van werken kon je bergen verzetten en dat was nog gezellig ook! Shirley, 
als post-doc vervul je een mooie rol op de afdeling. Zowel op onderzoeksvlak, waarbij 
je met passie de werkgroep stuurt, als ook persoonlijk vlak. Het was heerlijk dat je af en 
toe even om het hoekje kwam gluren tijdens de vele uurtjes in de ‘vissenkom’. Moniek en 
Dick, dank voor jullie wetenschappelijke inzichten, waardevolle adviezen en persoon-
lijke aandacht in de afgelopen jaren.
Speciale dank aan het secretariaat van de afdelingen hematologie, oncologie en alge-
mene kindergeneeskunde voor de waardevolle ondersteuning tijdens het promotie 
traject, maar vooral voor de samenbindende rol die jullie vervullen op de afdeling.
Natuurlijk wil ik ook de andere arts-onderzoekers in het Sophia en de Sophia Onder-
zoekers Vereniging bedanken. Door de jaren heen hebben jullie veel betekend voor de 
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promovendi in het Sophia. Het levert waardevolle informatie, collegialiteit, gezellige 
borrels en weekenden op, dank!
Sinds maart 2016 ben ik in opleiding tot huisarts aan het Erasmus MC te Rotterdam. 
Marleen, Carina en Irene, hartelijk dank voor het onderwijs, jullie steun, vertrouwen 
en begrip in mijn eerste maanden als huisarts in opleiding, waarbij ik ook de laatste 
hand heb gelegd aan deze dissertatie. Lieve collega HAIO’s, dank voor de gezellige en 
leerzame momenten afgelopen maanden!
Vrienden maken het leven zoveel mooier! Babs, je staat al vanaf het eerste jaar van onze 
studie naast me. Het begon met samen blokken voor de tentamens, waarbij we enorm 
efficiënt waren en vervolgens dus heel veel tijd hadden om over de echte dingen van 
het leven te praten. Het is uitgegroeid tot een hechte vriendschap. De afgelopen jaren 
heb je me meer dan eens aangemoedigd om door te gaan. Wat bijzonder dat je als 
paranimf naast me staat, dank! Gerdien en Hanneke, elk jaar een week zeilen hebben we 
niet volgehouden, maar de vriendschap is er niet minder om geworden. Dank voor al 
die gezellige momenten! Marian, de klik en verbondenheid is er altijd weer! Sija, Willem, 
Veerle, Maaike en Renske. Heerlijk om jullie als vrienden te hebben en me daaraan op 
te mogen warmen! Dank ook voor alle praktische hulp en alle uurtjes dat Jesse bij ‘de 
meiden’ mocht spelen. Corina, Talitha, Tabitha, Madelinde, Christine, wat leuk dat we 
nog steeds zo’n mooie vriendenkring vormen! Cristel en Frank, wat geniet ik altijd van 
de speeluurtjes van Jesse en Eva en inmiddels ook van Pim, Ben, Luuk en Nora. Al die 
momenten zijn uitgegroeid tot een mooie vriendschap, bedankt!
Mijn levensreis is begonnen in Papua, een fantastische plek om op te groeien. Een plek 
die passie vormt en bagage meegeeft voor de reis die voor je ligt. Lieve papa en mama, 
dank voor jullie onvoorwaardelijke steun, de vele gesprekken over geloof, hoop en 
liefde en over het ontwikkelen van je talenten. Dank ook voor de ruimte die jullie geven 
om onszelf te zijn en onze eigen verantwoordelijkheid te nemen. Joris en Willem, het is 
bijzonder fijn om broers zoals jullie te hebben. Wat zijn we hecht met elkaar! Joris, jouw 
talent is enorm. Bedankt dat je de voorkant van mijn boekje hebt ontworpen! Willem, je 
hebt je eigen pad gekozen en bent ook geneeskunde gaan studeren! Allebei kiezen we 
nog steeds onze eigen wegen, maar ze kruisen elkaar steeds opnieuw. Dank dat je mijn 
paranimf wilt zijn! Joris, Arianne, Janiek, Jarik, Willem, Deborah en Loïs, wat vormen jullie 
een fijne familie! Lieve schoonfamilie, ik bof met jullie! We hebben heel wat doorstaan 
de afgelopen jaren, maar altijd is er die hechte familieband.
Jesse, Luuk en Nora, wat kan ik eindeloos van jullie genieten! Jesse, je levendige ogen 
verraden dat je een grenzeloze fantasie hebt en een prachtig karakter! Luuk, je obser-
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veert, denkt erover na en doet het na als je denkt dat je het kunt. Je weet nu al zo goed 
wat je wilt! Nora, als je maar in beweging bent, dan is het goed! Wat geniet ik van je 
levendigheid en je karakter! Jullie hebben allemaal tijdens deze promotie het levens-
licht gezien en kennen me dus niet zonder. In die zin breekt er voor mij én voor jullie een 
periode aan met een heel nieuwe dynamiek.
Rob, dit dankwoord had ik natuurlijk met jou moeten beginnen. Wat heb jij een enorme 
betekenis voor me! Je hebt me de afgelopen jaren alle ruimte gegeven om mijn onder-
zoek uit te voeren en veel meer dan dat! Ik ontdek steeds meer hoe mooi je bent en 
hoeveel ik van je hou! ~Soli Deo Gloria~
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V PHD PORTfOLIO: SUMMaRY Of PHD TRaInInG anD TEaCHInG
Name PhD student:
Erasmus MC Departments:
Research School:
PhD period:
Promotors:
Supervisors:
J. Lock
General Pediatrics – Pediatric Hematology
NIHES
April 2010 – September 2016
Prof. dr. F.W.G. Leebeek and prof. dr. H.A. Moll
Dr. M.H. Cnossen
1. PHD TRaInInG Year
workload 
(ECTS)
General academic skills
Biomedical English Writing and Communication 2011 4.0
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2012 1.0
Course Research Integrity 2012 2.0
Proefschrift schrijfdriedaagse 2014 0.7
Research skills
Department Research Meetings, Department of General Pediatrics and 
Hematology, Erasmus MC, Rotterdam
2010-2015 3.0
Mini course Methodology of Patient-related Research Methodology, Rotterdam 2011 0.3
The National Institutes of Health Clinical Center, Principles of Clinical 
Pharmacology, e-course
2011-2012 2.0
Master of Science in Clinical Epidemiology, NIHES, Rotterdam
Core curriculum
Study Design 2011 4.3
Clinical Epidemiology 2011 5.7
Methodologic Topics in Epidemiologic Research 2011 1.4
Research proposal 2012 2.5
Advanced Short Courses
Biostatistical Methods I: Basic Principles 2011 5.7
Epidemiology of Infectious Diseases 2013 1.4
Bayesian Statistics 2013 1.4
Biostatistical Methods II: Popular Regression Models 2011 4.3
Missing Values in Clinical Research 2013 0.7
Regression Analysis for Clinicians 2010 1.9
Principles of Epidemiologic Data-analysis 2013 0.7
Courses for the Quantitative Researcher 2012 1.4
Quality of Life Measurements 2011 0.9
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Erasmus Summer Program Courses
Principles of Research in Medicine 2011 0.7
Introduction to Data Analysis 2010 1.0
Clinical Decision Analysis 2011 0.7
Methods of Public Health Research 2011 0.7
Clinical Trials 2010 0.7
Topics in Meta-analysis 2011 0.7
Pharmaco-epidemiology 2011 0.7
Health Economics 2011 0.7
Markers and Prognostic Research 2011 0.7
The Practice of Epidemiologic Analysis 2011 0.7
Seminars and workshops
Hematology Course “Hemophilia and von Willebrand’s Disease”, Netherlands 
Society of Hemophilia Patients (NVHP), Eerbeek
2010 0.7
PhD-day, Erasmus MC, Rotterdam 2010 0.3
2nd Hematology Symposium, Herfstpallet, Amsterdam 2010 0.3
Young Investigators Day, Congress of the Paediatric Association of the 
Netherlands, Veldhoven
2011 0.3
Expert meeting on Continues Infusion, Berg en Dal 2011 0.1
AMSTOL Symposium, State-of-the-art hemostasis, thrombosis, atherosclerosis 
and vascular medicine, Amsterdam
2012 0.3
COEUR Research Seminar on Hemostasis and Arterial Thrombosis, Rotterdam 2012 0.1
Symposium on “Kwaliteit en Implementatie: Durf de uitdaging aan!”, Rotterdam 2013 0.3
NVTH annual AIO course on hemostasis and thrombosis, Koudekerke 2014 0.7
(Inter)national conferences
XXIX World Federation of Haemophilia (WFH), Buenos Aires, Argentina 2010 1.0
Sophia Scientific Research Organization (SSWO), Erasmus MC – Sophia 
Children’s Hospital, Rotterdam [2x oral presentation and 2x poster 
presentation]
2010, 2011 1.0
Dutch Society on Pediatrics (NVK) symposium, Veldhoven, [oral presentation 
and 2x poster presentation]
2010, 2011 0.8
Annual Meeting Belgian Society on Thrombosis and Haemostasis, Gent, 
Belgium
2010 0.6
4th Annual Congress of the European Association for Haemophilia and Allied 
Disorders, Geneva, Switzerland [poster presentation]
2011 0.3
Rodin Symposium, Amsterdam 2011 0.25
XXX World Federation of Haemophilia (WFH) Congress, Paris, France [poster 
presentation]
2012 1.5
6th Annual Congress of the European Association for Hemophilia and Allied 
Disorders (EAHAD), Warsaw, Poland
2013 0.7
XXIVth Congress of International Society on Thrombosis of Haemostasis, 
Amsterdam [5x poster presentation]
2013 1.6
Dutch Society on Thrombosis and Hemostasis (NVTH) Symposium, Koudekerke 2014 0.3
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2. TEaCHInG
Supervising Master’s theses
G. Urhan, medical student, Erasmus MC 2012 3.0
H. Bouzariouh, medical student, Erasmus MC 2012 3.0
Supervising Scientific internship
M. Westenberg, medical student, Erasmus MC 2014 0.3
A. van Heusden, medical student, Erasmus MC 2013 0.3
About the author
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VI abOUT THE aUTHOR
Janske Lock werd geboren op 30 augustus 1983 in Ede. Zij groeide op in Papua, Indo-
nesië, waar zij met veel plezier haar jeugd heeft doorgebracht en waar haar passie voor 
ontwikkelingswerk is ontstaan. Na het behalen van haar VWO diploma in 2001 aan de 
Gomarus Scholengemeenschap in Gorinchem ging zij Geneeskunde studeren aan de 
Erasmus Universiteit te Rotterdam. In 2008 behaalde zij haar artsenbul. Om haar inte-
resse in het ontwikkelingswerk vorm te geven volgde zij in 2007 een keuze-coschap in 
Nicaragua. Na haar coschappen werkte zij als arts-assistent op de afdeling Kinderge-
neeskunde in het Albert Schweitzer ziekenhuis te Dordrecht en op de Intensive Care 
Kinderen in het Erasmus MC - Sophia Kinderziekenhuis te Rotterdam.
In 2010 begon ze aan haar promotieonderzoek op de afdeling Hematologie en Algemene 
Pediatrie in het Erasmus MC te Rotterdam onder begeleiding van dr. M.H. Cnossen, prof. 
dr. F.W.G. Leebeek en prof. dr. H.A. Moll. De resultaten van dat promotieonderzoek zijn 
beschreven in dit proefschrift.
Ook tijdens deze periode zette zij zich in voor kansarmen. Zij ging in 2013 met een 
medische missie van Medical Checks for Children naar de Filipijnen. Tevens werkte zij op 
vrijwillige basis gedurende 6 weken in een vluchtelingenkamp op de grens van Thailand 
en Myanmar voor de Shoklo Malaria Research Unit. Hier ontdekte zij, naast een enorm 
grote passie voor de kindergeneeskunde, ook een passie te hebben voor patiënten die 
de kindertijd inmiddels ontstegen zijn. In 2015 werkte zij gedurende een aantal maan-
den in een verpleeghuis van stichting Humanitas te Rotterdam, waarbij dit bevestigd 
werd. Sinds maart 2016 volgt zij met veel voldoening de opleiding tot huisarts in het 
Erasmus MC te Rotterdam. Zij is getrouwd en moeder van 3 kinderen (2012, 2014 en 
2014).
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